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1.1 Childhood asthma – the burden of a chronic disease 
Asthma is the leading chronic respiratory disease in children and adolescents, with a present prevalence 
varying from 10 to 30% in Western Europe and English-speaking countries1. Clinical features of 
asthma are characterised by respiratory symptoms such as wheeze, chest tightness, shortness of breath 
and cough together with variable expiratory airflow limitation2. These symptoms are widely assumed 
to be the result of chronic airway inflammation with early structural airway ‘remodelling’ and airway 
hyperresponsiveness (AHR) to certain external trigger factors. 
Current asthma management aims at effective symptom control and prevention of adverse disease 
outcomes. It involves two key treatments: (i) Inhaled corticosteroids (ICS), which target inflammatory 
processes, and (ii) b2-agonists (bronchodilators) that dilate the airways through bronchial smooth 
muscle relaxation. In paediatric asthma, leukotriene receptor antagonists (LTRA) complement therapy, 
and in patients with severe asthma, long-acting muscarinic antagonists (LAMA) and biological agents 
such as anti-immunoglobulin E antibody treatment are also considered2,3. More recently, novel 
biological therapies targeting the inhibition of the cytokines interleukin (IL)-4, IL-13 and IL-5 have 
been applied in paediatric patients as well. Non-pharmacological treatment of allergic asthma further 
includes allergen-specific immunotherapy (IT). 
Available therapeutic regimens provide symptom relief in most asthma patients, but cannot fully avert 
a progressive decline in lung function as a consequence of airway remodelling4. Furthermore, 
therapeutic options for patients with incomplete symptom control despite exhausted and high-dose 
standard therapy are still limited5,6. The heterogeneity in clinical presentation of asthma, with varying 
clinical course and different individual treatment responses is a reflection of the complexity of the 
underlying disease pathobiology5,7. Although several risk factors, including genetic determinants and 
environmental exposures, have been identified, the exact aetiology of asthma is still unknown8,9. 
Immunological pathways and inflammatory processes that provoke initiation, exacerbation and 
progression of the disease remain poorly understood. 
Clinical and epidemiological approaches in clustering specific observable clinical features and 
pathological characteristics have led to the definition of certain asthma ‘phenotypes’10-12 and 
‘endotypes’13, forming the basis for the development of new targeted treatment strategies for a subset 
of patients. Yet only a few of the identified phenotypes have been largely agreed upon, and particularly 
in pre-school children the natural course of the disease remains difficult to predict10,14-16. While clinical 
remission may be expected for some phenotypes during adolescence, persistence of symptoms beyond 
childhood and also relapse in adulthood is not uncommon17-19. These more severe forms of asthma have 
been associated with inadequate corticosteroid responsiveness and with allergic disease and 
sensitisation, as defined by elevated immunoglobulin E (IgE) levels20. Although anti-IgE treatment 
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(omalizumab) is already available, further personalised therapies targeting other known molecular 
pathways in severe paediatric asthma still await approval or have yet to be designed21. 
Severe and uncontrolled disease results in a substantial reduction in children’s health-related quality 
of life by limiting physical activity and social interaction. Persistent symptoms predispose children to 
develop chronic obstructive pulmonary disease (COPD) later in life22. Thus, paediatric asthma in many 
respects represents a major burden for those affected and for society as a whole23. It affects children 
and adolescents in their most productive years24, and due to direct and indirect costs, it represents a 
considerable economic burden for the global health care system25-27.  
1.2 Environmental factors and the development of allergic asthma 
1.2.1 Westernisation, urbanisation and the hygiene hypothesis 
Today, ‘allergic asthma’, based on allergen-specific IgE levels (i.e. allergic sensitisation) and allergy-
related characteristic respiratory symptoms28, is considered to be the most common asthma phenotype 
not only in the paediatric population29. 
Although few reports of allergic disease had already been documented in antiquity30, there had been 
no awareness of this condition until the first description of hay fever in 1870, and another hundred 
years went by before asthma was recognised as a ‘common’ disease31. However, the subsequent 
increase in allergic disease and asthma prevalence in affluent Western societies during the last 40 years 
of the 20th century was dramatic, reaching epidemic dimensions32,33. Given the dynamics and rapidity 
of this trend, epidemiological research focussed on the changes in environmental factors and social 
lifestyle that coincided with that period. Increasing relocation to urban environments and the 
accompanying adoption of a modern, ‘westernised’ lifestyle have early been identified to have 
substantially contributed to the global changes and geographical variations in prevalence observed 
across countries34-36 as well as within the same country37-39. 
In 1989, David Strachan postulated the idea that the reduced number of infections in early childhood 
and improved public hygiene in the developed world were responsible for the significant increase in 
atopic diseases40. He had previously demonstrated that a large number of older siblings, an indirect 
marker for a higher rate of cross-infections within the household, was associated with a reduced 
prevalence of hay fever and atopic dermatitis. To this day, this so-called ‘hygiene hypothesis’ has 
provided the theoretical framework for further research on atopic diseases, inspiring numerous 
scientists worldwide. Subsequent studies have consistently confirmed lower rates of atopy41-45, allergic 
disease46 and also asthma-related symptoms47 in children raised in larger and less affluent families. 
Similar effects have been reported in children with day-care attendance during infancy48-50, indicating 
that relevant protection is mediated by any exposure to many other children also outside the domestic 
environment (Figure 1). 
Despite clear data from mouse models51, epidemiological studies assessing the role of infections as the 
purported mediator for the protective sibling and day-care attendance effect have provided inconsistent 
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results and could not fully support the original statement of the ‘hygiene hypothesis’52. In fact, viral 
respiratory tract infections in particular have been proven to increase the risk of subsequent asthma 
development in predisposed children53,54. Robust evidence only exists for a protective effect of 
parasitic, i.e. helminth infections on allergic diseases55,56, while findings on exposure to mycobacteria57-
59 or orofecally transmitted organisms such as Hepatitis A virus60 or Helicobacter pylori61-63 among 
others64-68 remain contradictory. 
In view of these findings, the ‘old friends hypothesis’ has been formulated as an amendment to the 
‘hygiene hypothesis’69. Most relevant protective organisms thus represent archaic microorganisms 
(‘old friends’), which co-evolved with the human race in earlier eras and are still found in rural 
environments. The abundant presence of these microbes as (pseudo)commensals and subliminal rather 
than clinically apparent infections has been proposed as providing the beneficial immunoregulatory 
effects. The disruption of man’s symbiotic relationship with these environmental and commensal 
microbiota, as well as microbial deprivation as a consequence of lifestyle changes in the course of 
urbanisation, has resulted in dysregulated immunity in susceptible subjects69 (Figure 1). 
 
Figure 1. Protective and risk factors for the development of allergic disease in early life.  
Most of these factors may affect the microbiota of the skin, nasopharynx, lung and gut, particularly during a 
critical time window in the early postnatal period. Figure and caption adapted from Ref. 33. © Springer Nature.
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1.2.2 The farm effect – protection through external microbial exposure early in life 
In this respect, increasing rates of atopy and asthma have been identified particularly in urban areas 
compared to rural ones, with a high consistency in studies from both high-income70-73 and low- and 
middle-income countries74-76. Increased air pollution in metropolitan areas could not explain these 
regional differences77-80, but a protective factor of rural living could be identified, namely that of being 
raised in a farming environment81,80.  
At the beginning of the 21st century, reports from all over the world documented remarkably lower 
prevalence rates of atopy and asthma among children that had grown up on traditional farms when 
compared to their peers from non-farming families. First landmark publications about this protective 
‘farm effect’ on childhood atopy and asthma came from Switzerland, Germany, Austria and Finland80-
83, setting the framework for numerous further studies conducted in European80,83-97, and non-European 
environments98-108. Cross-sectional multicentre surveys followed109-112 and provided further evidence 
for this hypothesis on a large scale. Today, the protective ‘farm effect’ on childhood atopy113 and 
asthma114 has evolved to be a commonly accepted epidemiological concept. 
A certain ‘window of opportunity’ for farm-related exposure is widely considered to be critical to its 
beneficial effects33, supporting the notion that there is a sensitive early phase in infancy in which 
immune maturation and potential modulation occurs115 (Figure 1). In this respect, regular exposure 
including animal contact and farm milk consumption during the period from pregnancy until the first 
year of life109,107,85,108 has been associated with the strongest protection against asthma and allergic 
disease, and continual long-term or lifelong exposure seems to provide additive effects106. It has 
recently been shown in a birth cohort study that beneficial effects on lung function persist even into 
adulthood116. 
 
Neither genetic variations117,118 nor common lifestyle factors109,119-121 in which farm and non-farm 
populations apparently differ have proved likely to account for the reduced risk of allergic diseases 
among farm-children. Instead, distinct characteristics of the farming environment have been observed, 
thus relating protection only to certain types of farm-associated exposure122. Features of traditional 
farming, which comprise animal husbandry82,83,104, particularly (dairy) cattle farming112,123 and grain 
cultivation112 and associated regular exposure to animal sheds and barns as well as to grain or hay as 
animal feed112,109,107, have been identified to confer protection especially in European farming 
environments. These findings have been corroborated in a recent study among children from two 
farming populations in the United States, the Amish and the Hutterites, that engage in different farming 
practices. Traditional farming of the Amish, as opposed to the Hutterite’s modern, industrialised 
practice, was associated with significantly lower prevalence of atopy and asthma in Amish children118. 
Furthermore, the consumption of unprocessed cow’s milk124,125,109,122,88,105 has been described as an 
independent protective factor, suggesting that not only inhalative environmental exposures may play a 
role in mediating the protective effect126 (Figure 1). 
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Exposure to farm animals and stables is associated with increased concentrations of plant material from 
fodder127, but also a variety of microbial sources. Inspired by the ‘hygiene hypothesis’, further research 
focussed on the external microbial exposure encountered in the farming environments. In order to allow 
quantification and qualitative measurement of children’s daily exposure, samples of settled dust 
indoors128 from children’s mattresses and room floors and of airborne dust from stables and barns were 
collected and screened for microbes and their nonviable, but bioactive compounds such as fungal 
products129 and bacterial cell-wall components130-132.  
Lipopolysaccharide (LPS), or endotoxin, a major part of the outer membrane of Gram-negative bacteria 
and abundantly present particularly in livestock farming settings118,132-134 was used early as a generic 
marker to reflect environmental microbial load. Various studies conducted in farming135,108 as well as 
non-farming households131,135-137 have shown an inverse relation of early-life exposure to high levels 
of endotoxin and atopy or allergic asthma in children, while the risk for nonatopic-wheeze in infants 
and toddlers appears to be increased138,139.  
In addition, the evolution of molecular methods involving sequencing of bacteria-specific 16S rRNA 
has made it possible to identify distinct bacterial genera and species in the dust samples. Specific micro-
organisms including Eurotium species from the fungal taxon, and many Gram-positive bacteria like 
Listeria monocytogenes, Bacillus species140, Staphylococcus species141, Lactobacillus species and 
Gram-negative bacteria such as Acinetobacter species142 among others143,144 were consistently 
associated with protection from atopic diseases. Current knowledge suggests that a unique composition 
of many of these micro-organisms, the diversity of microbial sources145, as represented in farm dust 
samples, can best explain the protective effect of the farming environment against allergic diseases and 
asthma in particular146,143. 
1.3 Immunological mechanisms in the pathogenesis of asthma and the farm effect 
The epidemiological ‘farm effect’ comprising all its associated protective exposures has been 
unambiguously proven in a global context. The strong evidence provided by epidemiological studies 
on the farming environment is encouraging, as it suggests that causes for the rapid rise in childhood 
asthma prevalence may both be identified and prevented. However, epidemiology is unable to draw 
causal conclusions from any effects observed. Immunological research is needed to identify the 
relevant mechanisms underlying the asthma-protective ‘farm effect’, thus providing further insights 
into pathophysiological processes involved in the development of asthma. 
1.3.1 Basic principles of the innate and adaptive immune system 
In order to be able to place mechanisms of asthma immunopathology in the context of basic 
immunological concepts, the fundamental principles of the human immune system will be briefly 
outlined hereafter. Due to the limited scope of this work, the following explanations will focus on 
immunological aspects that are especially important for a clear understanding of the present study. 
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Innate and adaptive immunity are the two types of immunity operating in humans to protect them from 
acute infections as well as chronic inflammatory disease. Although the division into the two subtypes 
has proven artificial in many respects, their distinction makes it easier to understand the complex 
immunological network involved in the pathogenesis of asthma. 
1.3.1.1 Innate immunity 
The innate immune system is the human’s first line of defence against potentially infectious threats 
such as bacteria, viruses, fungi and certain parasites. It is programmed to detect features of these 
invading pathogens as well as structures of altered host cells, to discriminate between self and foreign 
molecules and to activate adaptive immune responses to the latter147.  
Apart from humoral components such as complement proteins, innate immune protection largely 
depends on cellular defence mechanisms provided by cells of both haematopoietic and non-
haematopoietic origin148. The major haematopoietic cells within innate immunity include neutrophils, 
macrophages and dendritic cells (DCs) as phagocytic cells, but also mast cells, eosinophils, basophils, 
innate lymphoid cells (ILCs), and natural killer T (NKT) cells (Figure 2). Non-haematopoietic innate 
immune cells, in turn, are represented by epithelial cells lining the skin and the mucosal surface barriers 
of the respiratory and the gastrointestinal tract148.  
These innate immune cells express a limited number of evolutionary conserved ‘pattern recognition 
receptors’ (PRRs) on the cell membrane or in the cytoplasm which recognise invariant molecular 
motifs of microbes, e.g. nucleic acids, secretory products, cell-wall-components such as LPS, called 
pathogen-associated molecular patterns (PAMPs)149,150. Likewise, non-infectious endogenous 
molecules which are released from damaged host cells, termed damage-associated molecular patterns 
(DAMPs) can trigger PRRs151,152. Five subgroups of these germline-encoded innate receptors have 
commonly been described. They consist of the membrane-bound Toll-like receptors (TLRs) and C-
type lectin receptors (CLRs) as well as the intracellular NOD-like receptors (NLRs), RIG-I-like 
receptors (RLRs), and the AIM2-like receptors (ALRs)149. Some PRRs require adaptor proteins in order 
to integrate, sort and transmit signals. The TIR-containing adaptor (TIRAP) and the myeloid 
differentiation primary response 88 (MyD88) protein are examples of such adaptors utilised by the 
TLR-family. 
When encountering PAMPs and DAMPs, most PRRs (and their adaptors) trigger complex downstream 
signalling cascades that lead to the activation of transcription factors such as nuclear factor 'kappa-
light-chain-enhancer' of activated B cells (NF-kB) and interferon regulatory factors (IRFs.) Their target 
genes encode proteins involved in inflammatory processes such as cytokines, interferons and 
chemokines, which in turn initiate innate and adaptive immune responses. Ligand binding may also 
trigger direct defence mechanisms such as the induction of phagocytosis, cell death, autophagy, and 
cytokine processing. 
         
 
7 
Several mechanisms are involved to tightly control and coordinate signalling pathways at multiple 
checkpoints, in order to allow effective clearance of pathogens and altered cells while preventing 
excessive inflammatory responses at the same time.  
1.3.1.2 Adaptive immunity 
In contrast to the innate immune system, immune responses of adaptive immunity are slower, yet highly 
sophisticated and target-specific processes. They are mediated by two types of lymphocytes, T and B 
cells. While T cells, once activated by antigen-presenting cells (APCs), mainly govern the cell-
mediated part of adaptive immune responses, B cells represent - through antibody-production – the 
humoral part of adaptive immunity (Figure 2). Following differentiation into plasma cells, B cells 
secrete highly specific antibodies which bind to antigens from foreign agents like bacteria and viruses, 
flagging them for subsequent elimination. The unique memory function of adaptive immunity is 
featured by memory T and B cells, which are able to mount an accelerated immune response upon re-
exposure to the same antigen153. 
Both T cells and B cells express a diverse repertoire of unique antigen-binding receptors on their cell 
surface, called T cell receptors (TCRs) and B cell receptors (BCRs), respectively. Unlike the PRRs of 
the innate immune system, these receptors are highly variable structures, generated through somatic 
Figure 2. Integrated and simplified view of the human immune system. 
Some elements, such as natural killer T (NKT) cells and dendritic cells (DCs), are difficult to categorize, since 
they act at the interface of innate and adaptive immunity. Figure from Ref. 148. © Elsevier Inc. 
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DNA rearrangement processes, allowing the recognition of a broad range of potential ligand molecules 
or fragments, the so-called antigens147.  
In order to recognise these specific antigens, T cells need to interact with antigen-presenting cells 
(APCs) of the innate immune system (mostly DCs and macrophages). These professional APCs have 
the capacity to take up foreign antigens, process them into fragments (i.e. peptides) and present these 
peptides to T cells through surface proteins termed ‘major histocompatibility complex’ (MHC). MHC 
are classified as either class I proteins, which are expressed on all nucleated cells and present 
endogenous cytoplasmic proteins, or class II molecules which are found only on certain APCs within 
the immune system. While cytotoxic CD8 expressing (CD8+) T cells are activated by the interaction 
of their TCR with the complex of antigen-peptides bound to MHC I molecules, CD4+ helper T cells 
are activated through TCR recognition of peptide/MHC II-complexes147. CD8+ T cells primarily kill 
host cells infected with intracellular pathogens, such as viruses, or tumour cells expressing foreign 
antigens. CD4+ helper T (Th) cells, in turn, are essential for activating, enhancing but also limiting both 
innate and adaptive immune responses. Besides the antigen-T cell receptor signal (primary signal), 
signalling through co-stimulatory molecules on APCs is required as a second signal for effective 
activation and differentiation of naive T cells154,155. In response to activation, CD4+ T cells proliferate 
and, depending on the cytokine milieu, develop into different subsets of helper T (Th) cells, with Th1, 
Th2 and Th17 cells as well as regulatory T (Treg) cells being the most common. They are distinguished 
by distinct effector functions156. 
Th1 cells mainly produce the cytokines IFN-γ and interleukin (IL)-2, which primarily promote and 
enhance cell-mediated responses, involving the activation of macrophages and cytotoxic CD8+ T cells 
for the destruction of intracellular foreign agents and virally infected cells. In contrast, Th2 cells are 
characterised by the production of IL-4, IL-5 and IL-13, which stimulate B cells to produce, among 
others, immunoglobulin E (IgE) antibodies, and promote the recruitment and activation of mast cells 
and eosinophils that are essential for an effective immune response against extracellular parasites. 
While the Th17 subset of Th cells, which produce cytokines of the IL-17 family, is known to be pro-
inflammatory157, Treg cells have been identified as important anti-inflammatory cells, suppressing 
immune responses and controlling aberrant reactivity against self-antigens158. 
 
Innate and adaptive immunity are essentially complementary systems; they act synergistically and 
communicate with each other. Defects in both systems may lead to ineffective or misdirected immune 
responses as observed in autoimmune disease, chronic inflammatory disorders, allergic disease and 
many more.
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1.3.2 The pathogenesis of asthma and what we have learnt from the farming studies 
Chronic airway inflammation, which is known as the cardinal feature in asthma, is sustained by a 
complex immunological network linking processes of innate and adaptive immunity. Studies on the 
environmental determinants that influence both the development of asthma and protection from it have 
led to substantial revision in the common understanding of the underlying pathobiology and related 
immunological pathways.  
1.3.2.1 Mechanisms of adaptive immunity 
Asthma has long been considered the prototype of adaptive Th2 cell-induced inflammatory disease, 
with the presence of high serum IgE being the hallmark especially for allergic asthma159. In individuals 
with the atopic phenotype of asthma, high levels of allergen-specific IgE are indeed a reflection of an 
inappropriate Th2-biased immune response to common environmental allergens160,161, and main 
clinical features of asthma can be traced back to excessive Th2-dominated immunity. Recently 
published data on beneficial effects of targeted therapies suppressing Th2-specific cytokines continue 
to underscore the central role of Th2 cells in mediating airway inflammation in allergic asthma162,163. 
Th2 cytokines drive B cell-mediated allergen-specific IgE production and induce accumulation of 
mucosal mast-cells (mainly via IL-4), basophils and eosinophils (via IL-5) in the airways (Figure 3), 
leading to increased mucus production, airway hyperreactivity (AHR) with airway narrowing also to 
nonspecific stimuli, and structural changes of the airway wall (‘remodelling’)164. These inflammatory 
processes that occur in the lungs are amplified by vasoactive mediators such as histamine, as well as 
chemokines and cytokines released from mast-cells and basophils upon IgE-crosslinking with their 
high affinity receptors FceRI (Figure 3). 
 
Further evolution of the Th2 concept was reflected in the ‘Th1/Th2 paradigm’ of asthma, which 
proposed an imbalance between T helper cell subsets with excessive Th2-type immune responses 
driving airway inflammation in the absence of counterbalancing Th1-type immunity165,166. In a variety 
of human studies, reduced levels of the Th1-specific cytokine IFN-γ at birth and failure to upregulate 
Th1 immunity during infancy167 have been consistently associated with increased risk of atopic 










Figure 3. Th2- and Th17-induced immune processes in (allergic) asthma. 
Upon allergen sensitisation, APCs interact with naive T cells in the local lymph nodes of the airways and promote 
their differentiation into different T cell subsets (only TH2 and TH17 shown here). Following maturation, TH2 
and TH17 cells produce cytokines which activate humoral and cellular processes to promote the development of 
asthma. The TH2 cytokines IL-4, IL-5 and IL-13 stimulate allergen-specific IgE production and induce migration 
and activation of mucosal mast-cells, basophils and eosinophils. Release of mediators such as leukotrienes and 
histamine from these cells induces allergic inflammatory responses as well as airway epithelial and smooth-
muscle cell changes. APC, antigen-presenting cell; TH, helper T cell; TGF-b, transforming growth factor beta; 
FceRI, high-affinity receptor for IgE. Figure designed by Regina Rehbach. All rights reserved. 
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Th2 cell sensitisation to common allergens and resulting aberrant immune responses in predisposed 
children are largely determined by environmental factors encountered during early childhood174. As 
Th1 cells are known to inhibit the proliferation and differentiation of Th2 cells156, the atopy-and 
asthma-protective effect of early childhood microbial stimulation was attributed to mechanisms of 
immune deviation towards Th1-type immunity counteracting allergen-induced Th2 cell development109 
(Figure 4). On this score, microbial exposure particularly encountered in farming environments has 
been shown to enhance Th1-associated immune responses in human in vivo175,176 and in vitro studies142 
while decreasing Th2-dependent markers177. However, animal models assessing the effects of different 
farm-derived agents on asthma development did not reveal signatures of Th1-polarisation while 
invariably confirming the inhibition of Th2-mediated allergic inflammation and experimental features 
of asthma178,179. Findings from mechanistic studies on the binary Th1-Th2 paradigm in mouse models 
of asthma further challenged the concept of Th1/Th2 immune deviation as a unifying explanation for 
both asthma development and protection180,181. 
Considering the fact that only a minority of children with atopy (i.e. Th2-dependent excessive IgE-
mediated reaction) also develop asthma182, and that Th2-skewed chronic helminth infections can even 
provide protection from allergic disease, general thinking shifted towards a more complex 
understanding of immune regulation in asthma than initially proposed55. Additional cell types and 
mechanisms were included in the pathophysiological network.  
 
Th2 responses to environmental antigens were shown to be controlled by distinct populations of IL-10 
and TGF-β producing T cells, the regulatory T (Treg) cells183. In fact, decreased percentages of distinct 
Treg phenotypes were detected in blood and bronchoalveolar lavage (BAL) fluid samples of children 
with asthma and severely affected adult patients, and their suppressive activity was found 
impaired184,185. Concurrently, specific farming exposures were associated with an increased number 
and enhanced function of Treg cells or their respective cytokines (IL-10 and TGF-β) in children’s blood 
samples186-188. Likewise, it was shown that chronic parasitic and bacterial infections reduced 
experimental allergic airway inflammation through the induction of Treg and IL-10-secreting B cells189-
192. The development of allergic disease was thus explained by a deficient regulatory network, with a 
loss of respiratory tolerance in the absence of microbial instruction174 (Figure 4).  
 
More recently, it has been proposed that Th17 cells are involved in this regulatory network by 
counteracting anti-inflammatory activities of Treg cells193. Th17 responses have been associated with 
neutrophilic inflammation in severe asthma194 and have proved to induce airway remodelling in chronic 
disease193 (Figure 3). These findings further confirm the assumption that additional, non-Th2-related 
pathways are engaged in the pathogenesis of different forms of asthma.  




1.3.2.2 Mechanisms of innate immunity 
Studies on the mechanistic underpinnings of the farm effect on asthma have led to an immunological 
paradigm shift, with increased appreciation of the essential role of innate immunity, and particularly 
of antigen-presenting dendritic cells (DCs) in the pathogenesis of asthma (Figure 4). 
Both inflammatory and regulatory T cell responses to allergens require activation by innate immune 
cells. In allergic asthma, maladaptive Th2- and Th17-mediated immune responses to intrinsically 
innocuous allergens are initiated by pulmonary DCs, which first encounter inhaled antigens at the 
mucosal surface of the respiratory tract195. Upon antigen ligation and uptake via PRRs, DCs migrate to 
Figure 4. Immune processes potentially underlying the impact of environmental conditions on the 
development of asthma. 
In a Western-lifestyle environment, allergen exposure triggers Toll-like receptors (TLRs) on epithelial cells, 
leading to the release of cytokines such as IL-33 and GM-CSF, which boost the TH2-promoting capacity of DCs. 
These cytokines also promote an innate immune response to allergens involving ILC2s, basophils and 
eosinophils. In a protective environment, chronic exposure to environmental farm dust and microbial-derived 
signals such as endotoxin or metabolites from the lung or gut microbiome may induce increased formation and 
differentiation of Treg and TH1 cells which suppress TH2 immune responses. Such exposure may further induce 
the regulatory enzyme TNFAIP3 in lung epithelial cells to inhibit the production of pro-inflammatory cytokines. 
RSV, respiratory syncytial virus; GM-CSF, granulocyte-macrophage colony-stimulating factor; TSLP, thymic 
stromal lymphopoietin; SCFA, short-chain fatty acids; DC, dendritic cell; Treg, regulatory T cell; TH, helper T 
cell. Figure and caption adapted from Ref. 33. © Springer Nature. 
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the draining bronchial lymph nodes to activate naive T cells by releasing cytokines and expressing co-
stimulatory molecules. In this way, DCs determine the outcome of subsequent adaptive immune 
responses196, involving the induction of both airway inflammation and tolerance to foreign antigens197.  
Distinct functional properties have been ascribed to different types of DCs. Based on phenotype 
characteristics, two major dendritic cell subsets have been identified in humans - plasmacytoid DCs 
(pDCs) and myeloid DCs (mDCs, also referred to as conventional DCs (cDCs)), which are further 
subdivided into mDCs type 1 and type 2198. Although the evidence for the distinct division of labour 
among human DCs is not as clear, mDCs have been shown to critically contribute to the development 
of allergic airway inflammation in mice199,200, whereas pDCs suppress inflammation by inducing Treg 
cell responses200-203. Supporting this notion, decreased numbers of pDCs have been associated with 
subsequent wheeze or asthma in children204,205. Conversely, mDC subsets were found in decreased 
numbers in asthma-protected farm children206,207 and exposure to farm-derived dust extracts was shown 
to modulate DC biology and function both in humans and in mice178,179,208. On this score, a decreased 
T cell stimulatory capacity of human monocyte derived DCs was observed when cultured in the 
presence of stable dust178. Prolonged in vitro exposure to farm dust extracts and derived products was 
shown to reduce the allergy-inducing capacities of murine DCs through an IL-10 dependent 
mechanism208,179. 
 
Another crucial mediator in both protection and disease is represented by structural components of the 
lung, airway epithelial cells (ECs). It has recently been demonstrated that ECs, acting in close crosstalk 
with DCs, constitute an integral part of the innate immunity network at the interface between host and 
environment209 (Figure 4). Like professional APCs, they express pattern recognition receptors from 
the TLR-family on their cell surface210. In response to TLR-stimulation, ECs release cytokines, 
chemokines and lipid mediators which control the activation of DCs and programme them to mount 
Th2-mediated immune responses upon allergen exposure211. 
 
Airway EC-derived cytokines may also control activation of innate lymphoid cells (ILCs), a most 
recently identified innate immune cell type212 (Figure 4). Being a major source of the Th2 cell-
associated cytokines IL-5 and IL-13, type 2 ILCs (ILC2), in particular, are increasingly emerging as 
important contributors of allergic airway inflammation213. Interaction with different types of DCs has 
been shown to either promote214 or suppress215 type 2 inflammatory response. ILC2 numbers were 
consistently found to be elevated in human asthmatic subjects, both in sputum and in peripheral 
blood216-218. Research studying the interaction of ILCs with the microbiota at mucosal surface barriers 
is now beginning to unravel their involvement in host-protective regulatory functions219 in the context 
of asthma development as well220. 
 
Recent data further suggest that, apart from ILCs, DCs and ECs, basophils contribute to the 
development of Th2-biased immune responses to allergens221-223, although their precise role in driving 
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disease processes of asthma remains to be defined. Innate immunity is also represented by natural killer 
T (NKT) cells, whose involvement has been described both in the pathogenesis of asthma224 and the 
protection from it through early life microbial exposure225.  
 
As demonstrated above, a variety of cellular mechanisms are considered to be involved in the 
pathogenesis of asthma and its environmentally mediated protection, but their relative contributions 
are still unclear. Although immunological research based on the ‘hygiene hypothesis’ and the ‘farm 
effect’ on asthma has significantly enhanced the current understanding of the disease, the overall 
picture remains fragmented and a unifying mechanistic concept has yet to be defined.  
1.4 Molecular mechanisms and pathways analysed in this work 
Allergic asthma constitutes inappropriate, i.e. inflammatory immune responses to innocuous 
environmental stimuli such as common allergens. Children growing up in farming environments are 
constantly exposed to high concentrations of these stimuli and a vast number of microbial agents, which 
harbour evolutionary conserved structural components such as endotoxin (LPS). Environmental LPS 
and many allergens are recognised by cells of the innate immune system, specifically DCs and 
macrophages but also airway ECs, through Toll-like receptor 4 (TLR4), which is expressed on their 
cell surface. TLR4 in complex with myeloid-differentiation protein 2 (MD-2) engages LPS. LPS 
binding with the help of CD14 initiates dimerisation of the TLR4-MD2 complex, which triggers the 
recruitment of Toll/interleukin-1 receptor (TIR) domain-containing adaptor proteins226 (Figure 5). 
Intracellular TLR4 signal transmission then takes place via two distinct pathways, the MyD88-
dependent and the TRIF-dependent pathway, both ultimately culminating in the activation of the 
transcription factor NF-κB. NF-κB represents a family of five transcription factors that regulate the 
transcription of genes involved in a variety of inflammatory processes227. In the presence of membrane-
bound CD14, the TLR4-MD2-LPS complex is internalised into endosomes, where it recruits the 
adaptors TRAM and TRIF, driving downstream signalling via the induction of type I interferons 
through IRF3 and NF-κB (TRIF-dependent pathway)228. Engagement with TIRAP (MAL) and MyD88 
adaptors mainly triggers the early phase of NF-κB-dependent induction of pro-inflammatory cytokines 
such as IL-6, IL-12 and TNF-a (MyD88-dependent pathway)226,229 (Figure 5). 
 
 




Figure 5. TLR4-dependent NF-kB signalling pathway and regulatory activities of TNFAIP3. 
Upon LPS binding with Toll-like receptor (TLR) 4 in complex with MD-2, several adaptor proteins including 
TIRAP, MyD88 and TRAF6 are recruited to the receptor. TRAF6 interacts with the ubiquitin conjugating 
enzymes Ubc13 and UbcH5c, leading to the K63-linked polyubiquitination of TRAF6, which promotes 
recruiting of the TAK1 kinase complex and of the IkB kinase (IKK) complex. TAK1 phosphorylates (P) and 
activates IKK, eventually resulting in proteasomal degradation of IκB proteins, release of NF-κB and subsequent 
translocation to the nucleus, where transcription of target genes is achieved. The enzyme TNFAIP3 inhibits NF-
kB signalling by disrupting the interaction of TRAF6 with Ubc13 and UbcH5c, K48-linked polyubiquitination 
and proteasomal degradation of Ubc13/H5c and by removing K63-linked polyubiquitin chains from TRAF6. 
TNFAIP3 activity is regulated by the binding proteins TAX1BP1 and TNIP1/2, which directly enhance 
TNFAIP3’s inhibitory effects on NF-κB. The paracaspase MALT1 negatively regulates TNFAIP3’s function. 
Anti-inflammatory regulators analysed in this thesis are highlighted in green, while pro-inflammatory pathway 
molecules are shown in (rust) red. Molecules with enzymatic functions are represented in an elliptical shape. 
Figure content and caption based on Ref. 251 as well as Ref. 272. Figure designed by Regina Rehbach. All rights 
reserved. 
Abbreviations: LPS, lipopolysaccharide; LBP, LPS binding protein; TLR4, Toll-like receptor 4; MD-2, Myeloid-
differentiation protein 2; TIRAP, TIR domain containing adaptor protein; MyD88, Myeloid differentiation 
primary response 88; IRAK, Interleukin-1 receptor-associated kinase; TRAF6, TNF receptor-associated factor 6; 
IkB, Inhibitor of kappa B; IKK, IkB kinase; NF-κB, Nuclear factor ‘kappa-light-chain-enhancer’ of activated B 
cells; TNFAIP3, Tumor necrosis factor alpha induced protein 3;  TNIP, TNFAIP3-interacting protein; TAX1BP1, 
Tax1-binding protein 1; MALT1, Mucosa-associated lymphoid tissue lymphoma translocation protein 1; Ub, 
ubiquitin; K63 (48), lysine (K) residue at position 63 (48) in the ubiquitin molecule.  
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Signalling through TLRs and the adaptor MyD88 is essential for effective DC activation230, and a 
prerequisite for the development and control of adaptive T cell responses231,232. Inappropriate TLR4 
activation through direct binding of distinct aeroallergens has been associated with allergic 
responses233. Some genetic variants of TLR4 were found to modify the risk for atopy and asthma 
development in children117,234,235. Findings from experimental mouse models of asthma also indicate a 
crucial role for TLR-dependent signalling in suppressing allergic airway inflammation236-239 
particularly upon farm dust exposure118. This is paralleled by human in vivo studies showing that 
different farming exposures correlate with the expression of innate immunity receptor genes, especially 
TLR4 and related signalling pathway genes118,122,188,240,241. 
 
MyD88 signalling adaptor is shared by almost all TLR family members and facilitates TLR-signal 
transduction by coupling TLRs with their downstream signalling molecules. It has been shown to be 
particularly essential for driving an effective immune response upon LPS stimulation242. MyD88 is also 
required for the induction of the proinflammatory cytokine IL-18243, which has been associated with 
allergic airway inflammation by inducing eosinophil accumulation244 and the production of Th2-
specific cytokines and histamine245.  
MyD88-dependent TLR signalling involves the recruitment of kinases from the Interleukin-1 receptor-
associated kinase (IRAK) family, which in turn interact with TNF receptor-associated factor 6 
(TRAF6), thus activating its E3 ubiquitin ligase activity (Figure 5). TRAF6 associates with the E2 
ubiquitin conjugating enzymes Ubc13 and UbcH5c allowing K63-linked polyubiquitination of 
TRAF6246, which ultimately leads to the activation of the ubiquitin-dependent kinase TAK1247 and the 
‘inhibitor of kappa B (IkB) kinase’ (IKK) complex. Following phosphorylation by IKK eventually 
leads to proteasomal degradation of IκB proteins, the release of NF-κB and subsequent translocation 
to the nucleus, where the transcription of target genes is achieved (Figure 5).  
 
NF-κB signalling has been shown to be critically involved in a large number of inflammatory diseases 
including asthma227,248. Excessive NF-κB activation appears when negative regulation of TLR-induced 
signalling is affected249. Tumor necrosis factor a-induced protein 3 (TNFAIP3), also referred to as 
A20, has been identified as one central negative regulator of TLR-mediated and NF-κB-dependent 
inflammatory responses250. TNFAIP3 is constitutively expressed at high levels in T and B cells, 
whereas only limited amounts are observed in most other types of immune as well as non-immune cells 
under resting conditions251. Once expression is induced by NF-κB252, TNFAIP3 exerts its enzymatic 
activity by modulating various ubiquitination processes253,254 critical to the activation of NF-κB255. 
Through direct256 or indirect interactions, TNFAIP3 engages with key signalling molecules thus 
attenuating NF-κB-dependent signalling in the form of a negative feedback loop. One essential 
mechanism by which TNFAIP3 restricts LPS-induced NF-κB activation in the TLR4 pathway is the 
inhibition of polyubiquitin chain assembly to TRAF6 through interfering with Ubc13 and UbcH5c254 
(Figure 5). 
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Various studies have consistently linked cell-type specific TNFAIP3 deficiency to severe inflammatory 
conditions in mice257-259. The essential role of TNFAIP3 in driving particularly severe Th17-mediated 
forms of allergic airway inflammation has been highlighted most recently260. In the context of human 
asthma, reduced TNFAIP3 gene expression was found in bronchial ECs of asthma patients when 
compared to healthy subjects261,262. In a genome wide association study (GWAS)117, a risk allele for 
asthma has been detected for a distinct TNFAIP3 gene polymorphism (SNP) inside the protein coding 
sequence263, and the same SNP has been significantly implicated in a gene-by-environment interaction 
with farming261. The same study has identified TNFAIP3 as a key player in mediating the protective 
effect of LPS and farm dust exposure in an animal model of allergic asthma261. More recently, in vivo 
farming exposure has been associated with increased TNFAIP3 gene expression in children from the 
Amish farming population118.  
 
TNFAIP3 expression and activity is regulated by a number of mechanisms and molecular pathways264. 
Interaction with the binding proteins Tax1-binding protein 1 (TAX1BP1)265 and TNFAIP3-interacting 
protein 2 (TNIP2), also referred to as ABIN-2266,267, directly mediates and enhances TNFAIP3’s 
inhibitory effects on NF-κB. TAX1BP1 was shown to recruit TNFAIP3 to polyubiquitinated TRAF6, 
thereby promoting its deubiquitination and inactivation268,269,254. Its essential role in controlling NF-
κB-mediated inflammation has been illustrated in a study using TAX1BP1 knockout mice269.  
TNIP2, a member of the TNIP-family, is known as another important regulatory protein, which 
functions as an adaptor between ubiquitinated signalling proteins and TNFAIP3266. Recent findings 
from animal models suggest that TNIP2 critically contributes to the pathogenesis of allergic airway 
inflammation270. 
In contrast to TAX1BP1 and TNIP2, the paracaspase ‘Mucosa-associated lymphoid tissue lymphoma 
translocation protein 1’ (MALT1) negatively regulates TNFAIP3’s function by cleaving TNFAIP3 
upon T cell stimulation271. MALT1 itself is a substrate targeted by TNFAIP3, which catalyses its 
deubiquitination272 (Figure 5). MALT1 was proposed as playing a crucial role in mediating FceRI-
dependent cytokine production in mast cells, thus linking it to IgE-induced chronic allergic 
inflammation273. 
 
LPS-induced TLR4-mediated signalling activates professional APCs, particularly DCs, which then 














Upon activation, DCs undergo cellular differentiation by expressing co-stimulatory molecules of the 
B7 family (B7-1, B7-2, B7-H1, among others) on their cell surface274 - an important step in reaching 
functional maturity (Figure 7). CD80 (B7-1) and CD86 (B7-2) are mainly expressed on APCs such as 
macrophages, B cells and DCs in particular, but are also found on T cells274. The CD86 molecule is 
constitutively expressed at low levels, whereas CD80 is only present when its expression is induced 
upon activation274. During T cell priming, CD80 and CD86 on APCs both interact with CD28 on T 
cells, thus allowing effective activation upon antigen-TCR encounter155 (Figure 7). The absence of 
such co-stimulation has been associated with the induction of tolerance275,276.  
Figure 6. Dendritic cell activation and control of T cell responses.  
Environmental antigens such as LPS and allergens are recognized and taken up by DCs across the mucosal 
barrier of the airways. Once activated, DCs mature and migrate to the draining lymph nodes where they interact 
with naive T cells and promote their differentiation into different effector T cell subsets. The combination of 
signals transmitted by cytokines and co-regulatory molecules during DC-T cell interaction determines the 
differentiation and expansion of certain T cell subsets, which may either promote or suppress the development 
of the allergic response. TGF-b, transforming growth factor beta. Figure designed by Regina Rehbach. All rights 
reserved. 





Recent studies in mice bearing TNFAIP3-deleted DCs have demonstrated that DC activation and 
maturation is controlled by TNFAIP3257,277. CD80 and CD86 expression was markedly increased on 
TNFAIP3-deficient DCs, and the cells exhibited exaggerated NF-κB-dependent cytokine production, 
resulting in aberrant adaptive immune responses277. In the context of asthma, the CD86 co-stimulatory 
molecule in particular has been related to allergen-induced Th2 cell immune responses and airway 
inflammation in mice278,279. A polymorphism in the human CD86 gene locus280 and dysregulated CD86 
expression have been associated with allergic asthma and atopy in human studies281-284. It has recently 
been demonstrated that asthma-protective LPS and dust exposure in vivo suppressed the maturation of 
murine DCs, and that TNFAIP3 mediated this effect to some extent261. 
Figure 7. DC-T cell interaction following antigen encounter. 
Stimulation via TLRs leads to the activation of DCs. Mature DCs interact with naive T cells via the T cell receptor 
(TCR), major histocompatibility complex class II (MHC II) and a distinct repertoire of co-regulatory molecules. 
The CD80 (B7-1) and CD86 (B7-2) molecules on DCs both bind to CD28 as well as to CTLA-4 on T cells. PD-
L1 (B7-H1) can interact with both the PD-1 receptor and the CD80 molecule on activated T cells. Crosslinking 
of CD80 and CD86 with CD28 transmits stimulatory signals to T cells, while CTLA-4 as well as PD-L1 binding 
provides inhibitory signals. CTLA-4, cytotoxic T lymphocyte-associated protein 4; PD-L1, programmed death 
ligand 1; PD-1, programmed death receptor 1. Figure designed by Regina Rehbach. All rights reserved. 
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The co-stimulatory repertoire of DCs is further represented by the Programmed Death Ligand 1 (PD-
L1) surface protein (B7-H1, encoded by the CD274 gene)285,286, which functions as a binding partner 
to both the PD-1 receptor and the CD80 (B7-1) molecule on activated T cells287 (Figure 7). Similar to 
CD86, PD-L1 is constitutively expressed on resting APCs and T cells and upregulated during 
activation288. Unlike CD86-mediated signalling, which mainly governs T cell activation, crosslinking 
of PD-L1 with either PD-1 or CD80 provides inhibitory bidirectional signals between T cells and 
APCs289,290. Abnormal PD-L1 expression in humans has been related to several autoimmune diseases, 
which underscores its role in controlling T cell mediated immune responses and the induction of 
tolerance291. However, its contribution to the pathogenesis of allergic asthma has been less clear. 
Experimental studies in mice have yielded contradictory findings on the role of PD-L1/PD-1 
interaction in regulating features of allergen-induced airway inflammation and AHR202,292. A more 
recent study has linked PD-L1 to atopic sensitisation and asthma in humans293. 
1.5 Aims of the study  
The prevalence of asthma has been increasing worldwide in recent decades, making it one of the most 
common chronic diseases among children particularly in Western countries. Despite substantial efforts 
in research, its aetiology and pathobiology remain poorly understood. Previous knowledge about 
mechanistic processes in asthma mainly relied on the concept of a dysregulated Th2 cell-dominated 
adaptive immune response, resulting in chronic inflammation. Current efforts increasingly integrate 
innate immune pathways and cellular networks, providing the framework for novel targeted therapies. 
However, available therapeutic options cannot provide cure and remain ineffective in some forms of 
asthma, leaving a considerable group of patients with residual and severely uncontrolled disease.  
Primary prevention of asthma is still a vision, although effective natural protection through early life 
farm exposure has been proven in epidemiological studies worldwide. From an immunological 
perspective, the underlying mechanisms of this association have not yet been clearly identified. A more 
comprehensive understanding of the immunobiology behind the asthma-protective ‘farm effect’ will 
provide the scaffold for disentangling the complexity of asthma pathophysiology, and ultimately 
developing new strategies of primary disease prevention and therapy. 
There is now mounting evidence suggesting that continuous exposure to microbial products, such as 
LPS, from farming environments induces critical regulatory pathways within innate immunity to 
maintain immune homoeostasis in a child’s developing immune system. In this context, the enzyme 
TNFAIP3, which attenuates NF-kB dependent inflammation, has recently evolved to be a key 
regulator. TNFAIP3 in bronchial epithelial cells has been shown to critically mediate asthma-protective 
effects of in vivo farm dust exposure in adult mice. Although these data strongly point towards a 
unifying molecular mechanism most relevant to both disease prevention and therapy, equivalent 
immunological studies in humans are missing. Moreover, a large body of evidence suggests that 
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immunoregulatory processes crucial to asthma development occur during infancy, and do not only 
involve the airway epithelium.  
Therefore, the experimental approach of the present study aimed to assess immune regulation in 
primary immune cells of children. The aim of this thesis was to unravel the role of the anti-
inflammatory regulatory molecule TNFAIP3 and related signalling pathways in both the inception and 
environmentally mediated prevention of allergic asthma in children.  
 
In particular, the following objectives were pursued:  
 
(i) To investigate if TNFAIP3 gene and protein expression and expression of genes related to 
NF-kB signalling and dendritic cell maturation was dysregulated in peripheral blood 
immune cells (PBMCs) of steroid-naive asthmatic children during asthma manifestation. 
 
(ii) To study whether in vitro exposure to dust extracts from different ‘asthma-protective’ 
farming environments, as well as LPS, altered expression of TNFAIP3 and related genes 
in children’s PBMCs. To analyse in particular whether such stimulation could 
counterbalance potentially maladapted pathways in asthmatic subjects. 
In this context, to specifically study whether distinct farm dust extracts featured 
differential immunoregulatory properties upon in vitro exposure. 
 
(iii) To assess whether continuous in vivo farm exposure early in life modulated TNFAIP3 
pathway gene expression in farm children’s immune cells by the age of 4.5, 6 and 10 years.  
To specifically assess immune responses in farm children’s immune cells upon acute in 
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2 Materials and methods 
2.1 Materials 
2.1.1 Reagents and chemicals  
ACK (Ammonium-Chloride-Potassium) Lysing 
Buffer  
Lonza, Basel, Switzerland 
Anti-A20/TNFAIP3 antibody 4625S Cell Signaling Technology, Cambridge, UK 
Anti-rabbit IgG, HRP-linked antibody 7074S Cell Signaling Technology, Cambridge, UK 
Anti-β-Actin antibody (C4) HRP sc-47778 Santa Cruz Biotechnologies, Santa Cruz, 
California, USA 
APS (Ammonium persulphate) Carl Roth, Karlsruhe, Germany 
Bromphenol blue Carl Roth, Karlsruhe, Germany 
BSA (Bovine Serum Albumin),  
heat shock fraction, pH 7, ≥ 98% 
Sigma-Aldrich, St. Louis, Missouri, USA 
cOmpleteTM Mini, EDTA-free protease inhibitor 
cocktail 
Roche, Basel, Switzerland 
diH2O (deionised water) Milli-Q® water purification system, Milli-
Q®, Merck, Darmstadt, Germany 
ECL Substrate (SuperSignal™ West Dura 
Extended Duration Substrate) 
Thermo Fisher Scientific, Thermo 
Scientific™, Waltham, Massachusetts, USA 
EDTA (Ethylenediaminetetraacetic acid) Carl Roth, Karlsruhe, Germany 
Ethanol 100% Sigma-Aldrich, St. Louis, Missouri, USA 
Ficoll-Paque™ PLUS solution GE Healthcare, Piscataway, New Jersey, 
USA  
Glycerol Sigma-Aldrich, St. Louis, Missouri, USA 
Glycine Carl Roth, Karlsruhe, Germany 
HCl (Hydrochloric acid) 37 % Carl Roth, Karlsruhe, Germany 
HPLC-grade water Milli-Q®, Merck, Darmstadt, Germany 
LPS from E. coli serotype O111:B4 Sigma-Aldrich, St. Louis, Missouri, USA 
Methanol Sigma-Aldrich, St. Louis, Missouri, USA 
Milk, powdered, blotting grade, low fat Carl Roth, Karlsruhe, Germany 
NaCl (Sodium chloride) Carl Roth, Karlsruhe, Germany 
NaF (Sodium fluoride) Sigma-Aldrich, St. Louis, Missouri, USA 
NP-40 Detergent Sigma-Aldrich, St. Louis, Missouri, USA 
Nuclease-free water Qiagen, Venlo, the Netherlands 
PageRuler™ Prestained Protein Ladder, 
10 to 180 kDa 
Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
PBS (Phosphate-Buffered Saline) Thermo Fisher Scientific, Gibco™, Waltham, 
Massachusetts, USA  
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2.1.2 Solutions and buffers 
Primers for use in qPCR Thermo Fisher Scientific, invitrogen™, 
Waltham, Massachusetts, USA 
RLT lysis buffer Qiagen, Venlo, the Netherlands 
Roti®-PVDF membrane, 0.45µm pore size Carl Roth, Karlsruhe, Germany 
Roti®-Quant 5X conc. Bradford staining 
solution 
Carl Roth, Karlsruhe, Germany 
Rotiphorese® NF-Acrylamide/Bis-solution  
30 % (29:1) 
Carl Roth, Karlsruhe, Germany 
RPMI 1640 Medium + GlutaMaxTM Thermo Fisher Scientific, Gibco™, Waltham, 
Massachusetts, USA  
SDS 20% (Sodium dodecyl sulphate, 20% 
solution) 
Carl Roth, Karlsruhe, Germany 
TEMED (Tetramethylethylenediamine) Carl Roth, Karlsruhe, Germany 
Tris base Carl Roth, Karlsruhe, Germany 
Tris-HCl Carl Roth, Karlsruhe, Germany 
Trypan Blue solution 0.4% Sigma-Aldrich, St. Louis, Missouri, USA 
Tween® 20 (Polysorbate) Detergent Sigma-Aldrich, St. Louis, Missouri, USA 
Whatman® filter paper Wagner & Munz, München, Germany 
X-VIVOTM 15 Medium Lonza, Basel, Switzerland 
2-Mercaptoethanol Sigma-Aldrich, St. Louis, Missouri, USA 
2-Propanol Sigma-Aldrich, St. Louis, Missouri, USA 
APS 10% 1.0 g APS  
add diH2O up to 10 ml total volume  
BSA stock solution (400 μg/ml) 20 mg BSA 
add diH2O up to 50 ml total volume 
BSA 5% (w/v)  2.5 g BSA 
add diH2O up to 50 ml total volume 
5X Laemmli sample buffer 
  
5 ml 1.5 M Tris, pH 6.8 
3 ml SDS 20% 
15 ml glycerol 
0.9 mg bromphenol blue 
add diH2O up to 50 ml total volume  
add 2-mercaptoethanol 
Milk 5% (w/v)  2.5 g milk powder 
add diH2O up to 50 ml total volume 
RIPA buffer 150 mM NaCl 
25.0 mM Tris HCl, pH 7.5 
1.0 mM EDTA 
1% NP-40 








2.5 mM pyrophosphate 
50 mM NAF 
add diH2O up to 50 ml total volume 
10X Running buffer 
 
  
30.3 g Tris 
144.1 g glycine 
50.0 ml of SDS 20% 
add diH2O up to 1 L total volume 
1X Running buffer Dilute 10X running buffer to a 1X working 
solution, using diH2O. 
 
1X running buffer contains 25 mM Tris, 192 
mM glycine, 0.1% SDS, pH 8.3 
10X Transfer buffer  30.3 g Tris 
144.1 g glycine 
add diH2O up to 1 L total volume 
1X Transfer buffer Dilute 10X transfer buffer to a 1X working 
solution, using 800 ml of diH2O, 100 ml of 
methanol, 100 ml of 10X transfer buffer stock 
solution. 
 
1X transfer buffer contains 25 mM Tris, 192 
mM glycine, 10% methanol. 




60.6 g Tris 
87.6 g NaCl  
dissolve in 800 ml of diH2O 
adjust pH to 7.6 using concentrated HCl 
add diH2O up to 1 L total volume 
1X TBS, 0.1% Tween 20 (TBS-T) 
  
Dilute 10X TBS to a 1X working solution, 
using diH2O. 
For 1X TBS-T, add 1 ml of Tween 20% to 1 L 
of 1X TBS. 
 
1X TBS-T working solution contains 50 mM 
Tris, 150 mM NaCl, 0.1% Tween® 20, pH 7.6 
1.5 M Tris, pH 8.8  181.7 g Tris 
add diH2O up to 1 L total volume 
adjust pH to 8.8 using concentrated HCl 
0.5 M Tris, pH 6.8 60.6 g Tris 
add diH2O up to 1 L total volume 
adjust pH to 6.8 using concentrated HCl 
         
 
25 
2.1.3 Reagent systems (kits) 
2.1.4 Consumables 
 
Limulus Amoebocyte Lysate (LAL) QCL-
1000™ Assay + ß-Glucan Blocker Kit 
Lonza, Basel, Switzerland 
QuantiTect® Reverse Transcription Kit  Qiagen, Venlo, the Netherlands 
RNeasy® Mini Kit Qiagen, Venlo, the Netherlands 
SsoAdvanced™ Universal SYBR® Green 
Supermix 
Bio-Rad, Hercules, California, USA 
Adhesive seals, Microseal® ‘B’ Bio-Rad, Hercules, California, USA 
Blood Collection Set, Vacutainer® Safety-
Lok™ 
BD, Franklin Lakes, New Jersey, USA 
Blood collection tubes Vacutainer® BD, Franklin Lakes, New Jersey, USA 
Borosilicate glass tubes, pyrogen free Lonza, Basel, Switzerland 
Conical centrifuge tubes Falcon® (50 ml, 15 ml) Corning, Corning, New York, USA 
Cryogenic vial (2.0 ml) Corning, Corning, New York, USA 
Filter tips 0.1-20 μl Biosphere® Sarstedt, Nümbrecht, Germany  
Filter tips 100 μl, low binding SafeSeal® Biozym Scientific, Hessisch Oldendorf, 
Germany 
Filter tips 100-1000 μl Biosphere® Sarstedt, Nümbrecht, Germany  
Filter tips 2-100 μl Biosphere® Sarstedt, Nümbrecht, Germany  
Filter tips, 1000 μl for use with the QIAcube® Qiagen, Venlo, the Netherlands 
LeucoSepTM centrifuge tubes (12 ml) Greiner Bio-One, Kremsmünster, Austria 
Microcentrifuge tubes (1.5 ml) Carl Roth, Karlsruhe, Germany  
Microcentrifuge tubes Safe-Lock (2.0 ml) Eppendorf, Hamburg, Germany 
Microcentrifuge tubes, Multiply® -μStrip Pro 8 
(0.2 ml) 
Sarstedt, Nümbrecht, Germany  
Pasteur pipettes, sterile VWR International, Radnor, Pennsylvania, 
USA 
Reagent reservoirs, sterile Lonza, Basel, Switzerland 
Rotor adapters (10 x 24) for use with the 
QIAcube® 
Qiagen, Venlo, the Netherlands 
Serological pipettes (2 ml, 5 ml, 10 ml, 50 ml) Sarstedt, Nümbrecht, Germany  
Syringe filters Millex® (0.22 µm pore size, 
sterile) 
Millipore®, Merck, Darmstadt, Germany 
Syringes 10 ml  BD, Franklin Lakes, New Jersey, USA 
24-well flat bottom cell culture plate, Primaria™ Corning, Corning, New York, USA 
96-well microplates Greiner Bio-One, Kremsmünster, Austria 
96-well skirted PCR plates, low-profile, Hard-
Shell® 
Bio-Rad, Hercules, California, USA 
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2.1.5 Laboratory equipment 
Balance Explorer® Analytical OHAUS, Parsippany, New Jersey, USA 
Centrifuge 5417 R  Eppendorf, Hamburg, Germany 
Centrifuge 5810 R  Eppendorf, Hamburg, Germany 
Centrifuge Jouan CR412 Thermo Fisher Scientific, Thermo 
Scientific™, Waltham, Massachusetts, USA 
CFX96 TouchTM Real-time PCR Detection 
System 
Bio-Rad, Hercules, California, USA 
ChemiDoc TM MP Imaging System Bio-Rad, Hercules, California, USA 
Electrophoresis chamber and gel casting 
equipment (Mini-PROTEAN® Tetra handcast 
system) 
Bio-Rad, Hercules, California, USA 
Freeze Dryer Lyovac® GT 2 GEA, Düsseldorf, Germany 
Incubator HERAcell® 240  Heraeus, Hanau, Germany  
Micro Centrifuge II  neoLab Migge, Heidelberg, Germany  
Microplate centrifuge PerfectSpin P  Peqlab Biotechnologies, Erlangen, Germany 
Microplate reader Synergy H1 BioTek, Winooski, Vermont, USA 
Microscope Axiovert 40C  Zeiss, Göttingen, Germany  
Milli-Q® water purification system  Milli-Q®, Merck, Darmstadt, Germany 
Neubauer counting chamber, depth 0.1 mm Karl Hecht, Assistent®, Sondheim/Rhön, 
Germany 
Orbital und horizontal shaker Stuart® Cole-Parmer, Vernon Hills, Illinois, USA 
PCR Thermocycler PeqSTAR 96 universal Peqlab Biotechnologies, Erlangen, Germany 
Pipette controller Easypet® Eppendorf, Hamburg, Germany 
Pipette Eppendorf Research® plus 0.1-2.5 μl Eppendorf, Hamburg, Germany 
Pipette Eppendorf Research® plus 0.5-10 μl Eppendorf, Hamburg, Germany 
Pipette Eppendorf Research® plus 2-20 μl Eppendorf, Hamburg, Germany 
Pipette Eppendorf Research® plus 10-100 μl Eppendorf, Hamburg, Germany 
8-channel pipettor Research® plus 10-100 μl Eppendorf, Hamburg, Germany 
Power supply PowerPac™ Basic Bio-Rad, Hercules, California, USA 
QIAcube® robotic workstation Qiagen, Venlo, the Netherlands 
Round-bottom flask Schott, Duran®, Mainz, Germany 
Spectrophotometer NanoDrop™ 2000  Thermo Fisher Scientific, Thermo 
Scientific™, Waltham, Massachusetts, USA 
Stirrer Stuart® Cole-Parmer, Vernon Hills, Illinois, USA 
Thermomixer Comfort 5355 Eppendorf, Hamburg, Germany 
Vacuum pump Millivac™ Millipore®, Merck, Darmstadt, Germany 
Vortex shaker VF2 Janke & Kunkel, IKA®, Staufen, Germany 
Wet/Tank blotting system (Mini Trans-Blot® 
Cell) 
Bio-Rad, Hercules, California, USA 




2.1.7 Primer sequences 
Bio-Rad CFX Manager™ Version 2.1 Bio-Rad, Hercules, California, USA 
EndNote X9 ISI ResearchSoft, Berkeley, California, USA 
Ensembl Genome Browser http://www.ensembl.org/index.html 
Gen5™ microplate data analysis software BioTek, Winooski, Vermont, USA 
GraphPad Prism 8 Graphpad Software, San Diego, California, 
USA 
Image lab™ software 6.0 Bio-Rad, Hercules, California, USA 
ImageJ software National Institutes of Health, Bethesda, 
Maryland, USA 
Primer-BLAST designing tool https://www.ncbi.nlm.nih.gov/tools/primer-
blast/ 
 
National Center for Biotechnology (NCBI), 
Bethesda, Maryland, USA 
R software Version 3.3.1 http://www.R-project.org/  
SPSS Version 25 IBM, Armonk, New York, USA 
Vector NTI software Version 10 Advance 11.5  Thermo Fisher Scientific, invitrogen™, 
Waltham, Massachusetts, USA 
Gene Forward primer sequence 
(5´® 3´ on plus strand) 
Reverse primer sequence 
(5´® 3´ on minus strand) 
18S AGTCCCTGCCCTTTGTACACA GATCCGAGGGCCTCACTAAAC 
TLR4  CTCAACCAAGAACCTGGACCTG TTGATAGTCCAGAAAAGGCTCCC 
MYD88  TGCCTTCATCTGCTATTGCCCC AGTCGCTTCTGATGGGCACCTG 
TRAF6 TGATGTAGAGTTTGACCCACCCCTG TGGAAGGGACGCTGGCATTG 
TNFAIP3  GCCCAGGAATGCTACAGATACCC CAGCCTTGGACGGGGATTTC 
TNIP2  CAAAGGAATGTGGGGGAGAGAAGTC TTCGTCCCTGCTGGCGTTGTAG 
TAX1BP1 GCAGCAGAGGCAGATTTTGACATAG TCACTTGTTCTTTCCATTTCAGCTCC 
MALT1  CTCAGCCCCCCAGGAATAAAG GCTCTCTGGGATGTCGCAAAC 
CD80  CTGGCTGGTCTTTCTCACTTCTGTTC ACTCGTATGTGCCCTCGTCAGATG 
CD86  GCGGCTTTTATCTTCACCTTTC AAAACACGCTGGGCTTCATC 
CD274  ACCACCACCAATTCCAAGAGAG CACATCCATCATTCTCCCTTTTC 
PDCD1 AGGGTGACAGAGAGAAGGGCAG TCCACAGAGAACACAGGCACG 




2.2.1 Author’s contribution statement 
The author herself was responsible for recruitment of participants and sample acquisition within the 
CLARA/CLAUS study protocol. This involved organisation and realisation of recruitment activities in 
schools and paediatrician’s offices in Munich, including questionnaire-based interviews, data entry, 
clinical assessment, blood collection and sample processing. Support was supplied by the study doctor 
during clinical workup. All laboratory experiments outlined below were performed independently and 
exclusively by the author. Statistical analyses and interpretation of data shown in this thesis were 
carried out by the author herself, with partial support provided by the biostatistician of the research 
group. 
Since the 4.5- as well as the 6-year follow-up of the PASTURE/EFRAIM birth cohort study had been 
conducted prior to the start of the present project, clinical workup and some sample processing steps 
were not performed by the author herself but by (former) members of the research group. Wherever 
this was the case, it is indicated by an asterisk (*) in the respective sections below.  
 
Details regarding the two study setups, recruitment and sample selection criteria, as well as clinical 
workup, will be outlined hereinafter.  
2.2.2 Study populations, sample selection criteria and clinical workup 
For the immunological experiments demonstrated in this work, blood samples of children from two 
different study populations were analysed. Firstly, a nested case-control design was applied for a 
sample of newly recruited allergic asthmatic (AA) and healthy control (HC) children (n = 48) as part 
of the CLARA/CLAUS study294. Secondly, a nested sample of farm (F) and non-farm (NF) children 
from the prospective birth cohort study PASTURE/EFRAIM was selected for analysis at ages 4.5 and 
6 years (n = 37 and n = 63, respectively).  
2.2.2.1 CLARA/CLAUS study 
The cross-sectional CLARA (CLinical Asthma Research Association) /CLAUS study was initiated in 
January 2009 at the Dr. von Hauner Children´s Hospital, Munich, and includes healthy and asthmatic 
4- to 14-year-old children294,295. More than six hundred children have been enrolled so far. Within 
CLARA, a total number of 275 children was recruited from 2010 to 2014, and another 334 children 
have been enrolled since 2014 within the ongoing cohort called CLAUS. The study is registered at the 
DRKS - German Clinical Trials Register (study ID DRKS00004635; https://www.drks.de/drks_web/) 
and approved by the human ethics committee of the Bavarian Ethical Board, LMU Munich, Germany 
(Nr. 379-08).  
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2.2.2.1.1 Enrolment of participants for the present study  
For this project, healthy control subjects (HC) and patients with mild-to-moderate allergic asthma (AA) 
were recruited between January 2015 and March 2016 a. Healthy controls were recruited at the Edith-
Stein Gymnasium grammar school, Munich, as well as at the Dr. von Hauner Children´s Hospital, 
Munich, and as part of the 10.5 year follow-up of the PASTURE/EFRAIM study296 cohort in Bad Tölz, 
Germany. More than 60 children (aged 10 to 14 years) at the Edith Stein grammar school were screened 
by questionnaires according to the inclusion criteria for HC (as will be described in detail below) prior 
to blood withdrawal. Patients with allergic asthma were recruited at the Dr. von Hauner Children´s 
Hospital, Munich, at the paediatrician’s offices of Dr. med. Christina v. Bredow & Dr. med. Beate 
Kusser and of Dr. med. Christian Schröter, both located in Munich, Germany.  
Upon enrolment, parents completed a detailed questionnaire assessing data on their children’s health 
as well as environmental and socioeconomic factors. Core questions regarding wheeze/asthma, hay 
fever and atopic dermatitis were based on the systematic, standardised questionnaire from the 
International Study of Asthma and Allergies in Childhood (ISAAC)34,297. Questions have been 
internationally validated and show a high specificity for the diagnosis of asthma298-300. 
The 60-item questionnaire of the CLARA/CLAUS study further contains detailed questions on 
pregnancy, early childhood, parental health, among others (see original questionnaire provided in the 
appendix (10.2)). Furthermore, data on common potential confounding variables such as family size, 
breast-feeding, parental education, family history of atopy or passive smoking were obtained from the 
questionnaires. Plausibility checks and checks for the completeness of questionnaire data were 
performed. Oral and written informed consent was obtained from the children’s parents for 
participation in the study and blood sample collection. 
2.2.2.1.2 Blood sampling and clinical assessment 
Upon enrolment, 28 ml of peripheral blood was collected from all study participants (n = 48). Complete 
blood count (CBC), C-reactive protein (CRP) values and total immunoglobulin (Ig) E levels were 
measured in the children’s blood samples. Furthermore, sensitisation to allergens was assessed by 
specific IgE in serum samples via radio-allergo-sorbent test (RAST). Positive sensitisation was defined 
as at least one positive test result for specific IgE [≥ 0.35 IU/ml], i.e. specific IgE class (SCI) 1 or 
greater, to a panel of 20 common allergens (Mediwiss Analytic, Moers, Germany), including 
dermatophagoides pteronyssinus, dermatophagoides farinae, birch pollen, grass pollen mix, hen’s egg, 
cow´s milk, soybean, hazelnut, peanut, carrot, wheat flour, latex, hazel, cat epithelium, horse 
epithelium, dog epithelium, Alternaria alternata, mugwort, timothy grass, plantain294. 
———————— 
a For enrolment of participants including clinical assessment and blood sampling, the author was partly supported by the     
  study doctor or a study nurse in charge.  
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All asthmatic children underwent full clinical examination and pulmonary function tests. Lung function 
parameters were assessed by body plethysmography using the MasterScreen™ PFT System 
(CareFusion, Höchberg, Germany), following international standards (American Thoracic Society 
(ATS)/ European Respiratory Society (ERS) guidelines)301. Children were instructed in detail before 
the measurement. The children’s height and weight without shoes were determined. Pulmonary 
function parameters, including the forced expiratory volume at the timed interval of one second (FEV1), 
forced vital capacity (FVC), mid-expiratory flow rate at 75%, 50% and 25% of FVC (MEF75, MEF50 
and MEF25, respectively), and measures of airway resistance and residual volume were evaluated at 
baseline (‘pre’) and after (‘post’) inhalation of the rapid-acting bronchodilator (i.e. b2-adrenergic 
receptor agonist) salbutamol. Individual z-scores of  FEV1 (zFEV1), and of FEV1/FVC ratio 
(zFEV1/FVC) were calculated, thus adjusting measured patient’s values for sex, age, height and 
ethnicity302,303. According to the Global Initiative for Asthma (GINA) guidelines304, reversibility of 
airflow limitation was defined as a significant relative increase in FEV1 of >12% predicted upon 
bronchodilator administration (bronchodilator (BD) response [(FEV1 post - FEV1 pre)/ FEV1 pre] x 100). 
2.2.2.1.3 Inclusion and exclusion criteria – definition of cases (AA) and controls (HC) 
Inclusion criteria for asthmatic children comprised typical asthma symptoms of wheezing, whistling in 
the chest, cough or shortness of breath triggered by allergens, exercise or infection at several time 
points (at least 3 episodes) during the last year AND/OR a doctor’s diagnosis of asthma AND/OR a 
history of asthma medication (such as inhaled b2-adrenergic receptor agonists, inhaled glucocorticoids 
or leukotriene receptor antagonists) AND/OR abnormal lung function tests, indicating significant 
variable airflow limitation (as described above)301. A clinical diagnosis of asthma was made according 
to the international GINA guidelines304 and the German „Nationale Versorgungs Leitlinie (NVL) 
Asthma“305. 
Children in this study were defined as allergic asthmatics (AA) based on the asthma criteria mentioned 
above, with pulmonary symptoms primarily triggered by allergens AND specific IgE levels ≥ 0.35 
IU/ml to any of the assessed allergens. Patients with symptoms of wheeze induced by physical exercise, 
respiratory tract infections, the common cold, or by cold air, but not upon allergen-exposure, and 
without objective measures of atopic sensitisation or allergy, were not included (‘non-allergic asthma’, 
n = 1; see Figure 10 in the results-section). 
Hay fever and atopic dermatitis were defined as having ever had a doctor’s diagnosis. Food allergy 
was defined as having distinct clinical symptoms of food allergy. 
 
Healthy children without any clinical symptoms of wheeze/asthma and allergic disease (e.g. sneezing, 
a runny or blocked nose, or itchy-watery eyes during pollen season) were included as healthy controls 
(HC). Within the group of HCs, those were classified as healthy farm-children (F-HC) that met the 
farming-criteria from the PASTURE/EFRAIM study (see below, 2.2.2.2.2).  
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Exclusion criteria for both AA and HC comprised any other diagnosis of acute infection, pulmonary, 
chronic, autoimmune or immunodeficiency disease. Current infections (i.e. within the last 14 days) 
were assessed by clinical examination and CRP levels. Children with a history of steroid-intake 
(including oral and inhaled glucocorticoids), or antibiotic or probiotic agents during the 14 days before 
blood withdrawal, were not included in the study. Likewise, children born preterm (defined as delivery 
at gestational age (GA) < 37 weeks) or with a birthweight below 2500 g were excluded. 
 
A final number of 43 samples was analysed, comprising 24 healthy children (HC) including non-farm 
(NF-HC, n = 19) and farm-children (F-HC, n = 5), and 19 patients with allergic asthma (AA). The 
number for single analyses, however, may differ slightly in some cases, due to technical issues and 
experimental specifics. 
2.2.2.2 PASTURE/EFRAIM study 
The Protection Against Allergy: Study in Rural Environments (PASTURE)/Mechanisms of Early 
Protective Exposures on Allergy Development (EFRAIM) study is a multinational prospective birth 
cohort study funded by the European Commission, which includes 1,133 farm-exposed and non-farm-
exposed children from rural environments in Germany, Austria, Switzerland, Finland and France296. 
Of these, one subgroup from the 4.5-year follow-up (n = 37 comprising German (n = 24) and Finnish 
(n = 13) children) and another from the 6-year follow-up (n = 63, with German (n = 24), Finnish (n = 
18) and French (n = 21) children) were selected for assessment in this work. The study was approved 
by the local research ethics committee of each country (Germany ethics number 02046, amendment 
2014; Austria E Nr. 401; Switzerland EKSG 021056; Finland 10/2008; France 07/448). 
2.2.2.2.1 Study design and follow-up* 
Pregnant women either from family-run livestock farms (these were assigned to the farm-group) or 
from the same rural areas but not living on a farm (the non-farming reference group)187 had been 
recruited between August 2002 and March 2005. Follow-up was performed from the third trimenon of 
pregnancy until the children’s age of 10.5 years, with a 16-year follow-up currently ongoing (10/2019). 
Comprehensive questionnaires were administered to the child’s mother at certain intervals (i.e. at the 
end of pregnancy, at birth and at the child’s age of 2 months, and 1, 1.5, 2, 3, 4, 5, 6 and 10.5 years), 
assessing details on farm characteristics, farm-related exposures, and the prevalence of allergic or 
asthma symptoms and diagnoses. Questionnaires further contained information on lifestyle factors 
such as nutrition, breastfeeding and maternal smoking, as well as family characteristics, socioeconomic 
status and family history of atopy. Items were largely derived from the earlier ALlergy and EndotoXin 
study (ALEX)109 and the Prevention of Allergy:  Risk Factors for Sensitization In Children Related  to 
———————— 
* Not performed by the author. See explanations above (2.2.1) 
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Farming and Anthroposophic Lifestyle (PARSIFAL) study111 as well as from the Asthma Multicenter 
Infants Cohort Study (AMICS)306 and the American Thoracic Society questionnaire307. Written 
informed consent was obtained from all parents.  
Blood sampling and clinical examination was performed during clinical visits at birth, and at 1, 4.5 and 
6 years of age187. A total of 628 children participated in blood sampling at 4.5 and 6 years308. Specific 
IgE for common inhalant and food allergens was measured in serum samples (Allergy Screen test panel 
for atopy; Mediwiss Analytic, Moers, Germany). The 13 inhalant allergens comprised 
dermatophagoides pteronyssinus, dermatophagoides farinae, cat, horse and dog epithelium, Alternaria 
species, mugwort, plantain, alder, birch, hazel, rye pollen and grass pollen mix. The 6 food allergens 
included hen’s egg, cow’s milk, peanut, hazelnut, carrot, and wheat flour187. Positive atopic 
sensitisation against seasonal, perennial or food allergens was defined by using the cut-off for specific 
IgE of 0.7 IU/ml or greater (i.e. specific IgE class (SCI) 2).  
2.2.2.2.2 Definition of farm exposures and allergic disease outcomes 
Children born to women living on a farm run by the family were defined as farm children (F), while 
children with mothers from the same rural areas but not living on a farm were assigned to the non-farm 
(NF) reference group296. Farming was characterised by traditional farming practices such as milking, 
feeding animals, removing dung, cleaning animal sheds and placing litter, among others. Detailed 
information on timing, frequency, and intensity of exposure to hay barns, stables, farm and pet animals 
and consumption of farm milk were assessed annually by means of questionnaires in both groups. 
Data on farm exposures presented in this thesis (Table 12) refer to the children’s first, second, third, 
fourth, fifth, and sixth years of life, with ‘regular’ exposure defined as at least once per week. An 
exposure of ‘farm milk consumption’ was indicated if children drank cow’s milk directly from a 
farm187. Contact with hay refers to any exposure to hay, such as by playing in the hay187. Contact with 
cows was defined as contact to (dairy) cattle or their calves during the fourth, fifth or sixth year of life 
(comparable variable not available for years 1-3). Exposures to animal stables and barns were defined 
as spending time in a stable or barn, respectively. Exposure time was assessed continuously in days per 
week and hours per day for farm-children, or hours per month for non-farm children, respectively, and 
respective exposure variables were dichotomised (yes/no) subsequently175. A single contact to a stable 
or barn was therefore sufficient to assign a child to the exposure category ‘stay in stable/barn’187. 
 
Asthma was defined as at least one parent-reported physician’s diagnosis of asthma OR recurrent 
diagnoses of spastic, obstructive, or asthmatic bronchitis187, assessed at the age of 6, when the clinical 
phenotype of asthma is rather stable10. The great majority of asthmatic children selected for the present 
study were allergic asthmatics, with a specific IgE level ≥ 0.7 IU/ml in RAST.  
Hay fever was defined as having ever had nasal symptoms such as sneezing or a runny nose, 
independent of upper respiratory tract infections, together with itchy or watery eyes OR a doctor’s 
diagnosis of hay fever reported by the parents at the child’s age of 4 and 6 years, respectively. Atopic 
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dermatitis and food allergy ‘ever’ were defined as a doctor’s diagnosis reported in year 1 or annually 
till year 4 or 6, respectively.  
 
The two populations selected for this work were enriched for asthmatic children among available 
samples of the whole PASTURE/EFRAIM cohort at ages 4.5 and 6 years and balanced for farming 
status (18 F vs. 19 NF at age 4.5 years and 32 F vs. 31 NF at age 6, respectively). F and NF children 
were equally distributed in terms of gender as well as asthma and allergic disease status. 
2.2.3 Farm dust samples 
2.2.3.1 Dust collection and extraction* 
Environmental dust samples that were used for PBMC stimulation in this project had been acquired 
from distinct rural environments in Germany (G), Finland (Fi), and China (Ch) within the 
TRILATERALb multi-centre project. Dust samples were also collected from barns of the Amish people 
(Am), a traditional farming population living in the U.S.309. Amish dust samples were collected in 
Middlebury, Indiana, USA by scraping from the walls in a cowshed. Settled airborne dust from G, Fi 
and Ch was collected with ‘Electrostatic Dustfall Collectors’ (EDCs), an effective and reliable method 
that has been validated in different farming environments310,311. EDCs are passive dust sampling 
devices consisting of a plastic folder containing electrostatic cloths which are exposed to the air. In 
2013 and 2014, EDCs had been deployed on traditional farms in Icking, Bavaria, Germany (G; ID 
PB838), in Kitee, Finland (Fi; ID TN01), and in rural Conghua, China (Ch; ID CH_5109), respectively, 
for a 4-week period312. In Conghua, China, EDCs were placed in living rooms, whereas both German 
and Finnish dust was collected in cowsheds from dairy farms. Date and time of EDC placement, as 
well as position of the folders in the room were documented in detail. Cloths from EDCs were 
immediately stored at -80°C after sampling and shipped to Munich for further processing. 
Preparation of aqueous dust extracts used in PBMC stimulation experiments was performed by Dr. P. 
C. Schröder, a former member of the research group. Dust was extracted from the cloths according to 
the method of cold sodium chloride extraction, established by Prof. Dr. Otto Holst (research centre 
Borstel, Germany)313. In brief, dust from cloths was dissolved in NaCl, 9% conc., in a sterile, pyrogen-
free glass container and stirred for 6 hours. The solution was centrifuged for 30 minutes at 10,000 rpm, 
4°C, and supernatant was desalinated by dialysis technique. Then, vacuum sterile filtration was 
performed, and dry extracts were obtained from dust-filtrates, using Freeze Dryer Lyovac® GT (GEA). 
Dried and processed dust from four cloths was pooled for each of the samples (G, Fi, Ch), stored at 
room temperature and protected from light and moisture. For cell culture experiments, dust extracts 
———————— 
*  Not performed by the author. See explanations above (2.2.1) 
b TRILATERAL is a multi-centre project between collaborating research groups from Kuopio (Finland), Hong Kong,   
  Guangzhou (China) and from Munich (Germany). Funded by the German Research Foundation (DFG), SCHA-997/3-1. 
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were resuspended in sterile PBS to a stock solution of 1mg/ml weight per volume (w/v) concentration 
and mixed 5 minutes before use for sample suspension and homogenisation. 
2.2.3.2 Assessment of endotoxin levels in farm dust samples 
Endotoxin concentration was measured in the German, Finnish and Chinese farm dust extracts using 
the endpoint chromogenic Limulus Amoebocyte Lysate (LAL) assay (QCL-1000™, Lonza), as 
described in previous studies314. Due to logistic reasons, the Amish dust sample was not measured. The 
assay was performed according to the manufacturer’s instructions. Only pyrogen-free borosilicate glass 
tubes (Lonza) and accessory materials that have been qualified for endotoxin testing were used in the 
assay. ß-1,3-Glucan-blocker (Lonza) was applied to reduce false positive assay results caused by yeast 
or cellulose-containing residues in the dust extracts. In order to evaluate product inhibition, an aliquot 
of every dust sample was spiked with endotoxin of a known concentration (1.0 EU/ml). The spiked 
solution was assayed along with the unspiked samples, and the difference between their determined 
endotoxin concentrations was supposed to equal the known concentration of the spike ± 25%. A 
standard curve was generated using dilutions of endotoxin standards (Escherichia coli serotype 
O111:B4, Lonza) from 1.0 to 0.1 EU/ml. All dust samples and standards were run in duplicates. The 
assay was performed in a 96-well microplate format and kept at a constant temperature of 37°C during 
all steps. Standards and samples were analysed at a wavelength of 405 nm using the microplate reader 
SynergyTM running Gen5TM software (BioTek). Endotoxin concentrations of the samples were 
determined from their absorbance values based on the standard curve. Results are expressed as 
endotoxin units per millilitre of aqueous dust extract (EU/ml). 
2.2.4 PBMC isolation and stimulation 
Whole blood from sodium heparin collection tubes (Vacutainer®, BD) was used for cell isolation and 
culture experiments. Blood samples of poor quality (i.e. haemolytic blood) or with insufficient cell 
count (< 15 x 106 cells) due to low total blood volume were excluded from final analyses (‘technical 
exclusion’ (n = 4), see Figure 10 in the results-section). 
Blood was processed within a 6- to maximum 24-hour-interval after blood withdrawal. Peripheral 
blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation. Whole blood was 
diluted 2:1 with phosphate-buffered saline (PBS, Thermo Fisher Scientific, Gibco™), and equal parts 
(5-8 ml) were aliquoted in LeucoSep™ tubes (Greiner Bio-One) filled with 3 ml of PBMC-separation 
medium Ficoll-Paque™ PLUS (GE Healthcare). Tubes were centrifuged at 1,400 x g for 10 minutes 
at 20°C, acceleration 9, deceleration 0 (no brake). PBMC layer was carefully transferred to 15 ml 
conical tubes using a sterile Pasteur pipette. RPMI 1640 cell culture medium (Thermo Fisher Scientific, 
Gibco™) was added to the cells up to a total volume of 14 ml, and the cell-medium suspension was 
centrifuged again at 1,100 x g for 10 minutes, at 20°C, accel 9, decel 9. Supernatant was decanted and 
cell pellet resuspended and homogenised softly in a final volume of 10 ml of RPMI 1640.  
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Red blood cell (RBC) lysis was performed in a 50 µl aliquot used for cell counting. Therefore, 50 µl 
of ACK Lysing Buffer (Lonza) was added to the 50 µl sample aliquot, and cells were incubated on ice 
for 7 minutes. 50 µl of trypan blue solution 0.4% (Sigma-Aldrich) was added, and the sample was 
mixed well. 10 µl of cell suspension was transferred into a Neubauer counting chamber (Karl Hecht, 
Assistent®), and PBMC count was assessed.  
Total cells in RPMI medium suspension were pelleted by centrifugation at 1,100 x g for 10 minutes at 
20°C, and supernatant was discarded. PBMCs were diluted to a concentration of 5 x 106 cells/ml by 
adding the appropriate volume of X-VIVOTM 15 cell medium (Lonza). 
A number of 2.5 x 106 cells per well were cultured in a 24-well plate format (Corning) in X-VIVOTM 
for 24 hours at 37°C, 5% CO2 either without stimulation (unstimulated U) or following stimulation 
with lipopolysaccharide (LPS, from E.coli-O111:B4) at a final concentration (f.c.) of 0.1 μg/ml, or 
with farm dust extracts (f.c. 40 μg/ml) from Germany (G), Finland (Fi), China (Ch) and from the Amish 
population (Am). LPS concentration had been selected based on previous findings from farming 
studies175,187,308. Concentration for farm dust stimulation was derived from preliminary experiments in 
which ideal conditions had been tested for the experimental setup of this project. 
Harvested cells were split in two parts. One fifth was used for protein extraction for subsequent Western 
Blot analyses (0.5 x 106 cells at least), the remaining cells were used to isolate mRNA for gene 
expression studies. Supernatants were collected, and 110 μl aliquots were immediately frozen at -80°C 
for use in cytokine studies. 
 
Blood samples from the 4.5- and 6-year-old PASTURE/EFRAIM children were processed as described 
previously187, using a standardised protocol at the local study centres. In brief, heparinised whole blood 
was diluted with RPMI medium supplemented with 10% human serum (Sigma-Aldrich) to a final 
concentration of 5 x 106 cells/ml and incubated for 24 hours at 37°C, 5% CO2 unstimulated (U) or 
stimulated with 0.1 μg/ml LPS. For the present study, frozen samples were analysed. 
2.2.5 Cell lysis for RNA and protein extraction 
A total number of 2.0 x 106 cultured cells were harvested after 24 hours incubation and centrifuged at 
1,100 x g for 10 minutes at 20°C. Supernatants were collected and stored, and remaining cell pellet 
was resuspended in 1 ml PBS. Cells were pelleted by centrifugation at 1,100 x g for 10 minutes at 
20°C, and supernatant was aspirated and discarded. Cells in pellet were disrupted properly and 
homogenised in 350 µl of buffer RLT (Qiagen) plus 1% (v/v) 2-mercaptoethanol (β-ME). Lysates were 
stored at -80°C until use. 
 
Cells for subsequent protein expression studies in Western Blot were pelleted by spinning at 3,700 x g 
for 10 minutes at 4°C. Supernatant was aspirated and discarded, and cell pellets were lysed in 100 μl 
of ice cold radioimmunoprecipitation assay (RIPA) lysis buffer plus freshly added protease inhibitor 
cocktail (cOmpleteTM Mini, Roche). Samples were incubated on ice for 30 minutes and mixed by 
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repeated flicking of the tubes. To pellet the cell debris, lysates were centrifuged at 20,200 x g for 15 
minutes at 4°C. Cell lysate supernatant was quickly collected, aliquoted and stored at -80°C. Pellet was 
discarded. Cells and lysates were kept on ice during all steps. 
2.2.6 RNA extraction and cDNA synthesis 
Total RNA of PBMCs was purified using the RNeasy® Mini Kit (Qiagen) according to the 
manufacturer’s instructions. Frozen cell lysates were thawed, 1 volume (350 µl) of 70% ethanol was 
added, and suspension was mixed well by vigorous pipetting. Lysates were transferred onto silica-
membrane coated RNeasy® spin columns that had been placed into a 2 ml collection tube. Tubes were 
centrifuged at 8,000 x g for 15 seconds at 20°C, and flow-through was decanted. In order to eliminate 
all contaminants effectively from the spin column membrane, a number of centrifugation steps (8,000 
x g, 15 seconds, at 20°C) were performed after addition of washing buffers RW1 and RPE (Qiagen), 
and flow through was decanted after each centrifugation. Steps were performed very carefully in order 
to avoid carryover of ethanol. Spin columns were placed in a new 2 ml collection tube and centrifuged 
at full speed for 1 minute, then transferred to a fresh 1.5 ml elution tube. Pure, concentrated sample 
RNA was eluted in 30 μl of RNase-free water during a last centrifugation step at 8,000 x g for 1 minute. 
 
RNA of whole blood samples from the PASTURE/EFRAIM cohort was extracted using QIAzol and 
chloroform.  
 
Sample RNA concentration was assayed with a Nanodrop 2000 spectrophotometer (Thermo Fisher 
Scientific). The absorbance of sample RNA was read at 260 nm. To rule out the presence of potential 
contaminants in the sample, the ratios of absorbance at 260 nm and 280 nm (A260/A280) as well as 
A260/A230 were determined. RNA purity was assumed for a A260/A280 value in the range of 2.0 to 
2.1 and a A260/A230 value range of 2.0 to 2.2.  
 
1 μg of total sample RNA underwent cDNA synthesis, using QuantiTect® Reverse Transcription Kit 
(Qiagen). RT reaction was run on PCR Thermocycler PeqSTAR 96 universal (Peqlab 
Biotechnologies). All reactions were set on ice to minimise the risk of RNA degradation. Genomic 
DNA (gDNA) wipe-out buffer, RNase-free water and RNA sample were combined in 0.2 ml tubes. 
Samples were incubated at 42°C for 2 minutes to eliminate gDNA residues. A master mix containing 
the reverse transcriptase enzyme, RT buffer, and a RT primer mix was prepared and distributed to the 
individual tubes, resulting in a total reaction volume of 20 µl. All components were mixed, and the 
tubes were centrifuged briefly. RT reaction was run at 42°C for 15 minutes, followed by an enzyme 
inactivation step at 95°C for 3 minutes. cDNA samples of a final concentration of 50 ng/µl were 
obtained and stored immediately upon receipt at -20°C for subsequent gene expression studies. 
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2.2.7 Gene expression analysis 
2.2.7.1 Primer design 
mRNA-specific oligonucleotide primers (forward/reverse) that were used for gene expression analysis 
in quantitative real-time PCR (qPCR) were designed using Vector NTI 10 Advance 11.5 program 
(Thermo Fisher Scientific, invitrogen™), and Primer-BLAST designing tool, provided by the National 
Center for Biotechnology Information (NCBI), Bethesda MD, USA315. PCR templates were based on 
DNA sequences listed in the genome database Ensembl316.  
Quality criteria regarding forward (fw) and reverse (rv) primer sequences for use in qPCR were as 
follows: Primer length between 18 and 27 base pairs for good specifity and binding abilities, obligatory 
primer location behind the gene’s ATG sequence, at least one guanine or cytosine at the 3’ end, 40-
60% of guanine and cytosine with no more than 10% difference between fw and rv primer, primer 
melting temperature (Tm) ranging between 54°C and 65°C with compatible Tm values of fw and rv 
primer (maximum of 0.5°C difference), primer-dimer- or hairpin-building energy lower than ± 2 
kcal/mol for good annealing efficiency, generated PCR product (amplicon) size of a maximum of 200 
base pairs, and – if possible – at least one primer to span an exon-exon junction site, and primer pair 
to be separated by at least one intron of great size to avoid amplification of gDNA residues. 
 
Primers were ordered from Thermo Fisher Scientific, invitrogen™, and were diluted in nuclease-free 
water (Qiagen) to a stock of 1 mM concentration. A 1 μM dilution containing both fw and rv primers 
was obtained after an intermediate step of a 0.1 mM dilution. 0.1 mM primer stock was stored at -20°C, 
1 μM primers were kept at +4°C for use in qPCR. Diluted primers underwent quality and specifity 
testing to ensure efficiency of reactions and avoid mispriming events. Optimal concentrations for 
primers in the qPCR setup were determined. Thorough melting curve analysis was performed to 
exclude primers with amplification of unintended mRNA, gDNA or RNA targets (see also 2.2.7.3). 
Primer sequences for the targets investigated in this work are listed in 2.1.7. 
2.2.7.2 Quantitative real-time PCR 
mRNA expression of the selected target genes (TLR4, MyD88, TRAF6, TNFAIP3, TNIP2, TAX1BP1, 
MALT1, CD80, CD86, CD274, PDCD1) was assessed in the samples by quantitative real-time PCR 
(qPCR). 18S-ribosomal-RNA (rRNA) was used as an endogenous reference gene in all experiments. 
In a 96-well format (skirted PCR plates, low-profile, Hard-Shell®, Bio-Rad), all reaction components 
were combined to a final volume of 10 μl per well. The qPCR reaction setup used for the assays in this 
project is shown in Table 1. All reagents and samples were processed on ice and briefly mixed and 
centrifuged just before assembling the reactions. Mastermix (SsoAdvanced™ Universal SYBR® 
Green Supermix, Bio-Rad) containing a thermostable Sso7d fusion polymerase, dNTPs, MgCl2, and 
SYBR® Green I dye was mixed thoroughly and equal aliquots of 5 µl dispensed into the wells of the 
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PCR plate. 1.8 μl of cDNA mix containing cDNA template and nuclease-free water was added, 
followed by 3.2 μl of 1 μM sequence-specific primers (fw and rv). For ‘no-template-controls’ (NTC), 
cDNA-template was replaced by an equal amount of nuclease-free water. Thorough mixing of the 
reaction components was ensured. After the pipetting process, the PCR plate was sealed with optically 
transparent film (Microseal®, Bio-Rad) and centrifuged at 500 x g for 15 seconds to spin down droplets 
and eliminate any air bubbles in the wells. qPCR was started, and reactions were run on the CFX96 
TouchTM Real-time PCR Detection System (Bio-Rad) according to the thermal cycling protocol 
depicted in Table 2. Data was processed and analysed by Bio-Rad CFX Manager™ software version 
2.1.  
 
Table 1. qPCR reaction setup. 
 
  
Table 2. qPCR thermal cycling protocol. 
 
 
Amplification of gene-specific PCR products was monitored during 40 cycles by measuring the 
increase in fluorescence signal caused by binding of SYBR® Green to double-stranded DNA (dsDNA). 
Baseline fluorescence signal for SYBR® Green was automatically determined by the software and 
used for threshold setting. The cycle threshold (Ct) value describes the number of cycles in a given 




SsoAdvanced™ Universal SYBR® Green Supermix (2x) 5 µl 1x 
Forward and reverse primers 3.2 µl 160 nM each 
cDNA template (50 ng/µl) 0.12 µl 0.6 ng/µl 
Nuclease-free H2O 1.68 µl --  
Total reaction mix volume 10 µl -- 
Step Times repeated Temperature Time 
Cycle 1 1x  2 min 
   Initial denaturation  95.0°C  
Cycle 2 40x   
   Denaturation  95.0°C 20 sec 
   Annealing + Elongation  62.5°C 30 sec 
Cycle 3 1x  2 min 
   Elongation  72.0°C  
Cycle 4 1x 95.0°C 30 sec 
Cycle 5 1x 55.0°C 30 sec 
Cycle 6 80x 55.0°C 5 sec 
Cycle 7 1x 20.0°C HOLD 
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amplification reaction, at which the fluorescence signal significantly exceeds the background 
fluorescence. It is assessed at the early exponential phase of amplification (Figure 8). During this 
phase, the reaction is most effective and precise, with the amount of PCR product doubling at each 
cycle. Since fewer PCR cycles are required for high amounts of starting template to be amplified and 
detected over the background signal, a lower Ct value is associated with a higher initial amount of 
template in the reaction. Individual Ct values in this work were normalised to 18S, which was used as 
reference gene. Data of the presented target genes (T) are reported as DCt values; ΔCt (T) = Ct (T) - Ct (18S) 



























2.2.7.3 qPCR assay optimisation and validation 
In accordance with the MIQE guidelines for qPCR experiments317, all relevant experimental conditions 
and assay characteristics were optimised prior to starting the project and evaluated throughout the 
whole process in order to generate reliable qPCR data allowing accurate and precise quantification of 
target gene expression. 
 
Sample quality control was ensured during RNA extraction and reverse transcription steps, as described 
above (2.2.6). Primer characteristics and concentrations were optimised (see 2.2.7.1) and ideal cDNA 
template concentrations were assessed. To ensure reproducibility, all reactions were processed under 
Figure 8. Graphical representation of qPCR data. Exemplary reaction amplification plot. 
Relative fluorescence units (RFU) are plotted against qPCR cycle number. Threshold line is 
set automatically above the baseline fluorescence signal (green horizontal line) in the early 
exponential phase of the plot. Ct (threshold cycle) value is determined at the intersection 
between the amplification curve and the threshold line. The different amplification curves in 
this chart represent data from different samples and their duplicates. 
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equal conditions including assay reagents, equipment and accessory items, and thermal-cycling 
protocol settings.  
Good pipetting practice was employed in advance to achieve maximum assay accuracy. All samples 
and controls were run in duplicates and standard deviation measures were determined. A Ct difference 
between duplicates of greater than 0.4 was set as cut-off to rule out values and repeat the sample. 
Samples with a Ct value below the detection limit (i.e. 40 PCR cycles) were excluded. No-template-
controls (NTC) were included in every reaction setup to identify potential contamination or primer-
dimer formation. Specificity of the reactions and reliability of the obtained signals was further 
evaluated by melting curve analysis assessing the presence of nonspecific products. A melting curve 
(Figure 9) charts the sudden change in fluorescence signal observed when double-stranded DNA 
(dsDNA) bound with SYBR® Green dye dissociates into single-stranded DNA (ssDNA) at a certain 
melting temperature (Tm). Since different properties of nucleic acids (such as length, GC content among 
others) result in modified melting characteristics, different PCR products can be distinguished by their 
specific melting temperature.  
For reliable quantitative gene expression analysis, 18S rRNA was validated as a reference control gene. 
It has shown to maintain stability of expression across samples regardless of treatment or clinical 




















Figure 9. Exemplary representation of melting curve analysis showing off-target amplicons. 
The negative first derivative of the change in relative fluorescence (-d(RFU)/dT) is plotted as a 
function of temperature to obtain a clear view of the melting dynamics. In this case, additional 
peaks (red and blue plots) are detected to the right of the target product-specific melting peaks at 
82.5°C (green plots), indicating the presence of off-target products. 
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2.2.8 SDS-PAGE and Western Blot analysis 
TNFAIP3 protein expression was assessed by Western Blot analysis in a subsample of children. 
Western blotting was performed with kind collaboration of Professor Christoph Klein’s lab and 
members, providing technical support and facilities at the Comprehensive Childhood Research Centre, 
Dr. von Hauner Children’s Hospital, Munich. 
The final protocol for this project has been established by the author herself after various preliminary 
experiments in accordance with recognised standardisation procedures318. All assay components and 
steps were extensively evaluated and optimised in advance, involving tests for ideal protein sample 
amount, gel type, appropriate primary and secondary antibody dilutions, incubation times, washing 
buffers for dilution and antibody incubation, and validation of the reference protein b-Actin against 
GAPDH. 
2.2.8.1 Gel casting 
15-well SDS 10%-gels of 1.5 mm thickness were hand-casted directly before use (Table 3), employing 
gel casting systems from Bio-Rad. For the separating monomer solution, diH2O, SDS 20% (Carl Roth), 
acrylamide/bis-solution 30% (Rotiphorese®, Carl Roth) and 1.5 M Tris pH 8.8 were combined. 
Ammoniumperoxiddisulphate (APS, Carl Roth) and Tetramethylethylenediamine (TEMED, Carl 
Roth) were added for polymerisation, accurate mixing was ensured, and the separating solution was 
smoothly poured into the gel cassette. The solution was immediately overlaid with 1 ml of 2-propanol 
in order to prevent shrinkage at the interface with air. 2-propanol was decanted after 30 minutes, and 
the top of the solidified separating gel was dried with filter paper. Stacking monomer solution (diH2O, 
SDS 20%, acrylamide, 0.5 M Tris pH 6.8, and APS and TEMED) was prepared and poured on top of 
the separating gel. Gel comb was inserted, and SDS polyacrylamide gels were ready for electrophoresis 
(SDS-PAGE) after solidification.  
 
 










separating gel 10% stacking gel 
  40 ml         
diH₂O 16.0 ml 
 
8.0 ml 
1.5 M Tris (pH 8.8) 10.0 ml 0.5 M Tris (pH 6.8) 1440.0 µl 
20% SDS 200.0 µl   57.5 µl 
30% Acrylamide mix 13.3 ml 
 
1950.0 µl 
10% APS 400.0 µl 
 
150.0 µl 
TEMED 16.0 µl 
 
11.5 µl 
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2.2.8.2 Protein quantification  
Total protein content of sample cell lysates (2.2.5) was determined by Bradford protein quantification 
assay. Bradford staining solution with Coomassie Brilliant Blue Dye G250 (Roti®-Quant. 5X, Carl 
Roth) was used. Bovine serum albumin (BSA, heat shock fraction, Sigma-Aldrich) was used as 
calibrating standard protein, and serial dilutions were performed. In a 96-well microplate format, 200 
µl of sterile filtered Bradford solution (diluted 1:2.75) was added to 50 µl of BSA-standards and diluted 
samples (1:40 in diH2O). Plate was incubated for 5 minutes at room temperature. Standards, samples 
and blanks (negative controls) were analysed for absorbance at 595 nm wavelength, using Synergy H1 
microplate reader running Gen5™ software (BioTek). Sample protein concentrations were determined 
by interpolation from a 10-point BSA-standard-curve (2.2.9). Quantification accuracy was ensured by 
a coefficient of determination R2 > 0.98 for all calibrating standard curves. All standards, samples and 
blanks were run in duplicates, and values with a coefficient of variation (C.V.) absorbance of greater 
than 10% were excluded.  
2.2.8.3 Sample preparation and SDS-PAGE gel electrophoresis 
Protein concentration was normalised across samples in order to obtain equal amounts of protein 
samples to be loaded on one gel (40 μg to 55 μg). Determined volume of protein sample was combined 
with 7 µl of 5X Laemmli sample buffer (including bromphenolblue as loading dye and 3% 2-
mercaptoethanol). Appropriate volume of 1X running buffer was added up to a total volume of 35 µl. 
Samples were boiled at 95°C for 10 minutes, centrifuged, and cooled on ice. Electrophoresis chamber 
(Bio-Rad) was assembled, casted gels were inserted, and chamber filled with 1X running buffer. 6 µl 
of PageRuler™ Prestained Protein Ladder (10 to 180 kDa, Thermo Fisher Scientific) and 35 µl samples 
were loaded onto the wells of the SDS-polyacrylamide gel. Gel electrophoresis was run at 80V for 10 
minutes until protein was condensed to a flat front, then 120V was applied for 110 minutes.  
2.2.8.4 Protein transfer  
Separated proteins were transferred to a PVDF membrane (Roti®, 0.45 µm pore size, Carl Roth). 
Therefore, the gel was removed from the electrophoresis rack and incubated in 1X transfer buffer for 
5 minutes. For improved transfer and protein binding, PVDF membrane was soaked in methanol for 2 
minutes. Blotting sandwich comprising foam pads, Whatman filter papers, gel and transfer membrane 
was assembled in 1X transfer buffer, and the sandwich holder cassette was placed into the transfer 
chamber. Cooling unit and 1X transfer buffer were added. Protein transfer was performed at 400 mA 
for 90 minutes, 4°C using the wet tank blotting system Mini Trans-Blot® Cell (Bio-Rad). 
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2.2.8.5 Membrane blocking and antibody staining 
After transfer, the blotted membrane was blocked in low-fat dry milk 5% (w/v) in 1X tris buffered 
saline (TBS) supplemented with 0.1% (v/v) Tween-20 (1X TBS-T), with gentle agitation for one hour 
at room temperature. Membranes were probed with primary antibody against A20/TNFAIP3 (#4625, 
Cell Signaling Technology), at 1:300 dilution in BSA 5% (w/v), 1X TBS-T, at 4°C with gentle agitation 
overnight. After subsequent washing steps (three times for 7 minutes each in 1X TBS-T), the 
membrane was incubated with Horseradish-peroxidase-conjugated goat anti-rabbit IgG (#7074, Cell 
Signaling Technology) at 1:1000 dilution in milk 5%, 1X TBS-T with gentle agitation for one hour at 
room temperature.  
ß-actin was used as loading control. The membrane was incubated with HRP-linked antibody against 
ß-actin (sc-47778 HRP, Santa Cruz Biotechnologies), diluted 1:3000 in milk 5%, 1X TBS-T, with 
gentle agitation for one hour at room temperature. 
2.2.8.6 Detection and imaging 
Antibodies were discarded and membrane was washed another three times for 7 minutes each in 1X 
TBS-T. Enhanced chemiluminescence (ECL)-HRP substrate SuperSignal™ West Dura (Thermo 
Fisher Scientific) was used for protein detection. Equal volumes of Luminol solution and buffered 
hydrogen peroxide solution were combined to a substrate working solution. The membrane was 
incubated with the substrate solution for 5 minutes, while ensuring constant wetting of the membrane 
and limiting exposure to light. Chemiluminescence was visualised by CCD imaging system 
ChemiDoc™ MP (Bio-Rad) using Image Lab™ analytical software. Optimal exposure time was 
acquired for imaging to avoid band signal saturation and allow observation of minor variations in 
density. Detected protein bands were quantified using ImageJ Software (National Institutes of Health, 
Bethesda, USA). 
2.2.9 Statistical analyses c 
Entry of clinical data was done with SPSS for Windows Version 25. Statistical analyses were 
performed with GraphPad Prism 8 (GraphPad Software Inc.) and R software version 3.3.1. Results 
were considered statistically significant at an unadjusted p-value less than 0.05. Visualisation was 
performed using GraphPad Prism 8 software. 
 
Differences in population and clinical characteristics were assessed by chi-square (χ²) test for categorial 
data or by Mann-Whitney U test for continuous variables. Median was reported with interquartile range 
(IQR) for continuous data.  
———————— 
c For statistical analyses, the author was partly supported by the biostatistician of the research group. 
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Gene expression data derived from qPCR were analysed using comparative quantitation algorithms. 
Mean Ct values were calculated for all technical replicates in qPCR. For comparative analysis, ΔCt was 
calculated as the difference of mean Ct values between the target gene (T) and the reference control 
gene 18S for each individual sample (i.e. ID) and stimulating condition (mean ΔCt (T) = mean Ct (T) – 
mean Ct (18S)). Differences in target gene expression (ΔCt comparison) between phenotypes (AA vs. 
HC) or exposure groups (F vs. NF) were assessed by parametric Welch’s t test, not assuming equal 
standard deviations in the groups. For graphical representation, mRNA data were expressed as 2-ΔCt 
values and plotted in bar charts with means and 95% confidence interval (CI). Gene expression changes 
upon stimulation were reported as fold change (fc) of expression compared to the unstimulated 
condition, expressed as 2-ΔΔCt (T). Using the ΔΔCt method, mRNA expression data from stimulated 
samples (s) were compared with both the unstimulated condition (u) and the reference gene 18S (ΔΔCt 
(T) = ΔCt (T, s) – ΔCt (T, u)). ΔΔCt scale (log2 fold change) was used for statistical calculations as well as 
plotting purposes. Statistical significance of stimulation effects was assessed by paired t test. 
 
Gene correlation analysis was performed using nonparametric spearman correlation.  
 
Concentrations of endotoxin in farm dust samples as well as protein in sample cell lysates were 
quantified by interpolation from linear standard curves. Linear regression analysis was applied to 
define the function of the standard curves based on absorbance measures of standard samples at given 
concentrations. 
 
Protein expression assessed in Western Blot was quantified by densitometric measurement using 
ImageJ Software (National Institutes of Health). Absolute density values from both target (TNFAIP3) 
and reference control (b-actin) protein bands were normalised within an individual sample (i.e. across 
stimulating conditions of a single sample ID). Therefore, each band’s density value was divided by that 
of the band with the highest value in the respective sample. Relative TNFAIP3 expression was defined 
as the ratio of normalised TNFAIP3 protein expression related to the normalised expression of b-actin, 
expressed as arbitrary units (A.U.) and displayed as mean values with 95% CI. Differences in protein 
expression between phenotypes were assessed by Welch’s t test, and significance of stimulating effects 
was determined using paired t test.  
 
Due to the exploratory nature of the study, with the principal objective of pattern detection, no 
adjustment for multiple testing was applied, and results should therefore be interpreted in a descriptive 
manner.




3.1 Immune regulation in school-aged children with allergic asthma  
3.1.1 CLARA/CLAUS study population 
3.1.1.1 Enrolment of allergic asthmatic (AA) and healthy control (HC) children 
In order to study immune regulation of steroid-naive children with allergic asthma (hereinafter ‘AA’) 
as compared to their healthy peers (‘healthy controls’, HC), a new study population was recruited for 
this work. A total of 48 children, aged 4 to 14 years, were enrolled within the CLARA/CLAUS294 
project. All study participants underwent clinical examination, blood was taken from a peripheral vein, 
and parents were asked to complete a detailed questionnaire. A doctor’s diagnosis, as well as 
questionnaire-data, clinical assessment, blood parameters and lung function testing were employed for 
the definition of cases (AA) and controls (HC). A number of 4 samples were excluded from the 
analyses for technical reasons. One child with the phenotype of non-allergic asthma (n = 1) was 
excluded, resulting in a final number of 43 samples with complete epidemiologic and immunologic 
data to be investigated (Figure 10). Findings that were reported in this work comprise data from 19 




















Figure 10. Enrolment flow chart CLARA/CLAUS study subsample. 
After exclusion of samples, complete epidemiologic and immunologic data were available for a final 
number of 43 4-14-year-old children. n, number of cases; HC, healthy controls; NF-HC, healthy 
non-farm children; F-HC, healthy farm children; AA, steroid-naive patients with allergic asthma. 
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It is noteworthy that for additional immunological studies in farm children (see 3.3), a subsample of 5 
healthy children born and raised in a farming environment (hereinafter farm children, ‘F-HC’ - as 
opposed to healthy non-farm children, ‘NF-HC’, see Figure 10) was recruited.  
The enrolment process as well as inclusion and exclusion criteria for participants were described in 
detail in the methods section 2.2.2.1 of this thesis.  
3.1.1.2 Epidemiological and clinical characteristics of the study population 
Based on the data derived from questionnaires, medical examination and from blood and lung function 
tests, the two study groups (HC and AA) were further characterised (Tables 4-7).  
 
Demographic data and family characteristics of the study population were described in Table 4. 
Healthy controls (n = 24) and allergic asthma patients (n = 19) showed no significant differences in 
distribution of age and body-mass-index. Gender-distribution, however, was slightly unbalanced 
between the groups, with lower female proportions in the group of children with allergic asthma (36.8% 
vs. 58.3% female children). As differences in childhood asthma prevalence are known to be gender-
related, analyses stratified for gender were conducted, but did not reveal different findings.  
Analysed questionnaire-data provided information about the children’s atopic conditions, namely hay 
fever, atopic dermatitis and food allergy as well as about parental history of atopy and asthma, 
socioeconomic status, number of siblings, and parental indoor smoking habits, among others. AA and 
HC differed significantly in all three atopic diseases with considerably higher proportions in patients 
with allergic asthma (p £ 0.002; Table 4). The two groups did not differ significantly regarding the 
number of older siblings and indoor smoking at home. 
It is noteworthy that maternal asthma and hay fever in particular were reported more often in the AA 
compared to the HC group (p = 0.04 and p = 0.0007, respectively). This was not seen for paternal 
atopy. Likewise, higher parental educational qualification was observed among AA children, with 
significant differences for maternal education (p = 0.0007). Despite potential confounding effects of 
maternal atopy319,320 and high educational level, the limited sample size in the study groups did not 
allow for valid confounding analyses. Thus, only unadjusted data were presented within this work.  
 
Neither AA nor HC displayed positive markers of ongoing or recent infection, as indicated by low 
levels of C-reactive protein (CRP) and normal white blood cell count (WBC) (Table 5). Neutrophils, 
lymphocyte and monocyte proportions of WBC did not differ between the groups and were within 
normal range.  
 
Children with allergic asthma demonstrated typical clinical characteristics of allergic disease. 
Eosinophil count (Table 5) and serum levels of both total and specific IgE (Table 6) were found to be 
elevated in AA and significantly increased compared to the healthy reference group.  
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Table 4. Demographic data and socioeconomic characteristics of the study population. 
 
HC, healthy controls; AA, patients with allergic asthma; n, number of cases; %, percentage of group total; y, 
years; BMI, body-mass-index. Values for continuous variables represent median and interquartile range (IQR).  
P values reflect χ² test for proportions, or the Mann-Whitney U test (†) for continuous variables, respectively. 
Tests were applied for non-missing data. *p < 0.05 (boldface). Total number of subjects might differ slightly for 












Parameter HC AA P value 
n 24 19  
Female sex, n (%) 14 (58.3) 7 (36.8) 0.16 
Age (y), median 
(IQR) 
10.7 
(10.4 – 12.6) 
10.5 
(9.3 – 11.4) 
0.35† 
BMI (kg/m2), median 
(IQR) 
17.4 
(15.9 – 21.5) 
17.3 
(15.6 – 20.0) 
0.54† 
Doctor’s diagnosis of hay fever (ever), n (%) 0 (0.0) 12 (63.2) < 0.0001* 
Doctor’s diagnosis of atopic dermatitis (ever), n (%) 0 (0.0) 11 (57.9) < 0.0001* 
Food allergy, n (%) 0 (0.0) 6 (31.6) 0.002* 
Older siblings, n (%) 13 (54.2) 6 (31.6) 0.14 
Smoking at home, n (%) 2 (8.3) 2 (10.5) 0.81 
Maternal diagnosis of asthma (ever), n (%) 0 (0.0) 3 (15.8) 0.04* 
Maternal diagnosis of hay fever (ever), n (%) 1 (4.2) 9 (47.4) 0.0007* 
Maternal diagnosis of atopic dermatitis (ever), n (%) 2 (8.3) 1 (5.3) 0.67 
Paternal diagnosis of asthma (ever), n (%) 4 (16.7) 3 (15.8) 0.95 
Paternal diagnosis of hay fever (ever), n (%) 8 (33.3) 3 (15.8) 0.19 
Paternal diagnosis of atopic dermatitis (ever), n (%) 0 (0.0) 2 (10.5) 0.09 
Maternal education   0.0007* 
Elementary or middle school, n (%) 13 (54.2) 1 (5.3)  
High school or university, n (%) 11 (45.8) 18 (94.7)  
Paternal education   0.06 
Elementary or middle school, n (%) 11 (45.8) 4 (21.1)  
High school or university, n (%) 11 (45.8) 15 (78.9)  
Missing/Other, n (%) 2 (8.3) 0 (0.0)  
         
 
48 
Table 5. Laboratory parameters of HC and AA. 
 
n, number of cases; CRP, C-reactive Protein; WBC, white blood cell count; Neutrophils, Lymphocytes, 
Monocytes, Eosinophils: percentage (%) of WBC. Values represent median and interquartile range (IQR).               
P values reflect the Mann-Whitney U test. Tests were applied for non-missing data. *p < 0.05 (boldface). Total 




Specific IgE levels were dichotomised at the detection limit of 0.35 IU/ml (i.e. SCI 1), and three 
categories of sensitisation were defined: Positive specific IgE to perennial allergens 
(dermatophagoides pteronyssinus, dermatophagoides farinae, cat epithelium, horse epithelium, dog 
epithelium, Alternaria alternata); positive IgE to seasonal allergens (birch pollen, hazel, grass pollen 
mix and mugwort, timothy grass, plantain); and positive IgE to food allergens (hazelnut, peanut, hen’s 
egg, cow’s milk, carrot, wheat flour, soybean). Most of the AA within this study (73.7% of total) were 
sensitised to perennial allergens. Four healthy subjects showed a positive specific IgE to a single 
allergen (Table 6) without any clinical symptoms of allergic disease. 
 
 
Table 6. Sensitisation to allergens in HC and AA. 
 
IU, international units; n, number of cases; %, percentage of group total. Total IgE values represent median and 
interquartile range (IQR). Specific IgE levels were dichotomised at the detection limit of 0.35 IU/ml. P values 
from Mann-Whitney U test (†) for continuous variables, or χ² test for proportions. *p < 0.05 (boldface).  
Parameter HC (n = 24) 
median  






(0.1 – 0.1) 
0.1 
(0.1 – 0.1) 
-- 
WBC (cells x 109/L) 
(IQR) 
5.95 
(4.93 – 7.75) 
6.80 





(37.5 – 52.0) 
41.0 





(35.5 – 48.8) 
40.0 





(7.0 – 8.3) 
8.0 





(1.8 – 5.0) 
9.0 
(6.0 – 10.0) 
0.0003* 
Parameter HC (n = 24) AA (n = 19) P value 
Total serum IgE (IU/ml), median 
(IQR) 
100.0 
(45.5 – 206.0) 
345.0 
(234.3 – 817.0) 
0.0003*† 
Specific IgE (≥ 0.35 IU/ml)    
to perennial allergens, n (%) 2 (8.3) 14 (73.7) < 0.0001* 
to seasonal allergens, n (%) 1 (4.2) 11 (57.9) < 0.0001* 
to food allergens, n (%) 1 (4.2) 5 (26.3) 0.04* 
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Children who met the criteria of asthma according to the GINA guidelines304, and had not taken steroids 
within the 14 days prior to blood withdrawal, were enrolled in the study. Lung function data of 
asthmatic children were depicted in Table 7. In the CLARA study population lung function parameters 
were shown to be within normal range in healthy control subjects294. In the specific subgroup presented 
in this work, lung function testing was not feasible due to logistic reasons. 
Asthmatic patients in this study presented features of expiratory airflow obstruction, as demonstrated 
by reduced forced expiratory volume in one second (FEV1) together with a reduced mean FEV1/FVC 
ratio as compared to predicted reference population values (adjusted for age, sex, height and ethnicity 
using the 2012 Global Lungs Initiative (GLI) equations303). Decreased values for mid-expiratory flow 
at 50% (MEF50, 75.6% predicted; Table 7) and especially at 25% of FVC (MEF25, 69.5% predicted) 
particularly demonstrate affection of the small airways in the asthmatic children. Negative z-score 
values for FEV1 before bronchodilation (zFEV1 pre, -0.88) and for FEV1/FVC (zFEV1/FVC, -1.11) in 
particular indicate asthmatic children’s impaired lung function performance as compared to the 
reference population. Z-scores define how many standard deviations the individual measured value is 
from the predicted mean. A positive z-score indicates an individual’s value above the population mean, 
while a negative z-score indicates a value below the mean. The majority of AA patients demonstrated 
positive reversibility testing, as illustrated by a significant mean increase in FEV1 of 18.5% after 
inhalation of rapid-acting bronchodilator (BD) salbutamol304. 
 
 
Table 7. Descriptive measures of lung function in AA. 
 
Lung function parameters from study patients with allergic asthma (n = 19), presented as mean values with 95% 
CI. Total number of subjects might differ slightly for some parameters due to data availability. 
Abbreviations:  FEV1 , forced expiratory volume in one second;  FVC, forced vital capacity; MEF50 / MEF25 , 
mid-expiratory flow rate at 50 % (or 25%, respectively) of FVC; z[…], z-score for specific parameter, 
dimensionless quantity; FEV1 pre , FEV1 before bronchodilation; FEV1 post , FEV1 after bronchodilation;                      
∆ FEV1 , FEV1 post - FEV1 pre  
 
 
Parameter  mean  95% CI  
FEV1 (% predicted)  89.5  (81.5    to 97.5)  
FEV1/FVC (% predicted)  90.4  (84.6    to 96.1)  
MEF50 (% predicted)  75.6  (61.3    to 90.0)  
MEF25 (% predicted)  69.5  (48.6    to 90.3)  
zFEV1/FVC pre  -1.11  (-1.73    to -0.50)  
zFEV1 pre  -0.88  (-1.56    to -0.20)  
zFEV1 post  -0.12  (-0.91    to 0.66)  
Bronchodilator response 
(∆ FEV1/ FEV1 pre) x 100 (%) 
 18.5 
 
(2.0    to   34.9) 
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The subgroup presented in this thesis was comparable to the CLARA/CLAUS cohort294 regarding 
distribution of sex, age, the number of older siblings, indoor smoking, breastfeeding, and parental atopy 
and asthma. Leukocyte proportions including eosinophils were found to be similar between the two 
cohorts. HC in the present study population had higher IgE-levels compared to HC of the whole cohort 
(data not shown). 
3.1.1.3 Differential baseline expression levels of target genes in PBMCs of study participants 
Baseline mRNA expression levels of TLR4, MyD88, TRAF6, TNFAIP3, TNIP2, TAX1BP1, MALT1, 
CD80, CD86, CD274, and PDCD1 were measured in both AA and HC children’s PBMCs (total n=43). 
Optimal qPCR performance was achieved throughout all experiments and uniform sampling conditions 
were ensured for valid comparisons (see 2.2.7.3). Target gene DCt values from qPCR analysis express 
gene expression values, relative to the reference control gene 18S. In order to demonstrate dispersion 
of data for each gene in the human immune cell samples, DCt values were displayed in scatter dot plots 
in Figure 11, representing data points with mean DCt values and their range from minimum to 
maximum. Since a lower DCt value corresponds to a higher expression level, the y-axis was displayed 
in reverse direction, which may facilitate graphical interpretation of the data.  
As can be seen in Figure 11, all genes were expressed and detected in qPCR in children’s PBMC 
samples. TNFAIP3 was the gene at highest, PDCD1 at lowest expression among all genes. Individual 
values scattered widely in some genes (e.g. TLR4, MyD88, CD274 and PDCD1), while other genes, 
particularly those involving TNFAIP3 and its regulatory molecules (TNIP2, TAX1BP1, MALT1), were 
confined within a narrow expression range.  
PDCD1 was the only gene not detectable in a limited number of samples (n = 2). A Ct value below the 
detection limit (i.e. 40 PCR cycles) did not occur in any of the other target genes. Since a considerable 
amount of data was censored for PDCD1, and overall expression was very low-level in all children, 
PDCD1 was excluded from further statistical analyses, and data for this gene were not reported in this 
work. Detailed information on sample exclusion is provided in Table E1, which can be found in the 
appendix of this thesis.  
 






3.1.2 Inflammatory innate immune phenotype in AA children 
The first aim of this work was to investigate whether TNFAIP3 gene and protein expression and 
the expression of genes related to NF-kB signalling and dendritic cell maturation was 
dysregulated in PBMCs of children with allergic asthma (AA) compared to healthy control 
subjects (HC).  
 
mRNA expression of the selected target genes was assessed at baseline (i.e. in cultured, unstimulated 
PBMCs) and data was analysed for differences between the two phenotypes. Statistical significance 
was determined using Welch’s t test. The following graphs show relative mRNA expression data (2-ΔCt 

















































Figure 11. Overview of baseline mRNA expression levels of all target genes in the CLAUS subsample. 
Comparative expression levels, relative to 18S (ΔCt values), in unstimulated peripheral blood mononuclear cells 
(PBMCs) of all study patients, aged 4 to 14 years (AA and HC, n=43 for TNFAIP3; n=38 for all other genes 
except PDCD1 (n=36)), as assessed by quantitative real time PCR (qPCR). Scatter dot plots show single sample 
data points and mean ΔCt values with minimum and maximum range. Higher values reflect lower expression     
(y-axis in reverse direction). 
         
 
52 
3.1.2.1 Increased TLR4 and MyD88 expression in AA 
In unstimulated cells, asthmatic children displayed significantly increased TLR4 expression compared 
to healthy controls (p < 0.001; Figure 12, A). Likewise, expression of its adaptor molecule MyD88 
was significantly elevated (p = 0.03; Figure 12, B), whereas no difference between AA and HC was 





3.1.2.2 Decreased TNFAIP3 gene and protein expression in AA 
Under unstimulated conditions, AA children displayed significantly decreased anti-inflammatory 
TNFAIP3 gene expression compared to their healthy peers (p = 0.02; Figure 13, A). Of note, stratified 
analysis for comorbid allergic diseases (i.e. hay fever, atopic dermatitis and food allergy) revealed 
significantly (p = 0.035) decreased TNFAIP3 gene expression levels in children with asthma and 
additional hay fever (n = 12) compared to children suffering from allergic asthma only (n = 7) (DCt 
9.41 (+/- 0.76) vs. DCt 8.74 (+/- 0.50)). However, no similar effect was found for asthmatic children 
with combined food allergy or atopic dermatitis, respectively321. 
To confirm lower TNFAIP3 levels of AA on protein level, Western Blot (WB) was performed in a 
subsample of 11 HC and 14 AA children. The two WB subsample groups did not differ significantly 
in age distribution (HC 11.2 years (IQR 10.3 – 12.6) vs. AA 10.4 years (IQR 7.2 – 11.7), p = 0.30) nor 



















































































Figure 12. Expression of TLR4-pathway genes in HC and AA.  
(A) TLR4, (B) MyD88 and (C) TRAF6 baseline mRNA expression levels, as measured by qPCR in unstimulated 
PBMCs of HC (n=22) and AA (n=16). Expression relative to 18S, displayed as 2-DCt mean values, error bars 
indicate 95% CI. P values reflect Welch’s t test for DCt comparison between HC and AA. *p < 0.05; ns, not 
significant. 
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comparable with the whole groups (not shown). Consistent with the findings for TNFAIP3 gene 
expression, significantly decreased levels of TNFAIP3 protein (82 kDa) were detected in AA patients 












TNFAIP3 protein expression values scattered widely within the group of asthmatics, indicating great 
heterogeneity (Figure 14). While some patients presented with manifestly lacking protein, there were 
also a few with TNFAIP3 levels that were comparable to those seen in healthy subjects.  
Remarkably, TNFAIP3 protein bands of two different sizes were visible on the immunoblots. A broad 
and stronger band was detected at the predicted molecular weight of 82 kDa. Additionally, a TNFAIP3 
band that migrated more slowly in the gel (~ 100 kDa size) was observed in all measured PBMC 
samples (not shown here, see Figure E1, appendix). All analyses in this work refer to TNFAIP3 

























































* p = 0.03
Figure 13. TNFAIP3 mRNA and protein expression in HC and AA. 
(A) TNFAIP3 baseline gene expression levels, as measured by qPCR in unstimulated PBMCs of HC (n=24) and 
AA (n=19). Expression relative to 18S, displayed as 2-DCt-values. (B) Protein levels in HC (n=11) and AA (n=14), 
as analysed by Western Blot. Expression relative to b-Actin. A.U., arbitrary units. Mean values with 95% CI.     
P values reflect Welch’s t test. *p < 0.05. 















To further investigate TNFAIP3-related pathways, gene expression of TNFAIP3 regulatory molecules, 
namely TNIP2, TAX1BP1 and MALT1 was analysed. 
A trend for higher TNIP2 expression was observed in AA compared to HC (p = 0.06; Figure 15, A). 
Neither the gene TAX1BP1 nor MALT1 appeared to be differentially expressed in AA and HC under 































Figure 14. Scatter plot of TNFAIP3 protein expression. 
Protein levels, as analysed by Western Blot in unstimulated PBMCs of HC (n=11) and AA (n=14). (A) Scatter 
plot with individual sample values and means of TNFAIP3 protein expression of predicted 82 kDa size. Results 
from densitometric analysis of protein bands. Normalized protein expression, relative to b-Actin. A.U., arbitrary 
units. (B) Representative immunoblot membrane-cut-out. Molecular weight in kDa. b-Actin was used as loading-



















































































Figure 15. Expression of TNFAIP3 regulatory genes in HC and AA. 
(A) TNIP2, (B) TAX1BP1 and (C) MALT1 baseline mRNA expression levels, as measured by qPCR in 
unstimulated PBMCs of HC (n=22) and AA (n=16). Expression relative to 18S, displayed as 2-DCt mean values 
with 95% CI. P values reflect Welch’s t test. *p < 0.05; ns, not significant. 
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3.1.2.3 Alterations in markers of dendritic cell activation in AA 
In this study population, immune cells of AA expressed significantly lower levels of CD80 (p = 0.002) 
than those of HC (Figure 16, A). In contrast, no significant effect was observed for the co-stimulatory 
molecule CD86 (Figure 16, B). Levels of CD274 were trend-wise lower (p = 0.15) in AA compared 
to the HC group (Figure 16, C). Since the function of DCs may depend on the net co-regulatory signal 
provided by co-stimulatory and co-inhibitory molecules, their expression was also determined relative 
to one another. In this context, the expression of CD86 relative to CD80, i.e. CD86/CD80 ratio, was 












































































































































p =  0.02* 
Figure 16. Expression of dendritic cell associated genes in HC and AA. 
(A) CD80, (B) CD86, (C) CD274 baseline mRNA expression levels and (D) respective expression ratios, as 
measured by qPCR in unstimulated PBMCs of HC (n=22) and AA (n=16). Expression relative to 18S, displayed 
as 2-DCt mean values with 95% CI. CD86/CD80 and CD274/CD86 expression ratios were built by relating DCt 
values of CD80 to CD86 and of CD86 to CD274, respectively. P values reflect Welch’s t test. *p < 0.05;               
ns, not significant.  
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3.1.2.4 Overview TNFAIP3, NF-kB pathway and DC- related gene expression in AA vs. HC 
Table 8 may outline the findings of chapter 3.1.2, reviewing baseline gene expression patterns of AA 
compared to HC children.  
 
In summary, allergic asthmatic children showed significantly increased expression of TLR4-
related genes, while TNFAIP3 as a negative regulator of NF-kB mediated inflammation was 
significantly decreased in these children when compared to healthy subjects. Likewise, CD80 as 
marker of dendritic cell activation was decreased in asthmatic children. 
 
 













mRNA expression levels of 10 genes were measured by qPCR in unstimulated PBMCs. Comparison 
of gene expression between HC (n=22 and n=24 for TNFAIP3) and AA (n=16 and n=19 for 
TNFAIP3). ­ up-arrow (blue) represents elevated mRNA expression in AA vs. HC, ¯ down-arrow 
(red) indicates decreased mRNA expression in AA vs. HC. Coloured arrows without asterisks 
indicate trend-wise effects. ↔ indicates no difference. Statistical significance of differences is 
indicated by the number of asterisks. P values from Welch’s t test. *p < 0.05, **p < 0.01,                   
*** p < 0.001. 
 
3.1.2.5 Strong correlation of TNFAIP3 with expression of the other innate genes in AA 
As TNFAIP3 is considered to be one of the key players within this concept of ‘immunological 
imbalance’ in childhood allergic asthma, its correlation with the other genes that were determined in 
the children’s PBMCs was assessed both in HC and AA. 
As depicted in Figure 17, the expression of all target genes was highly correlated with TNFAIP3 
expression in AA, whereas only a weak or no linear relationship was visible in HC. TNFAIP3’s 
regulatory molecules TNIP2, TAX1BP1 and MALT1, and also the DC markers CD80, CD86, CD274, 
Gene Stimulus mRNA expression level 
AA vs. HC P value 
TLR4 unstim.                    ↑ *** 0.0007 
MyD88 unstim.   ↑* 0.027 
TRAF6 unstim. ↔ 0.688 
TNFAIP3 unstim.   ↓* 0.015 
TNIP2 unstim. ↑ 0.061 
TAX1BP1 unstim. ↔ 0.784 
MALT1 unstim. ↔ 0.939 
CD80 unstim.      ↓ ** 0.002 
CD86 unstim. ↔ 0.428 
CD274 unstim. ↔ 0.153 
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and TRAF6 in particular (p = 0.0003) were all positively correlated at a significant level with TNFAIP3 
expression in the AA group. Also, TLR4 and MyD88 levels showed borderline significance in AA        






















Correlation with TNFAIP3 gene expression
Figure 17. Correlation of all target genes with TNFAIP3 expression, stratified by clinical phenotype. 
Correlation of mRNA expression of TLR4, MyD88, TRAF6, TNIP2, TAX1BP1, MALT1, CD80, CD86 and 
CD274 with TNFAIP3 mRNA expression in healthy controls (HC, n=20) and allergic asthmatic patients (AA, 
n=16). Colour code of gene boxes reflects spearman correlation coefficient values (r). Blue colour indicates a 
positive correlation, red colour a negative correlation. Colour saturation reflects the strength of correlation. 
Statistical significance of correlation is indicated by the number of asterisks. *p < 0.05, **p < 0.01, ***p < 0.001 
(boldface). 
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3.2 Studying asthma-protective farm exposure in vitro – immunomodulatory effects 
  of farm dust 
In mouse models, TNFAIP3 deficiency was reported to be a risk factor for disease, whereas normal or 
elevated levels were ascribed to have protective effects. Against this background, the present study 
aimed to assess whether in vitro exposure to dust extracts from ‘asthma-protective’ farming 
environments as well as lipopolysaccharide (LPS) could upregulate reduced TNFAIP3 levels in 
asthmatic children’s PBMCs and whether it could counterbalance increased pro-inflammatory 
gene expression in these patients.  
3.2.1 Characterisation of farm dust extracts 
Dust extracts that had been collected from ‘asthma-protective’ farming environments in Germany (G), 
Finland (Fi), China (Ch) and from the Amish population (Am) were used for stimulation of study 
patients’ PBMCs. The concentration of endotoxin (LPS), known as a major compound of farm dust, 
was determined in dust extracts (G, Fi, Ch) by Limulus Amoebocyte Lysate (LAL) assay prior to the 
start of the experiments. Due to logistical reasons, LPS concentration of the Amish dust sample could 
not be measured. 
Endotoxin (LPS) concentrations measured in German and Finnish dust samples exceeded the greatest 
value of the test standards by far and were significantly higher than those of the Chinese samples (mean 
values 1082 EU/ml for the G sample, and 887 EU/ml for Fi, vs. 0.17 EU/ml for Ch, respectively; see 


































Figure 18. Endotoxin (LPS) concentration in 
farm dust extracts. 
German (G), Finnish (Fi) and Chinese (Ch) farm 
dust. Different aliquots were used for each dust 
sample and assay. Concentration was measured 
by endpoint chromogenic Limulus Amoebocyte 
Lysate (LAL) assay. Mean values. Error bars 
indicate SEM. P values reflect Welch’s t test.    
*p < 0.05, **p < 0.01; ns, not significant. 
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To further characterise the bacterial composition of the farm dust extracts, sequencing of bacterial 16S 
rRNA was performed in German and Finnish dust samplesd. This revealed a high percentage of gram 
negative bacteria from the Proteobacteria phylum (90.1%), but also sequences from gram-positive 
Firmicutes (8.6%) and Actinobacteria (1%), respectively321. 
3.2.2 Anti-inflammatory immune response in AA and HC upon in vitro LPS and farm dust 
  treatment 
Changes in expression of the NF-kB signalling pathway genes and dendritic cell associated genes upon 
24 hour-stimulation with LPS and the farm dust extracts were analysed.  
3.2.2.1 Downregulated TLR4 and MyD88 expression 
For TLR4 and for its downstream molecules MyD88 and TRAF6 as well, a distinct pattern of mRNA-
downregulation was observed upon treatment with all conditions except for Ch (Figure 19, A-C). 
TLR4 level was significantly decreased, both in HC and in AA upon LPS and dust stimulation when 
compared to mRNA levels of the unstimulated (U) condition (p < 0.0001 for all stimulating conditions 
except Ch; Figure 19, A). Chinese dust treatment reduced TLR4 expression only in the AA children, 
and showed overall the weakest effects. This pattern consistently continued in TLR4-adaptor MyD88, 
although effects in HC were not comparably strong to those in the AA children. Treatment with LPS 
and all dust samples significantly reduced MyD88 expression in AA (p < 0.001 for all stimulating 
conditions except Ch; Figure 19, B). Similar, yet weaker effects were visible for TRAF6 in AA 
children, with significant downregulation upon G and Am stimulation (p = 0.004 and p = 0.01, 
respectively) and trend-wise effects for LPS and Fi (p = 0.10 and p = 0.09, respectively; Figure 19, 
C).  
 
Overall, AA presented stronger responses to treatment than did HC. LPS and the dust extracts 
downregulated mRNA expression of both TLR4 and MyD88, which was significantly, or at least trend-
wise (p £ 0.10), stronger in asthmatic patients compared to the healthy reference group (Figure 20, A 
and B). While TLR4 expression changed impressively, TRAF6 in particular was regulated within 
tighter limits, however significantly different between AA and HC (Figure 20, C). 
 
In summary, asthmatics showed increased TLR4 and adaptor MyD88 gene expression compared 
to healthy controls in unstimulated cells, but expression was significantly downregulated upon 
in vitro stimulation with LPS and the farm dust extracts (G, Fi, Am).  
 
———————— 
d 16S rRNA sequencing in the farm dust samples was not performed by the author herself, but by a member of the  
  research group. 













































































































































Figure 19. Effects of LPS and farm dust stimulation on expression of TLR4-pathway genes. 
PBMCs of HC (n=22) and of patients with AA (n=16) were stimulated 24 hrs with either LPS [0.1µg/ml] or farm 
dust [40µg/ml] from Germany (G), Finland (Fi), China (Ch) and from the Amish people (Am). (A) TLR4, (B) 
MyD88 and (C) TRAF6 mRNA expression displayed as mean values (2-DCt), error bars indicate 95% CI. P values 
from paired t test are indicated for comparisons of stimulated (LPS, G, Fi, Ch, Am) vs. unstimulated (U) 
condition in both AA and HC, or from Welch’s t test for phenotype comparison (AA vs. HC) in unstimulated 
cells, respectively. # indicates trend-wise effects (p £ 0.10). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; 
ns, not significant. 


























































































Figure 20. Fold change of TLR4-pathway gene expression upon LPS and farm dust stimulation.  
(A) TLR4, (B) MyD88 and (C) TRAF6 gene expression fold change, compared to unstimulated conditions          
(2-DDCt, log2 scale), as assessed by qPCR in PBMCs of healthy control children (HC; n=22) and children with 
allergic asthma (AA; n=16) after 24 hrs stimulation with LPS or farm dust extracts from Germany (G), Finland 
(Fi), China (Ch) and from the Amish people (Am). Scatter dot plots represent single sample values with means 
and 95% CI. P values reflect Welch’s t test for fold change comparison between HC and AA. # indicates trend-
wise effects (p £ 0.10). *p < 0.05, **p < 0.01; ns, not significant.  
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3.2.2.2 Upregulated TNFAIP3 gene and protein expression 
Upon LPS stimulation, TNFAIP3 mRNA expression was significantly increased in both HC and AA 
(p < 0.001; Figure 21, A). Although effects of the dust samples were not as strong as observed for 
LPS, treatment with the Finnish and the Amish sample significantly elevated TNFAIP3 mRNA in AA 
children (p = 0.03, and p = 0.005, respectively), but not HC. In contrast, stimulation with farm dust 
samples from China significantly decreased TNFAIP3 levels in PBMCs of both groups (p = 0.004 for 
HC and p = 0.04 for AA, respectively). No difference to the unstimulated condition was seen upon 
treatment with German dust extracts. 
Western Blot analysis of TNFAIP3 confirmed findings on protein level (Figure 21, B), again with 
TNFAIP3 upregulation only seen in AA patients and again, with significant effects only for Fi and Am 
farm dust stimulation (p = 0.02 and p = 0.04, respectively). G and Ch stimulation demonstrated similar 
trend-wise effects in AA (p = 0.09 and p = 0.08, respectively). Of note, 24-hour stimulation with LPS 
did not affect TNFAIP3 protein expression in HC or in AA. Overall, no significant effects of any of 
the treatments were seen on TNFAIP3 protein levels in healthy children. 
It is remarkable that, through stimulation with LPS and with the Finnish and Amish farm dust extracts, 
asthmatics reached TNFAIP3 levels comparable to those of healthy children under unstimulated 
conditions (Figure 21, C). This was true for both gene and protein expression. German farm dust 
stimulation also yielded a significant increase of TNFAIP3 protein to healthy levels (Figure 21, C, 
right panel).  
A representative immunoblot membrane showing a single HC and AA sample with the different 
treatment conditions and TNFAIP3 and b-Actin protein bands is depicted in Figure 21, D. 
 
Fold change of TNFAIP3 mRNA expression following LPS and dust treatment did not differ between 
AA and HC (Figure 22, left panel) and levels appeared to be confined at a defined range. Slight 
upregulation was seen in all treatment conditions except Ch. However, there were significant 
differences between AA and HC regarding TNFAIP3 regulation on protein level (Figure 22, right 
panel). AA patients displayed a stronger increase in TNFAIP3 protein expression than did HC. This 
was true for all the dust treatment conditions (p = 0.03 for G,  p = 0.009 for Fi,  p = 0.01 for Ch,  and  
p = 0.06 for Am).  
 
In summary, allergic asthmatic children exhibited decreased baseline TNFAIP3 expression (i.e. 
in unstimulated cells) on both transcriptional and translational levels compared to healthy 
control subjects, but it was possible to upregulate expression upon in vitro stimulation with LPS 
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Figure 21. Effects of LPS and farm dust stimulation on TNFAIP3 mRNA and protein expression. 
Mean values with 95% CI. (A) TNFAIP3 mRNA expression in PBMCs of HC (n=24) and AA (n=19) after 24 hrs stimulation with LPS or farm dust extracts (G, Fi, Ch, Am). 
(B) TNFAIP3 protein (82kDa) levels in HC (n=11) and AA (n=14), as assessed by Western Blot analysis after 24 hrs stimulation with LPS or farm dust extracts (G, Fi, Ch, Am). 
Results from densitometric analysis of protein bands. Normalized protein expression, relative to b-Actin. A.U., arbitrary units. P values from paired t test are indicated for 
comparisons of stimulated (LPS, G, Fi, Ch, Am) vs. unstimulated (U) condition in both AA and HC, or from Welch’s t test for phenotype comparison (AA vs. HC) in unstimulated 
cells, respectively. # indicates trend-wise effects (p £ 0.10). *p < 0.05, **p < 0.01, ***p < 0.001; ns, not significant. (C) LPS- and farm dust-induced upregulation of TNFAIP3 
mRNA and protein expression in AA compared to levels of HC under unstimulated conditions. Green-shaded area reflects 95% CI of TNFAIP3 expression, as measured in 
unstimulated samples of HC. (D) Representative image from TNFAIP3 immunoblot, showing detected protein bands of 1 HC (left) and 1 AA (right) sample in all stimulating 
conditions. b-Actin was used as loading-control. Molecular weight in kDa.  







TNIP2, TAX1BP1 and MALT1 as regulatory factors of TNFAIP3’s activity and function were also 
analysed for changes in expression levels after the treatment (Figure 23, A-C).  
 
Neither in HC nor in AA was a clear pattern of up-or downregulation of the TNFAIP3 regulators 
visible upon LPS or dust treatment, respectively. In AA, mRNA levels of all three genes were 
decreased from baseline after treatment with the German dust. Yet, this was not the case in HC children. 
Chinese farm dust treatment significantly reduced TNIP2 levels in both HC and AA (p = 0.04 and p = 
0.002, respectively; Figure 23, A). Other treatment conditions (LPS, Fi and Am) did not exert any 
significant effects on TNIP2, TAX1BP1 and MALT1 expression in this experiment.  
 
No difference between HC and AA regarding fold change of expression after stimulation was detected 
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Figure 22. Fold change of TNFAIP3 mRNA and protein expression upon LPS and farm dust stimulation. 
TNFAIP3 gene (left) and protein (right) expression fold change, compared to unstimulated conditions (log2 
scale), as assessed in PBMCs of HC (n=24 for mRNA; n=11 for protein) and AA (n=19 for mRNA; n=14 for 
protein) after 24 hrs stimulation with LPS or farm dust extracts (G, Fi, Ch, Am). Scatter dot plots represent single 
sample values with means and 95% CI. P values reflect Welch’s t test for fold change comparison between HC 
and AA. # indicates trend-wise effects (p £ 0.10). *p < 0.05, **p < 0.01; ns, not significant.  















































































































Figure 23. Effects of LPS and farm dust stimulation on expression of TNFAIP3 regulatory genes. 
(A) TNIP2, (B) TAX1BP1 and (C) MALT1 mRNA expression in PBMCs of HC (n=22) and AA (n=16) after 
24 hrs stimulation with LPS or farm dust extracts (G, Fi, Ch, Am). Expression displayed as mean values (2-DCt) 
with 95% CI. P values from paired t test are indicated for comparisons of stimulated (LPS, G, Fi, Ch, Am) vs. 
unstimulated (U) condition in both AA and HC, or from Welch’s t test for phenotype comparison (AA vs. HC) 
in unstimulated cells, respectively. # indicates trend-wise effects (p £ 0.10). *p < 0.05, **p < 0.01; ns, not 
significant. 
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3.2.2.3 Opposing regulation of the co-stimulatory molecules CD80 and CD86 
To observe the influence of LPS and dust treatment on DC activation and maturation markers, CD80, 
CD86 and CD274 expression was analysed. Unlike TNFAIP3 and its regulators, DC markers showed 
very sensitive kinetics and a wide regulatory range of expression upon treatment with LPS and all dust 
samples except for Ch (Figure 24, A-C).  
CD80 as a marker of DC activation was significantly increased from baseline expression in both 
healthy and asthmatic children’s cells upon treatment with LPS and the Finnish and Amish farm dust 
(p < 0.0001 for AA and p < 0.05 for HC, respectively; Figure 24, A). In AA, CD80 levels were also 
increased upon German dust treatment (p = 0.002).  
 
In summary, CD80 gene expression was significantly decreased in asthmatic children at baseline, 
but expression was upregulated upon LPS and farm dust (G, Fi, Am) stimulation. In contrast, 
the co-stimulatory molecule CD86, which was expressed at a high basal level in children’s 
PBMCs, was significantly decreased in both groups after stimulation (p < 0.001 for treatment with 
LPS and G, Fi, Am dust in HC and AA, respectively; Figure 24, B). Again, only the Chinese dust did 
not induce such responses. Like CD80, mRNA of CD274, the immune-suppressive marker on 
dendritic cells, was significantly upregulated after LPS and dust treatment in HC and AA (p < 
0.0001 for LPS and G, Fi and Am; Figure 24, C). 
 
These findings were also expressed by a remarkable decrease in the CD86/CD80 ratio, accompanied 
by an increased CD274/CD86 ratio in response to LPS and all farm dust samples except Ch (p < 0.0001 
for both HC and AA; Figure 25, A and B).  
 
Overall, asthmatics showed a significantly stronger decrease in CD86 mRNA expression after LPS 
treatment when compared to the healthy control group (p = 0.009; Figure 26, B). This was also 
observed for stimulation with the G, Fi, and Am farm dust samples (p = 0.04, p = 0.06 and p = 0.09, 
respectively). For CD80 (Figure 26, A) and CD274 (Figure 26, C), no differences between HC and 
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Figure 24. Effects of LPS and farm dust stimulation on expression of dendritic cell associated genes. 
(A) CD80, (B) CD86 and (C) CD274 mRNA expression in PBMCs of HC (n=22) and AA (n=16) after 24 hrs 
stimulation with LPS or farm dust extracts (G, Fi, Ch, Am). Expression displayed as mean values (2-DCt) with 
95% CI. P values from paired t test are indicated for comparisons of stimulated (LPS, G, Fi, Ch, Am) vs. 
unstimulated (U) condition in both AA and HC, or from Welch’s t test for phenotype comparison (AA vs. HC) 
in unstimulated cells, respectively. # indicates trend-wise effects (p £ 0.10). *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001; ns, not significant. 



























































Figure 25. Effects of LPS and farm dust stimulation on CD86/CD80 and CD274/CD86 expression ratio. 
mRNA expression in PBMCs of HC (n=22) and AA (n=16) after 24 hrs stimulation with LPS or farm dust 
extracts (G, Fi, Ch, Am). (A) CD86/CD80 and (B) CD274/CD86 expression ratios were built by relating DCt 
values of CD80 to CD86 and of CD86 to CD274, respectively. Scatter dot plots represent single sample values 
with means and 95% CI. P values from paired t test are indicated for comparisons of stimulated (LPS, G, Fi, Ch, 
Am) vs. unstimulated (U) condition in both AA and HC, or from Welch’s t test for phenotype comparison (AA 
vs. HC) in unstimulated cells, respectively. ****p < 0.0001; ns, not significant. 


























































































Figure 26. Fold change of dendritic cell associated gene expression upon LPS and farm dust stimulation. 
(A) CD80, (B) CD86 and (C) CD274 gene expression fold change, compared to unstimulated conditions (2-DDCt, 
log2 scale), as assessed by qPCR in PBMCs of HC (n=22) and AA (n=16) after 24 hrs stimulation with LPS or 
farm dust extracts (G, Fi, Ch, Am). Scatter dot plots represent single sample values with means and 95% CI.       
P values reflect Welch’s t test for fold change comparison between HC and AA. # indicates trend-wise effects 
(p £ 0.10). *p < 0.05, **p < 0.01; ns, not significant.  
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3.2.2.4 NF-kB signalling downstream effects – downregulation of IL-18 
To further investigate TNFAIP3- and NF-kB related pathways in the context of allergic asthma, 
subsequent experiments were conducted by our research group in this specific cohort. Focussing on 
downstream effects of NF-kB signalling, gene expression of the pro-inflammatory cytokine interleukin 
18 (IL-18) was assessed in allergic asthmatic and healthy childrene.  
 
In line with the findings of increased TLR4-/MyD88-expression and decreased anti-inflammatory 
TNFAIP3 in asthmatic children, significantly elevated mRNA levels of IL-18 were found in 
unstimulated cells of AA compared to HC (p = 0.002; Figure 27).  
However, upon stimulation with German, Finnish and Amish farm dust, IL-18 was significantly 
downregulated in both HC and AA children (p < 0.03 in HC, p < 0.0001 in AA; Figure 27). As already 
observed for TLR4, MyD88, TRAF6 and CD86 expression, asthmatic children showed a significantly 
stronger decrease in IL-18 expression upon LPS (p = 0.002) and German, Finnish and Amish farm dust 

















e qPCR for IL-18 gene expression analysis was not performed by the author herself, but by a member of the research  
  group. 
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Figure 27. Effects of LPS and farm dust stimulation on IL-18 mRNA expression. 
IL-18 gene expression in PBMCs of HC (n=17) and AA (n=17) after 24 hrs stimulation with LPS or farm dust 
extracts (G, Fi, Ch, Am). Expression displayed as mean values (2-DCt) with 95% CI. P values from paired t test 
are indicated for comparisons of stimulated (LPS, G, Fi, Ch, Am) vs. unstimulated (U) condition in both AA and 
HC, or from Welch’s t test for phenotype comparison (AA vs. HC) in unstimulated cells, respectively. *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant. 
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3.2.2.5 Overview of in vitro LPS and farm dust stimulation effects in AA and HC 
Heat maps presented in Figure 28 summarise the findings of chapter 3.2.2, providing colour-coded 
information about the mRNA response (i.e. up-/and downregulation) to the different treatment 
conditions for both phenotypes (AA and HC) and for each gene. The direction of regulation was 
represented as red-/blue-gradient, with blue indicating upregulation and red representing 
downregulation of gene expression. Colour saturation reflects the strength of the effect in terms of the 
fold change of expression (2-DDCt, log2 scale). Significant regulation compared to the unstimulated 
condition was indicated by asterisks (*p < 0.05, **p < 0.01. ***p < 0.001, ****p < 0.0001). 
Additionally, comparisons in fold changes of gene expression between the two phenotypes (allergic 
asthmatics (AA) vs. healthy controls (HC)) were included, and significant differences were marked 
with a black rectangle around the respective gene’s cell.  
 
Overall, stimulation with LPS and dust extracts from German (G), Finnish (Fi) and Amish (Am) 
farms significantly decreased the expression of the pro-inflammatory genes TLR4, MyD88 and 
CD86 (red), while it increased anti-inflammatory TNFAIP3, CD80 and CD274 (blue) in both 
healthy and asthmatic children.  
 
Regulation was significantly stronger for some of the genes (TLR4, MyD88 (Am), TRAF6, MALT1 (G), 
CD86 (LPS, G)) in AA as compared to HC (Figure 28, black rectangle around the gene’s cell for p < 
0.05).  
 
Similar effects were observed for T cell associated gene expression in the same cohort, with the pro-
inflammatory T cell co-stimulatory molecule CD28 being decreased and anti-inflammatory CTLA-4 
on T cells being significantly increased in asthmatic children after stimulation with LPS and farm dust 
extractsf (data not shown here, but included in the publication321). As mentioned before, stimulation 
with Chinese dust samples did not exert similar responses in healthy or in asthmatic children.  
 
It is noteworthy that the key findings of TLR4 downregulation and TNFAIP3, CD80 and CD274 
upregulation respectively were replicated in a Chinese cohort of 49 children including AA (n = 20) and 







f qPCR for CD28 and CTLA-4 gene expression analysis was not performed by the author herself, but by a member of the    
  research group. 





3.2.2.6 Overall stimulation effect – inflammation ratio 
In order to further demonstrate the pooled effect of LPS and the environmental dust extracts on 
inflammatory immune responses, an ‘inflammation ratio’ was calculated by relating pro- to anti-
inflammatory gene expression321 (Figure 29). The average DCt value of all investigated genes 
exhibiting anti-inflammatory properties (TNFAIP3, TNIP2, TAX1BP1, CD274) was divided by the 
average DCt value of all pro-inflammatory genes (TLR4, MyD88, TRAF6, MALT1, CD86).  
 
Children with allergic asthma displayed a significantly increased inflammation ratio compared 
to healthy controls in unstimulated (U) cells (p = 0.01; Figure 29), indicating a higher pro-
inflammatory basal immune state in asthmatic children.  
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Figure 28. Overview of in vitro LPS and farm dust stimulation effects in HC and AA. 
Colour-coded up-/and downregulation of mRNA expression of TLR4, MyD88, TRAF6, TNFAIP3, TNIP2, 
TAX1BP1, MALT1 and the dendritic cell associated genes CD80, CD86 and CD274. Fold change of gene 
expression compared to unstimulated conditions (2-DDCt, log2 scale) in PBMCs of children with allergic asthma 
(AA; n=19 for TNFAIP3 and n=16 for all other genes) and healthy control children (HC; n=24 for TNFAIP3 
and n=22 for all other genes respectively), measured by qPCR following 24 hrs  treatment with either LPS 
[0.1µg/ml] or farm dust [40µg/ml] from Germany (G), Finland (Fi), China (Ch) and from the Amish people 
(Am). Blue colour of cells indicates upregulation, red colour indicates downregulation of gene expression. 
Saturation reflects the strength of the fold change effect. Statistical significance of differences of gene expression 
compared to the unstimulated condition is marked by asterisks based on paired t test analysis. *p < 0.05,              
**p < 0.01. ***p < 0.001, ****p < 0.0001. Significant differences of regulation between the two phenotypes 
(AA vs. HC), as assessed by Welch’s t test are marked with a black rectangle around the respective gene’s cell. 
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Upon 24-hour stimulation with LPS and farm dust extracts (G, Fi, Am), this inflammation ratio 
was significantly reduced in both healthy and asthmatic children (p < 0.001; Figure 29), thus 
highlighting the anti-inflammatory properties of in vitro LPS and farm dust exposure on children’s 
immune cells. 
 
Significant differences could also be observed when the ratio was calculated by the two central genes 












































Figure 29. Inflammation ratio in HC and AA and the effect of LPS and farm dust stimulation. 
Inflammation score defined as ratio of pro-inflammatory (TLR4, MyD88, TRAF6, MALT1, CD86) against anti-
inflammatory gene expression (TNFAIP3, TNIP2, TAX1BP1, CD274) in unstimulated (U) and LPS or farm dust 
(G, Fi, Am) stimulated PBMCs of HC (n=15) and AA (n=16). Scatter dot plots represent single sample values 
(inflammation ratio) with means and 95% CI. P values from paired t test are indicated for comparisons of 
stimulation vs. unstimulated condition in both AA and HC, or from Welch’s t test for phenotype comparison 
(AA vs. HC) in unstimulated cells, respectively. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 
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3.3 Gene expression changes upon chronic early life in vivo farm exposure 
Children from farming environments were shown to be naturally protected from the development of 
atopic diseases and asthma. Therefore, the third aim of this study was to investigate potential 
effects of sustained early life in vivo farm exposure on the expression of TNFAIP3 and associated 
NF-kB pathway genes in immune cells of those children at the age of 4.5, 6 and 10 years. 
3.3.1 PASTURE/EFRAIM study cohort 
Gene expression was assessed in a subset of the European farming birth cohort PASTURE/EFRAIM 
including both healthy and asthmatic children at three different time points. Whole blood samples from 
a 4.5-year-old group of 37 children, comprising a total of 19 non-farm (NF) and 18 farm children (F) 
from three different study centres (Germany, Finland, France), and samples from the follow-up 6-year-
old group of 63 children, comprising 31 non-farm and 32 farm children were analysed (Figure 30). 
For study design and setup details, see 2.2.2.2 in the methods section of this thesis.  
To analyse sustained immunomodulatory effects in older farm children as well, a small sample of 5 
healthy German farm children (F-HC) was enrolled for this study within the PASTURE/EFRAIM 10-






Figure 30. Enrolment flow chart PASTURE/EFRAIM study subsample. 
n, number of cases; HC, healthy controls; F-HC, healthy farm children; NF-HC, healthy non-farm 
children; AA, patients with allergic asthma; F-AA, farm children with allergic asthma; NF-AA, non-
farm children with allergic asthma. 
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3.3.1.1 Study population and clinical characteristics of farm (F) and non-farm (NF) children 
Characteristics of the PASTURE/EFRAIM subpopulation at 4.5 and 6 years were given in Tables        
9-11. Similar distribution of gender was ensured when selecting the two groups of farm (F) and non-
farm (NF) children at both time points (Table 9). Likewise, both 4.5- and 6-year-old farm and non-
farm groups were balanced in terms of potential confounding factors like comorbid allergic diseases 
(hay fever, atopic dermatitis, food allergy), parental atopy, indoor smoking at home and the number of 
older siblings. Significant differences were only observed for paternal education in the 6-year-old 
group, with a higher educational status of fathers from non-farm children when compared to the 
farming group. However, this was not seen in the 4.5-year-old children, and no differences were found 
for maternal education in both age groups.  
  
Laboratory parameters of the 6-year-old F and NF children were outlined in Table 10. White blood 
cell count and lymphocyte proportions did not differ significantly between F and NF. Furthermore, F 
and NF were equally distributed regarding sensitisation to common perennial, seasonal or food 
allergens (Table 11). 
 
In the 10-year-old group, F (n = 5) and NF children (n = 15) were unequally distributed in terms of sex 
(80% female children in NF-HC vs. 20% in F-HC; p = 0.01), mainly due to the small sample size of 
the farming subsample. Farm children were younger than their non-farming peers, with borderline 
statistical significance (p = 0.07; median age 10.4 (10.4 – 10.6) vs. 11.7 (10.4 – 13.3)). However, the 
two groups were not significantly different regarding blood cell counts, immune cell proportions and 
further clinical and epidemiological parameters (data not shown).
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4.5 years 6 years 
Parameter NF F P value NF F P value 
n 19 18  31 32  
Female sex, n (%) 10 (52.6) 7 (38.9) 0.40 15 (48.4) 15 (46.9) 0.90 
BMI (kg/m2), median (IQR) 15.8 (15.3 - 16.9) 15.4 (14.8 - 16.5) 0.37† 15.9 (14.9 - 17.1) 15.6 (14.4 - 16.5) 0.33† 
Asthma (6y), n (%) 7 (36.8) 4 (22.2) 0.33 10 (32.3) 7 (21.9) 0.35 
Hay fever (ever), n (%) 2 (10.5) 1 (5.6) 0.58 4 (12.9) 3 (9.4) 0.66 
Doctor’s diagnosis of atopic dermatitis (ever), n (%) 5 (26.3) 3 (16.7) 0.48 13 (41.9) 8 (25.0) 0.15 
Doctor’s diagnosis of food allergy (ever), n (%) 2 (10.5) 3 (16.7) 0.59 3 (9.7) 5 (15.6) 0.48 
Maternal diagnosis of asthma (ever), n (%) 3 (15.8) 0 (0.0) 0.08 5 (16.1) 3 (9.4) 0.42 
Maternal diagnosis of hay fever (ever), n (%) 8 (42.1) 3 (16.7) 0.09 9 (29.0) 7 (21.9) 0.51 
Maternal diagnosis of atopic dermatitis (ever), n (%) 5 (26.3) 3 (16.7) 0.48 8 (25.8) 3 (9.4) 0.09 
Paternal diagnosis of asthma (ever), n (%) 3 (15.8) 1 (5.6) 0.32 4 (12.9) 1 (3.1) 0.15 
Paternal diagnosis of hay fever (ever), n (%) 6 (31.6) 3 (16.7) 0.29 8 (25.8) 3 (9.4) 0.09 
Paternal diagnosis of atopic dermatitis (ever), n (%) 1 (5.3) 2 (11.1) 0.52 1 (3.2) 2 (6.2) 0.57 
Smoking at home, n (%) 0 (0.0) 0 (0.0) -- 0 (0.0) 0 (0.0) -- 
Maternal education   0.64   0.80 
Elementary or middle school, n (%) 12 (63.2) 10 (55.6)  15 (48.4) 14 (43.8)  
High school or university, n (%) 7 (36.8) 8 (44.4)  16 (51.6) 17 (53.1)  
Other, n (%) 0 (0.0) 0 (0.0)  0 (0.0) 1 (3.1)  
Paternal education   0.58   0.01* 
Elementary or middle school, n (%) 10 (52.6) 11 (61.1)  13 (41.9) 24 (75.0)  
High school or university, n (%) 8 (42.1) 6 (33.3)  16 (51.6) 7 (21.9)  
Missing/Other, n (%) 1 (5.3) 1 (5.6)  2 (6.5) 1 (3.1)  
Older siblings, n (%) 11 (57.9) 11 (61.1) 0.84 21 (67.7) 22 (68.8) 0.93 
NF, non-farm children; F, farm children. n, number of cases; %, percentage of group total; BMI, body-mass-index. Values for BMI represent median and interquartile range (IQR). 
P values reflect χ² test for proportions, or the Mann-Whitney U test (†) for continuous variables, respectively. Tests were applied for non-missing data. *p < 0.05 (boldface). Total 
number of subjects might differ slightly for some parameters due to data availability.  
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Table 10. Laboratory parameters of NF and F children (6 years). 
 
Healthy and asthmatic farm (F) and non-farm (NF) children. n, number of cases; WBC, white blood cell count. 
Values represent median and interquartile range (IQR). P values reflect the Mann-Whitney U test. *p < 0.05 




Table 11. Sensitisation to allergens in NF and F children. 
 
Healthy and asthmatic farm (F) and non-farm (NF) children. IU, international units. n, number of cases. %, 
percentage of group total. Specific IgE levels were dichotomised at the detection limit of 0.70 IU/ml and 




3.3.1.2 Farming exposures of F and NF children 
Data on children’s early life farming activities were assessed annually by questionnaires among all 
farm and non-farm children. Specific farm exposures that have been shown relevant in the context of 
protection against asthma and allergic disease in different farming cohorts112,122 were analysed in the 
4.5- and 6-year-old PASTURE study subgroups (Table 12).  
 
Farm children were documented to have higher regular consumption of farm-produced cow’s milk 
(77.8 % in F vs. 5.3 % in NF; p < 0.001), more frequent exposure to stables and barns, and regular 
contact with hay and cows when compared to the non-farm group (p < 0.001 for all exposure variables; 
Table 12).  
 
 
Parameter NF (n = 31) 
median  
F (n = 32) 
median 
P value 
WBC (cells x 109/L) 
(IQR) 
7.45 
(5.58 – 9.10) 
7.6 
(6.70 – 9.10) 
0.49 
Lymphocytes (cells x 109/L) 
(IQR)  
3.05 
(2.58 – 3.75) 
3.10 
(2.30 – 3.80) 
0.98 
 
4.5 years 6 years 
Parameter NF 
(n = 19) 
F 
(n = 18) 
P value NF 
(n = 31) 
F 
(n = 32) 
P value 
Specific IgE (≥ 0.70 IU/ml) 
   
   
to perennial allergens, n (%) 5 (26.3) 7 (38.9) 0.41 8 (25.8) 4 (12.5) 0.18 
to seasonal allergens, n (%) 4 (21.1) 2 (11.1) 0.41 6 (19.4) 4 (12.5) 0.46 
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Table 12. Specific farming exposures in NF and F children. 
 
Healthy and asthmatic farm (F) and non-farm (NF) children. n, number of cases. %, percentage of group total.   
# Regular is defined as at least weekly exposure. Exposures refer to the children’s first, second, third, fourth, fifth 
or sixth year of life. P values reflect the χ² test. *p < 0.05 (boldface).  
 
 
3.3.2 Decreased expression of TNFAIP3 and dendritic cell marker genes in F children 
Upon unstimulated conditions, differences regarding gene expression of TNFAIP3 and TLR4 as well 
as the dendritic cell associated genes CD80 and CD274 were analysed in the 4.5-, 6- and 10-year-old 
farm and non-farm children.  
 
In the 4.5-year-old subjects, no significant difference in TNFAIP3 expression between farm (n = 18) 
and non-farm (n = 19) children was detected (Figure 31, A). However, TNFAIP3 was found 
significantly decreased in the 6-year-old group of 32 farm compared to 31 non-farm children (p = 0.04). 
Supporting these findings, baseline TNFAIP3 levels in the small 10-year-old group was found trend-
wise to be decreased in the farm (n = 5) compared to the non-farming (n = 17) cohort. No difference 
in TLR4 expression levels was present between farm and non-farm children at ages 4.5, 6 and 10 years 
(Figure 31, B).  
Gene expression of CD80 and CD274, however, was lower in F compared to NF children among all 
ages, with significant effects at the age of 4.5 years, in particular (p = 0.05 for CD80 and p = 0.03 for 
CD274, respectively; Figure 32, A and B). CD274 expression was also significantly reduced in the 6-
year-old farm children upon unstimulated conditions (p = 0.03; Figure 32, B).  
It is noteworthy that the observed effects between F and NF remained significant in the 6-year-old 
children, and at least at a trend-wise level also in the smaller 4.5-year-old group, when the data for 
children with asthma were excluded from the analysis (see Figures E3 and E4, appendix).  
 
All of the investigated genes were expressed at a significantly higher baseline level in the 10-year-old 
groups (PBMCs) compared to 4.5- and 6-year-old subjects (whole blood samples), regardless of the 
farming status.  
 
4.5 years  6 years 
Parameter NF 
(n = 19) 
F 
(n = 18) 
P value  NF 
(n = 31) 
F 
(n = 32) 
P value 
Regular# farm milk consumption,  
n (%) 1 (5.3) 14 (77.8) < 0.001* 
 
5 (16.1) 26 (81.2) < 0.001* 
Stay in stable, n (%) 3 (15.8) 17 (94.4) < 0.001*  8 (25.8) 30 (93.8) < 0.001* 
Stay in barn, n (%) 0 (0.0) 12 (66.7) < 0.001*  5 (16.1) 25 (78.1) < 0.001* 
Regular contact with hay, n (%) 4 (21.2) 15 (83.3) < 0.001*  8 (25.8) 28 (87.5) < 0.001* 
Regular contact with cows, n (%) 0 (0.0) 13 (72.2) < 0.001*  1 (3.2) 25 (78.1) < 0.001* 
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mRNA expression was also assessed for the genes MyD88, TRAF6, TNIP2, TAX1BP1, MALT1, and 




































































































































































4.5 years 6 years 10 years
B
Figure 31. TNFAIP3 and TLR4 mRNA expression in NF and F children. 
Baseline gene expression levels of TNFAIP3 (A) and TLR4 (B), as measured by qPCR in unstimulated whole 
blood samples of healthy and asthmatic farm (F) and non-farm (NF) children, assessed at ages 4.5 years (n=37, 
18 F/ 19 NF) and 6 years (n=63, 32 F/31 NF), and in unstimulated PBMCs of healthy 10-year-old children (n=22, 
5 F/17 NF). Expression relative to 18S, displayed as 2-DCt mean values with 95% CI. P values reflect Welch’s     
t test for DCt comparison between NF and F. *p < 0.05; ns, not significant. 





































































































































































4.5 years 6 years 10 years
B
Figure 32. CD80 and CD274 mRNA expression in NF and F children.  
Baseline gene expression levels of dendritic cell markers CD80 (A) and CD274 (B), as measured by qPCR in 
unstimulated whole blood samples of healthy and asthmatic farm (F) and non-farm (NF) children, assessed at 
ages 4.5 years (n=37, 18 F/ 19 NF) and 6 years (n=63,  32 F/31 NF), and in unstimulated PBMCs of healthy    
10-year-old children (n=22, 5 F/17 NF). Expression relative to 18S, displayed as 2-DCt mean values with 95% CI.    
P values reflect Welch’s t test for DCt comparison between NF and F. *p < 0.05; ns, not significant. 
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Table 13 summarises the findings of chapter 3.3.2, reviewing baseline gene expression patterns (i.e. 
in unstimulated cells) of farm (F) compared to non-farm (NF) children.  
 
Altogether, farm children showed a significantly lower expression of TNFAIP3 at the age of 6, 
while no difference in TLR4 expression was seen when compared with non-farm children at all 
three time points of assessment (4.5, 6 and 10 years of age). Similarly, both CD80 as a marker of 
dendritic cell activation and CD274, the T cell suppressive molecule on dendritic cells, were found 
decreased in farm children. 
 
It is noteworthy that findings of significantly lower TNFAIP3, CD80 and CD274 gene expression in 
farm children have been replicated in another non-European cohort comprising a total of 112 7-year-
old children from asthma-protective rural Conghua108 (n = 58) and urban Hong Kong (n = 54)                  
(p < 0.001; data not shown here, but integrated in the publication321). 
 
 
Table 13. Differential baseline expression of TNFAIP3, TLR4, CD80, CD274 among F and NF. 
 
mRNA expression levels of TNFAIP3, TLR4, CD80 and CD274, as measured by qPCR in unstimulated whole 
blood (for 4.5- and 6-year-old children) or PBMCs, respectively (10-year-old children). Comparison of gene 
expression between farm children (F) and non-farm children (NF) at ages 4.5 years (18 F vs. 19 NF), 6 years (32 
F vs. 31 NF) and 10 years (5 F vs. 17 NF). ¯ down-arrow (red) represents decreased mRNA expression in F vs. 
NF. Coloured arrows without asterisks indicate trend-wise effects. ↔ indicates no significant difference. 
Statistical significance of differences is indicated by the number of asterisks. P values from Welch’s t test for 
DCt comparison between NF and F. *p < 0.05. 
 
3.3.3 Decreased TNFAIP3 expression in farm children with allergic asthma 
To study TNFAIP3 expression at the very interface between protection and disease, stratified analysis 
for farm exposure and clinical phenotype was performed in a small subset of 6-year-old children within 
the German PASTURE/EFRAIM cohort (total n = 22). Immune cells of farm children with allergic 
asthma (F-AA; n = 4) were analysed for TNFAIP3 expression and compared to their healthy farm        
(F-HC; n = 7) and healthy and asthmatic non-farming peers (NF-HC; n = 7 and NF-AA; n = 4). The 
limited number of cases is partly due to the very low natural prevalence of atopic conditions and asthma 
in farm children.  
Gene Stimulus mRNA expression level  –  F vs. NF 
4.5 years 6 years 10 years 
TNFAIP3 unstim. ↔   ↓* ↔ 
TLR4 unstim. ↔ ↔ ↔ 
CD80 unstim. ↓ ↔ ↔ 
CD274 unstim.   ↓*  ↓* ↔ 
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First, the previous finding of decreased baseline TNFAIP3 levels in patients with allergic asthma (see 
3.1.2.2) was confirmed in this subsample cohort (14 HC vs. 8 AA, p = 0.05; Figure 33, ‘all’). When 
stratifying for farming exposure, consistently lower TNFAIP3 expression was found in F-AA compared 
to F-HC (p = 0.047; Figure 33, ‘F’-bars), while phenotype differences were not significant among 
non-farm children under unstimulated conditions (Figure 33, ‘NF’-bars).  
Within the group of allergic asthmatics (n = 8), F-AA children exhibited even decreased TNFAIP3 
expression compared to NF-AA children (p = 0.05). Overall, TNFAIP3 expression levels were lowest 















3.3.4 Anti-inflammatory immune response upon in vitro LPS and farm dust stimulation in F 
  and NF 
In order to assess specific immune responses of the farm children upon acute in vitro LPS and farm 
dust exposure, changes in expression of the selected genes TNFAIP3, TLR4 and CD80, CD274 were 
analysed upon 24 hour-stimulation with LPS and the farm dust extracts (G, Fi, Am).  
 
In line with the findings observed in the urban CLARA/CLAUS cohort, in vitro LPS stimulation 
resulted in upregulation of anti-inflammatory TNFAIP3 in farm and non-farm children’s immune cells 
of all age groups (*p < 0.05, **p < 0.01; Figure 34, A). Significant effects were also achieved for 
stimulation with the Amish farm dust extract in the 10-year-old farm children (p = 0.002; Figure 34, 
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Figure 33. TNFAIP3 mRNA expression in healthy and asthmatic NF and F children. 
Gene expression levels, as measured in unstimulated whole blood samples of 6-year-old healthy and asthmatic 
children from the German PASTURE subset (‘all’ n=22, 14 HC/8 AA). Healthy non-farm (NF-HC, n=7) and 
farm children (F-HC, n=7) and asthmatics (NF-AA, n =4, and F-AA, n=4, respectively). Mean values with 95% 
CI. P values reflect Welch’s t test for phenotype comparisons (AA vs. HC). *p < 0.05; ns, not significant. 
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Furthermore, TLR4 expression was significantly downregulated in both F and NF children at all ages 
and upon both LPS and farm dust (G, Fi, Am) stimulation (*p < 0.05, **p < 0.01, ***p < 0.001; Figure 
34, B), again confirming the results from stimulation experiments in the urban cohort that have been 
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Figure 34. Fold change of TNFAIP3 and TLR4 mRNA expression upon stimulation in NF and F. 
(A) TNFAIP3 and (B) TLR4 gene expression fold change, compared to unstimulated conditions (2-DDCt, log2 
scale), as assessed by qPCR after 24 hrs stimulation with LPS and farm dust extracts (G, Fi, Am). LPS stimulated 
whole blood samples of 4.5 year-old farm (F) (n=17) and non-farm (NF) (n=19) and 6 year-old F (n=30) and NF 
(n=30) healthy and asthmatic children, and LPS and farm dust (G, Fi, Am) stimulated PBMCs of 10-year-old 
healthy F (n=5) and NF (n=17) children. Scatter dot plots represent single raw data fold change values with 
sample means and 95% CI. Statistical significance of differences of gene expression compared to the 
unstimulated condition is marked by asterisks based on paired t test analysis. *p < 0.05, **p < 0.01,                     
***p < 0.001, ****p < 0.0001.  
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Consistent findings were also observed for gene expression of the dendritic cell molecules CD80 and 
CD274. LPS and dust stimulation resulted in a strong upregulation of these genes both in F and NF 
children (*p < 0.05, **p < 0.01, ***p < 0.001; Figure 35, A and B). 
 
In summary, the capacity to increase the expression of the anti-inflammatory genes TNFAIP3 
and CD274 and to decrease the expression of pro-inflammatory TLR4 was preserved in farm 
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Figure 35. Fold change of CD80 and CD274 mRNA expression upon stimulation in NF and F. 
(A) CD80 and (B) CD274 gene expression fold change, compared to unstimulated conditions (2-DDCt, log2 scale), 
as assessed by qPCR after 24 hrs stimulation with LPS and farm dust extracts (G, Fi, Am). LPS stimulated whole 
blood samples of 4.5 year-old farm (F) (n=17) and non-farm (NF) (n=19) and 6 year-old F (n=30) and NF (n=30) 
healthy and asthmatic children, and LPS and farm dust (G, Fi, Am) stimulated PBMCs of 10-year-old healthy F 
(n=5) and NF (n=17) children. Scatter dot plots represent single raw data fold change values with sample means 
and 95% CI. Statistical significance of differences of gene expression compared to the unstimulated condition is 
marked by asterisks based on paired t test analysis. *p < 0.05, **p < 0.01. ***p < 0.001, ****p < 0.0001.  
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Heat maps depicted in Figure 36 summarise the findings of chapter 3.3.4, providing colour-coded 
information about the mRNA response (i.e. up-/and downregulation) to the different treatment 
conditions for farm and non-farm children (F and NF) and for each of the genes TNFAIP3, TLR4, 
CD80, CD274. The direction of regulation is represented as red-/blue-gradient, with blue indicating 
upregulation and red representing downregulation of gene expression. Colour saturation reflects the 
strength of the effect in terms of the fold change of expression (2-DDCt, log2 scale). Significant regulation 
compared to the unstimulated condition is indicated by asterisks (*p < 0.05, **p < 0.01. ***p < 0.001, 
****p < 0.0001).  
 
Overall, stimulation with LPS and dust extracts from German (G), Finnish (Fi) and Amish (Am) 
farms significantly decreased gene expression of the pro-inflammatory TLR4 (red), while it 
increased anti-inflammatory TNFAIP3, CD80 and CD274 (blue), with similar effects in F and NF 
children at all investigated time points (4.5, 6 and 10 years of age). 
 
In the 10-year-old farm children, stimulation with German (G) dust samples yielded different responses 
regarding the strength and direction of effects when compared to Finnish (Fi) and Amish (Fi) dust 
stimulation (Figure 36, panel F, 10y). 
 
Again, TLR4 downregulation and TNFAIP3, CD80 and CD274 upregulation effects have been 
replicated in PBMCs of both rural (n = 55) and urban (n = 49) children from the above-mentioned 
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Figure 36. Overview of in vitro LPS and farm dust stimulation effects in NF and F.  
Colour-coded up-/and downregulation of mRNA expression of TNFAIP3, TLR4, CD80 and CD274. Fold change 
of gene expression compared to unstimulated conditions (2-DDCt, log2 scale) in LPS stimulated whole blood 
samples of 4.5- and 6-year-old farm (F) (n=17 and n=30) and non-farm (NF) (n=19 and n=30) healthy and 
asthmatic children, and LPS and farm dust (G, Fi, Am) stimulated PBMCs of 10-year-old healthy F (n=5) and 
NF (n=17) children. Blue colour of cells indicates upregulation, red colour indicates downregulation of gene 
expression. Saturation reflects the strength of the fold change effect. Statistical significance of differences of 
gene expression compared to the unstimulated condition is marked by asterisks based on paired t test analysis. 
*p < 0.05, **p < 0.01. ***p < 0.001, ****p < 0.0001.  
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As outlined before (Figure 36), in the 10-year-old group of German farm children, stimulation with 
the German dust samples resulted in gene expression responses that differed from those observed after 
stimulation with LPS and the Finnish or Amish dust samples (Figure 37). TLR4 downregulation was 
significantly stronger upon German dust stimulation, while anti-inflammatory TNFAIP3 as well as 
CD80 and CD274 were less upregulated compared to LPS, Fi and Am. Despite the very small sample 
size of this farming children subgroup (n = 5), effects partly yielded significant levels (for TLR4               
p = 0.031 for comparison G vs. LPS, p = 0.037 for G vs. Am; Figure 37). However, the majority was 

























































Figure 37. Fold change of TLR4, TNFAIP3, CD80 and CD274 mRNA expression upon stimulation in 
German F children. 
Gene expression fold change, as measured in PBMCs of 10-year-old German farm children (n=5) after 24 hrs 
stimulation with German (G) farm dust extract as well as LPS, Finnish (Fi) and Amish (Am) farm dust. Mean 
log2 of fold change values (2-DDCt). Error bars indicate SEM. P values based on paired t test analysis for 
comparisons of G stimulation vs. LPS, Fi and Am, respectively. # indicates trend-wise effects (p £ 0.10).               
*p < 0.05; ns, not significant. 




4.1 Summary of the main findings 
The aim of this study was to investigate the role of TNFAIP3 and related signalling pathways in the 
development of allergic asthma and its environmentally mediated protection in children. Gene 
expression and protein levels were assessed in 148 peripheral blood immune cell samples of healthy 
and asthmatic children of different ages from two distinct paediatric study cohorts. Analyses in 
peripheral blood mononuclear cells revealed a reduced expression of anti-inflammatory TNFAIP3 gene 
and protein in allergic asthmatic children, while the expression of the pro-inflammatory pathway genes 
TLR4 and MyD88 was increased. In vitro stimulation with LPS as well as dust extracts from different 
asthma-protective farming environments restored TNFAIP3 expression of asthmatic patients to healthy 
levels and reduced the expression of the pro-inflammatory TLR4-pathway-related target genes (TLR4, 
MyD88, TRAF6). The observed anti-inflammatory effects were accompanied by significant 
downregulation of dendritic cell associated co-stimulatory molecule CD86 and upregulation of the co-
inhibitory molecule CD274 upon stimulation. Whole blood samples of farm children at ages 4.5, 6 and 
10 years exhibited decreased expression levels of both pro- and anti-inflammatory genes compared to 
their non-farming peers, but the capacity to induce TNFAIP3 and CD274 expression and to 
downregulate TLR4 levels upon LPS and farm-dust stimulation was preserved at all ages.  
In the following these findings will be discussed in the context of the present state of relevant studies, 
considering both methodological and content-related aspects. 
4.2 Discussion of the study methods and experimental design  
4.2.1 Survey data and conjoint analyses in the PASTURE/EFRAIM study population 
Blood samples from the PASTURE/EFRAIM farming birth cohort provided a unique opportunity to 
examine (innate) immune regulation in farmer’s children within the scope of this work. Experimental 
research studying the immunology of the protective ‘farm effect’ on asthma in humans is rarely found, 
thereby highlighting the significance of the current investigations. The prospective nature of the study 
avoided recall bias and supports reliability of questionnaire-based data on farming exposures and atopic 
outcomes. Since a random selection of farm and non-farm children was not possible due to limited 
sample availability and the aim of a balanced distribution regarding demographic and clinical aspects, 
the presence of sample selection bias cannot be excluded.  
 
Samples from three different study centres (Germany, Finland, France) were assayed for 
immunological analyses. Both fieldwork and laboratory procedures that were conducted prior to the 
experiments demonstrated herein had been checked for coherence between the centres. Blood sampling 
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and processing steps in particular had been standardised and validated by a series of extensive quality 
control measures beforehand296. Therefore, conjoint analysis of the present data was possible. Please 
refer to corresponding earlier publications of the PASTURE study project for more detailed 
considerations regarding the study design. 
4.2.2 Time points of clinical and immunological assessment  
Blood samples of the PASTURE/EFRAIM farming cohort were screened for the selected target genes 
at three different time points, thus making it possible to address the question of long-lasting effects of 
early pre- and postnatal farming exposures322. However, valid longitudinal analysis was only possible 
to a limited extent, since blood samples of some children were not available at age 4.5 years. Moreover, 
blood samples from children younger than 4.5 years were not available for analysis in this particular 
study cohort. However, protective effects of microbial exposure are considered to be greatest during 
early infancy109, and similar timeframes for concomitant immunological changes are proposed323. It 
must be conceded that, on the basis of the above mentioned, the crucial time window in which decisive 
immunological processes may develop might have been missed in the current immunological 
assessment. On the other hand, assessment at ages 4.5 to 10 years captures the time period when allergic 
asthma manifests itself in most children, thus making it possible to investigate immunoregulatory 
effects in the context of both farming exposures and children’s health outcomes at the same time. This 
is a major strength of this study despite limited group sizes particularly of asthmatic farm children, 
which is largely due to the naturally low prevalence of atopic conditions in farm children.  
 
Since a doctor’s diagnosis of asthma is a criterion possibly to be biased in patients under 6 years of 
age, as children with transient wheeze may also be included324,325, asthma cases in farm and non-farm 
children of the PASTURE/EFRAIM population were investigated only at the age of 6 years.  
In the CLARA/CLAUS study sample, however, a small number of children under 6 years (n = 2) were 
also included as ‘allergic asthmatics’. Since these two patients were seen by a paediatric allergology 
specialist, demonstrating typical asthma symptoms, with corresponding clinical history and impaired 
lung function results, inclusion in the present study was possible. 
4.2.3 Investigated sample material – PBMCs and whole blood  
Principal among the limitations of the study is the fact that immunological assessment focussed on 
systemic immunity by using peripheral blood samples as the primary material. It is conceded that any 
such model system may not adequately represent the in vivo local situation. Undoubtedly, decisive 
disease determining inflammatory changes do occur in the respiratory tract209, and circulating 
peripheral immune cells may be unlikely to reflect these local immunological processes. Furthermore, 
a considerable proportion of PBMCs isolated from whole blood is likely to be phenotypically and 
functionally distinct from immune cells of the respiratory mucosa or pulmonary lymphatic tissue.          
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In vitro findings from children’s PBMCs can therefore not be directly related to immune responses 
which occur at the critical site of action, i.e. the lungs. 
The demonstrated experimental approach may yet be interpreted in the light of the inherent limitations 
of a clinically based study in young children, which requires an easy and ethically reasonable access 
to appropriate sample material. In fact, any immunological study involving the acquisition of 
bronchoalveolar lavage (BAL) or even bronchial biopsy samples in a paediatric cohort of non- or 
mildly to moderately disease-affected individuals would not undergo approval by the human ethics 
committee, nor by the children’s parents for comprehensible reasons. 
Notwithstanding this, pulmonary immune cells are also largely recruited from systemic circulation, 
and increasing evidence suggests that processes other than those happening locally in the airways may 
be involved in the pathogenesis of childhood asthma. The proposed causal relationship between 
adipose-related systemic chronic inflammation and asthma326 may exemplify this conception. Not least 
because of the farming studies and recent microbiome research, it has become clear that different sites 
of the body are most likely involved in controlling innate and adaptive immune functions influencing 
asthma development126,327,328. In view of this, and because of the fact that the above-reported in vitro 
findings obtained from children’s PBMCs replicated previous findings from animal in vivo model 
systems118,261,329, relevant physiological significance of the observed effects may well be assumed.  
 
Data derived from unfractionated cells (i.e. PBMCs, or whole blood samples in the PASTURE cohort, 
respectively) are likely to be confounded by even minor differences in cell proportions between groups. 
PBMCs constitute a heterogeneous group of peripheral immune cells, comprising the lymphocyte 
populations (T cells, B cells, and NK cells), as well as monocytes and a small proportion of dendritic 
cells330, whereas whole blood samples additionally contain nucleus-free red blood cells and 
polymorphonuclear granulocytes (neutrophils, basophils and eosinophils). Since peripheral blood 
samples of cases (AA) and controls (HC), or farm and non-farm children respectively, exhibited similar 
proportions of leukocyte subsets, the observed gene expression profiles are largely unlikely to be due 
to differential composition of cell populations. 
Mechanistic interpretation of the immunological findings gained from PBMCs is further complicated 
by the fact that an observed effect cannot be allocated to a distinct cellular source. This particularly 
applies to the dendritic cell population, which accounts for only about 1-2 percent of human PBMCs331. 
Cell-type specific gene expression effects might be overlaid by opposing effects or even be lost within 
the summed signal of the bulk sample.  
 
Notwithstanding these considerations, the use of unfractionated cells constituted a reasonable 
experimental approach in the present project, whose objective was considered to be essentially 
exploratory. In fact, the current data provided the basis for experiments subsequent to this work, which 
were able to confirm the present findings in isolated cell populations321. Several follow-up projects on 
isolated dendritic cells as well as regulatory T cells are in progress, with data to be published by the 
research group in the near future. These more elaborate model systems are certainly required in order 
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to gain further mechanistic insights and ultimately be able to translate findings into the human in vivo 
system. 
4.2.4 Immunological assessment methods 
Immunological phenotype signatures as well as in vitro stimulation effects in children’s PBMCs and 
whole blood leukocytes were assessed by analysing gene expression and protein levels. Quantitative 
real time PCR (qPCR) was considered an appropriate experimental readout method for the purposes of 
this work, as it allows objective and precise quantification of target genes. Given the fact that qPCR is 
still a technique very liable to interference, extensive quality control measures were performed (as 
outlined in the methods section), allowing high process standards throughout all experiments.  
Gene expression profiling per se, however, provides only limited information about functional 
outcomes. For evaluating DC-T cell-dependent immune responses in particular, further experimental 
readouts such as cytokine studies are required. Furthermore, it remains subject to speculation whether 
detected mRNA is also translated into protein, and to what extent mRNA regulation is associated with 
changes in functional protein at all. To answer this question at least for TNFAIP3 as the key molecule 
in this project, Western Blot analysis was performed. Particular effort was made to optimise all process 
steps and components and establish an ideal standard operating procedure (see methods section), which 
provided the basic framework for further experimental projects of the study group.  
4.2.5 In vitro LPS and farm dust stimulation model 
The in vitro farm dust stimulation model performed in this work was a valuable experimental approach 
towards a clearer understanding of the mechanisms underlying the farm effect. Limitations and 
challenges inherent in this model-based approach will be reflected in the following. 
 
Firstly, a single dose stimulation regimen was employed, although it must be considered that this may 
not ideally mirror the effects of chronic in vivo exposure in the natural farming environment. Since 
stimulation significantly affects the natural viability of human primary immune cells, however, 
repetitive stimulation and a long-term cell-culture setting would have biased immunological outcomes 
due to increased cytotoxic side effects. Moreover, experimental studies in animal models have shown 
that single high dose LPS as well as farm dust exposure generated similar beneficial effects as did 
chronic low-dose administration261.  
A robust protective effect of a certain exposure is characterised by preventing or suppressing the 
development of pathophysiological features defining the disease phenotype. Inflammatory responses 
in allergic asthmatic patients are mostly triggered when re-exposed to specific allergens, which 
highlights the importance of allergen challenge in any model-based approach. In fact, unlike previous 
in vivo and in vitro experimental studies investigating the protective effect of farming 
exposures118,178,238,261,332, the current experiments did not employ assessment of immunological 
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outcomes upon allergen exposure. Thus, the observed treatment effects of LPS and the farm dust 
extracts may predict the in vivo outcome in allergic asthmatic children only to a limited extent, and 
care must be taken when drawing conclusions about their asthma-protective properties from the present 
model system. 
To address the issue of dose-dependency of effects and gene expression kinetics, preliminary 
experiments were carried out in children’s PBMCs prior to the start of the study. Comparative analyses 
of two time points of assessment (8 hrs and 24 hrs), and of three different doses of farm dust extracts 
respectively, revealed only minimal differences regarding target gene expression (data not shown), 
suggesting that the potency of farm dust treatment is widely guaranteed. Considering the observation 
of a dose-dependent dual effect of LPS in vivo333, however, it is admitted that further experiments are 
necessary to address the question of a safe and ‘protective’ LPS and farm dust dose.  
Finally, in vitro LPS and farm dust exposure was modelled in peripheral blood immune cells, most 
equivalent to a systemic treatment approach. Following the ‘proof of concept’ principle, this was a 
reasonable and straight-forward approach to further elucidate the characteristic immunomodulatory 
effects of farm dust exposure in the human system. Although asthma-protective effects have actually 
been demonstrated for systemic (i.e. intravenous or intraperitoneal respectively) LPS exposure in 
murine model systems239,238, it is conceded that this constitutes an artificial route of exposure. In vivo 
farming exposures are most likely to occur through inhalation and oral ingestion126, which strengthens 
the notion of the mucosal barriers as being the critical site of action in the natural system. There is 
increasing evidence to suggest that the complex interplay of incorporated farm-derived microbiota and 
allergens with the interacting network of immune cells and barrier epithelial cells is decisive for the 
protective in vivo farm-effect33. In the natural setting, direct engagement between immune cells and 
certain farm dust constituents might be limited, since macromolecules, for instance, may not cross the 
epithelial tight-junction barrier. Organotypic cultures of primary human cells are therefore required to 
illustrate processes at the mucosal interface in the best way possible. In this context, elaborate work 
establishing air-liquid interface (ALI) cultures of human adult airway epithelial cells (ECs) has already 
been done261. Findings from such models, together with a more detailed knowledge about chemical and 
physical properties of composed dust samples (e.g. molecular weight fractions (work in progress)), 
will greatly improve our understanding and provide the basis for subsequent experimental approaches 
in paediatric cohorts as well.  
Only if there is absolute certainty about the impact of dosage, timing, composition and mode of 
exposure may the vision of a farm dust-derived treatment strategy for childhood asthma be further 
pursued. 
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4.3 Discussion of the main findings  
4.3.1 Clinical characterisation of the allergic asthmatic phenotype 
Allergic asthma is the most common asthma phenotype in children and is represented by a clear pattern 
of well-established clinical and biological features11,29,334. Allergic asthmatic children that were 
recruited for the current project demonstrated the distinctive biological characteristics of the 
phenotype, as defined by positive sensitisation to allergens, elevated levels of total IgE and peripheral 
blood eosinophilia28. Consistent with a mild to moderate disease severity profile which has been 
typically associated with this phenotype11, prebronchodilator lung function parameters were only 
mildly affected (FEV1 > 80% predicted in most AA patients) and were reversed to normal in the 
majority of children. The varying degree of clinical symptom severity among AA children, which was 
also reflected in the large variance of lung function measures, may be partly due to recruitment during 
different pollen seasons.  
In accordance with the commonly defined risk factors for early-onset allergic asthma, questionnaire 
data revealed an increased rate of allergic comorbidities such as hay fever and atopic dermatitis among 
AA children29,11, as well as an increased prevalence of a maternal history of asthma and allergic 
disease335,336 and a higher level of parental education. Despite a strong association of atopy and asthma 
in school-age children, atopic sensitisation per se has not been finally proven to be an independent 
predictive factor for asthma susceptibility337. In fact, around 17% of healthy control children enrolled 
in the study exhibited positive atopic sensitisation to a single allergen without clinical symptoms of 
allergic disease, which is consistent with prevalence rates derived from large-scale epidemiological 
studies338. In contrast, poly-sensitisation (i.e. sensitisation to multiple allergens) and higher levels of 
allergen-specific IgE were observed in AA children, supporting the assumption that the intensity of 
sensitisation largely determines asthma risk in this age group182. Both allergen specific IgE and 
comorbid allergic diseases remained strong discriminating factors between AA and HC in the present 
study. Since valid confounding analyses were not feasible due to limited sample size, however, it 
cannot be excluded that the observed immunological effects in AA children were at least partly 
mediated by the atopy component rather than arising from the asthmatic condition per se.  
 
Together, the clear characterisation and precise definition of AA cases and HC subjects 
underscores the validity of the reported findings with respect to the distinct clinical phenotype 
of allergic asthma in school-age children.  
4.3.2 Inflammatory innate immune signature of school-age children with allergic asthma 
The present study revealed a distinct and conclusive gene expression profile in asthmatic children’s 
peripheral blood mononuclear cells, particularly highlighting the role of TNFAIP3 and NF-kB 
pathway-related target genes. Compared to healthy controls, school-aged urban children with allergic 
         
 
93 
asthma showed significantly increased expression of TLR4 and its adaptor MyD88, while levels of the 
anti-inflammatory molecule TNFAIP3 were significantly reduced on transcriptional and translational 
level under unstimulated conditions (i.e. at baseline). Similarly, baseline mRNA expression of the co-
stimulatory dendritic cell surface molecule CD80 was decreased. 
 
It is now well known that TLRs as innate immune receptors do not only play a vital role in sensing and 
transmitting signals, but are also critically involved in modulating adaptive immune responses232. 
Direct TLR stimulation is required for effective DC activation and subsequent T cell priming231. The 
role of TLRs - especially TLR4 - and ensuing signalling in the development of allergic responses and 
asthma pathogenesis is complex, and its contribution to airway inflammatory responses remains 
incompletely understood. Genetic alterations in TLR4 were found to modify asthma risk, although 
results are conflicting (as reviewed by Tesse et al.234). In the present study population, significantly 
elevated TLR4 expression was visible in asthmatic patients’ PBMCs compared to healthy controls. So 
far, few other studies have assessed the role of TLR4 in patients with allergic asthma, and those studies 
conducted in adult patients exhibited major limitations and provided inconsistent results339-341. Aside 
from differences in the patients’ age, a valid comparison with these studies is hampered by a number 
of differing factors concerning methodology and study design (i.e. clinical characteristics including 
atopy status, investigated sample material, and readout method, among others). Furthermore, the highly 
dynamic nature that TLR4 expression in vivo and in vitro is known for makes it difficult to interpret 
and compare data between experimental settings, and it is certainly one reason for the discrepancy of 
findings on TLR4 expression in human immune cells. However, recent evidence has supported the 
present data with respect to the atopy component of allergic asthma, linking elevated TLR4 expression 
to high levels of IgE in asthmatic patients342. In fact, TLR4-mediated signalling, particularly from 
airway epithelial cells343,344, has been proven essential for the determination of Th2-dominated immune 
responses to allergens and airway inflammation in experimental animal models of allergic asthma345,346. 
Landmark studies have demonstrated that some common aeroallergens can elicit allergic responses 
through direct or indirect engagement with TLR4233,347,348. In light of these findings, increased TLR4 
expression in allergic asthmatic children in the present study may constitute a reduced baseline 
threshold within innate immunity for mounting Th2-mediated inflammatory responses to varying 
environmental stimuli. Given the fact that the expression of TLR4 signalling adaptor MyD88 was 
equally increased in asthmatic subjects, relevant downstream effects of enhanced TLR4 signalling may 
indeed be assumed. Moreover, MyD88 levels paralleling those of TLR4 may indicate that the MyD88-
dependent rather than the TRIF-dependent TLR4 signalling pathway is affected in children with 
allergic asthma. Since MyD88 is involved in multiple convergent innate receptor signalling cascades, 
however, the contribution of other non-TLR4-related pathways must still be considered. 
 
Chronic inflammation in asthma may result from a skewed balance of activation and control 
mechanisms of immunological processes and signalling pathways. Thus, impaired regulatory 
mechanisms would lead to exaggerated activation of immune responses, causing the development of 
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inflammatory disease. TNFAIP3 is critically involved at this point, acting as a negative regulator of 
TLR4-induced NF-kB activity, which has been associated with the pathogenesis of allergic asthma248. 
Few animal studies have provided evidence for a key function of TNFAIP3 in suppressing airway 
inflammatory responses upon allergen exposure349,261. Subsequent human in vitro approaches have 
primarily focussed on local processes in the lung, investigating the role of TNFAIP3 in airway 
epithelial cells350,261. However, TNFAIP3 expression in myeloid cells and especially DCs has recently 
been proven to be equally required for suppressing allergen induced airway inflammation260. Against 
this background, the present finding of decreased TNFAIP3 gene and protein expression in peripheral 
blood immune cells of allergic asthmatic children is of particular relevance. The fact that TNFAIP3 
was highly correlated with all other NF-kB pathway-related target genes in these patients further 
underscores the conception of TNFAIP3 as a biological determinant of dysregulated innate immunity 
pathways in childhood asthma. Recent data from our study group have reinforced this assumption with 
particular regard to the early determination of the disease. Cord blood mononuclear cell (CMBC) 
samples of newborns with subsequent asthma development in childhood exhibited decreased TNFAIP3 
expression, suggesting that TNFAIP3 levels may even help to predict the individual’s asthma risk at 
birth (see publication321). Since a similar association was found for TNFAIP3 expression and comorbid 
hay fever in the present AA group, it may be hypothesised that TNFAIP3-dependent regulatory 
processes are particularly relevant in the development of the early-onset allergic asthma phenotype 
rather than the asthmatic condition per se.  
Overall, the present data strongly point towards a pivotal role of the anti-inflammatory molecule 
TNFAIP3 in the development of allergic asthma in children. The current observations of elevated 
levels of TLR4 and MyD88 along with decreased TNFAIP3 gene and protein expression in 
asthmatic subjects strongly suggest that inflammatory processes are insufficiently contained in 
these patients.  
 
Decreased TNFAIP3 protein levels were found in asthmatic children at a statistically significant level, 
although a remarkably large variance for the individual values was observed within this group. Schuijs 
et al. have shown a relation between TNFAIP3 levels in airway epithelial cells and asthma severity in 
a small sample of adult patients261. Although some heterogeneity in disease severity was actually 
observed in the present paediatric cohort, the current sample size was not sufficient to detect a reliable 
effect on TNFAIP3 protein levels. Thus, it may only be speculated on a similar association at this point. 
On this score, recent findings suggest that TNFAIP3 expression in DCs is essential for controlling the 
development of Th17-mediated neutrophilic airway inflammation, associated with a more severe 
asthma phenotype260. These observations are most intriguing due to the fact that the functional role of 
TNFAIP3 in DCs is directly linked to the determination of a specific immunological phenotype.  
Notwithstanding this, the observed heterogeneity of expression may also reflect a different genetic 
makeup in these patients. Several functional domains have been identified in the TNFAIP3 gene, and 
two of these have been directly linked to its ubiquitin-modifying activity351,352. Animal studies have 
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impressively demonstrated that selective disruptions in these domains can result in varying phenotypic 
traits257,277. This is particularly intriguing considering the fact that a distinct gene polymorphism located 
in the functional deubiquitinase domain of TNFAIP3 has recently been associated with increased 
susceptibility for asthma in a large-scale GWAS261. The variety of polymorphisms in the TNFAIP3 
gene locus which have been associated with many other inflammatory and autoimmune diseases263,353-
358 highlights the great potential for further attempts in genetic research in paediatric asthma.  
Apart from genetic modifications, a vast number of mechanisms have been determined to regulate the 
functional activity of TNFAIP3264. Post-translational modifications such as phosphorylation were 
shown to critically affect its enzymatic activity359. The additional TNFAIP3 protein band, which had 
been detected at slightly higher molecular weight than expected in all children’s samples in Western 
Blot, may be interpreted against this background, although its definite relevance certainly needs to be 
addressed in future mechanistic approaches.  
The activity of TNFAIP3 is further regulated by direct interactions with specific proteins, such as 
TNIP2, TAX1BP1 and MALT1, which were also addressed in the present study. Unlike TNFAIP3, the 
genes encoding these proteins did not appear to be differentially expressed in healthy and asthmatic 
children. TNIP2 (ABIN-2) constitutes one of three known TNIP (ABIN) proteins which act as negative 
regulators of NF-kB by enhancing TNFAIP3’s ubiquitin-modifying activities on target proteins267,266. 
The functional role of the TNFAIP3- and ubiquitin-binding protein TAX1BP1 has been characterised 
very similarly265. Both TNIP1 and TNIP2 have been independently shown to be critically involved in 
regulating allergic airway inflammation in mice360,270, but a potential relevance for human asthma has 
only been demonstrated for TNIP1361. The current findings might therefore illustrate the minor 
role TNIP2 plays in mediating TNFAIP3’s anti-inflammatory function. However, it may well be 
supposed that the complex regulation of TNFAIP3’s activity provided by a variety of molecules and 
mechanisms is governed by additive and complementary rather than exclusive effects. This also applies 
to the negative regulation of TNFAIP3, where proteolytic processing by MALT1 is only one among 
many other mechanisms that suppress TNFAIP3’s inhibitory function on NF-kB dependent 
inflammatory responses272,362. Therefore, redundancy of biological activities within the whole 
regulatory network may explain why no differences between phenotypes were observed for the 
individual genes.  
 
By controlling NF-kB activation, TNFAIP3 critically regulates the biology and function of dendritic 
cells. Selective TNFAIP3 deletion in murine DCs results in spontaneous DC maturation, 
hyperresponsiveness to TLR-signals, and aberrant adaptive immune responses363. In the context of 
asthma, the functional role of TNFAIP3 in DCs has been further defined as particularly regulating T 
cell differentiation into the Th17 cell subset260. 
Acting as ‘gatekeepers of the immune system’364, DCs are the key checkpoints in governing both 
immunity and tolerance. Changes in their phenotypic features, involving the expression of co-
regulatory molecules, usually coincide with changes in their functional activity. The outcome of DC-
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T cell encounter, i.e. the resulting T cell-mediated immune response, however, is not determined by 
the co-regulatory molecule expression status per se, but by the intricate network of immunogenic or 
tolerogenic signals transmitted during interaction with the different receptors on T cells. Bearing this 
in mind, the present data demonstrating gene expression of co-regulatory molecules unrelated to their 
counterpart receptors are of little significance. Considering the distinct receptor binding affinities of 
the co-regulatory molecules, however, more valid assumptions can be made about the T cell response 
they might induce. The finding of significantly decreased CD80 expression in asthmatic children’s 
PBMCs shall be discussed against this background.  
It was very early proposed that CD80 (B7-1) and CD86 (B7-2) differentially affect T cell 
development365. Like CD86, CD80 is known to interact with the stimulatory receptor CD28 on T cells, 
but engages the inhibitory molecules CTLA-4 (CD152) and CD274 (PD-L1) with higher affinity366,367. 
Interaction of CD80, yet not CD86 with CTLA-4, was shown to enhance the suppressive capacity of 
regulatory T (Treg) cells368. Likewise, signalling through the co-inhibitory molecule CD274, which 
can specifically bind CD80287, promotes the development and functional maintenance of Treg 
cells369,370. Although there is still some disagreement regarding the role of CD274 in the development 
of allergic asthma371,292,293 more recent studies have provided evidence of its inhibitory function, 
particularly in controlling severe, Th17-mediated disease372. In contrast, CD86 expression appears to 
be essential for DC-dependent Th17 differentiation373 and has been particularly associated with 
allergen-induced Th2 cell immune responses in both animal278,279 and human282 experimental models. 
A higher CD86/CD80 expression ratio on human DCs was associated with an allergic phenotype and 
a Th2-dominated rather than Th1-preferential immune response upon in vitro allergen exposure282. 
Thus, increasing evidence suggests that CD80 and CD86 may have opposing roles in regulating Th 
cell differentiation and that the type of co-regulatory molecules expressed on DCs and their relative 
expression levels may substantially determine the outcome of the adaptive immune response in the 
development of allergic asthma. The current finding of a significantly elevated CD86/CD80-ratio 
in asthmatic children may therefore indicate a shift in the balance of co-regulatory molecules on 
activated DCs favouring the induction of inflammatory Th2 and Th17 cells rather than 
suppressive Treg or counterregulatory Th1 cells under steady-state conditions.  
However, mechanistic interpretation is complicated by the fact that DCs are not the only source of 
CD80 and CD86 expression in PBMCs. T cells were also shown to constitutively and inducibly express 
both molecules on their cell surface, thereby modulating immune responses through mainly CTLA-4-
mediated T-T cell interactions374. Therefore, co-regulatory molecule expression cannot be exclusively 
related to the function of DCs. Furthermore, it may well be questioned whether the assessment of the 
steady, inactive state of circulating peripheral blood DCs, i.e. their maturation state under unstimulated 
conditions, represents an adequate model to illustrate the true pathological immunophenotype, which 
may manifest only upon allergen challenge and particularly in the diseased tissue, i.e. the lungs of 
asthmatic subjects. However, the strength and consistency of effects observed under unstimulated 
conditions suggests that the immune phenotype of allergic asthmatic children is determined by major 
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disruptions in innate immune pathways, which are even clearly distinguishable during steady state in 
the peripheral blood. 
 
Taken together, the present study revealed features of an inflammatory immune phenotype in 
school-aged children with allergic asthma, suggestive of dysregulated TLR4-induced NF-κB 
mediated signalling. It may be proposed that impaired negative regulation by TNFAIP3 in 
asthmatic children results in altered DC biology, potentially driving aberrant immune responses 
in allergic asthmatic subjects. 
4.3.3 Anti-inflammatory effects of in vitro farm dust exposure 
Growing up in a farming environment constitutes a strong protective factor against childhood asthma 
and allergic disease375. The protective in vivo ‘farm effect’ is supposed to be mediated by exposure not 
only to high concentrations, but also to a great diversity of microbial agents135,143. It has been shown 
that airborne dust samples collected from traditional farming sites can highly reflect this in vivo 
environmental exposure of farm children128. To disentangle innate immune mechanisms that may 
explain this ‘farm effect’ on asthma, in vitro stimulation experiments with different farm-derived dust 
extracts and LPS were performed in children’s PBMCs of the CLARA/CLAUS study cohort.  
The present data clearly demonstrate that in vitro exposure to LPS and German (G), Finnish (Fi) and 
Amish (Am) farm dust extracts induces anti-inflammatory processes by increasing the expression of 
NF-kB inhibitor TNFAIP3, while consistently suppressing pro-inflammatory TLR4-pathway signalling 
genes in both healthy and asthmatic children. In the presence of LPS or farm dust (G, Fi, and Am) 
respectively, the expression of DC maturation markers CD80, CD86, CD274 changed significantly, 
which indicates a crucial role for DCs in mediating the anti-inflammatory effects of LPS and farm dust 
treatment.  
 
Numerous animal studies have shown the beneficial effects of exposure to microbial products238,376, 
single bacterial species329,142,332, or farm-derived dust samples178,261,118 in controlling allergic airway 
inflammation and reducing cardinal features of allergic asthma. Mechanistic approaches have 
demonstrated that innate immune signalling particularly via the TLR4329,238-MyD88118-dependent 
pathway plays a key role in mediating these asthma-protective properties. The present results of farm 
dust induced downregulation of the LPS receptor TLR4 and its associated signalling adaptors 
MyD88 and TRAF6 corroborate these findings, indicating an immediate counter-regulatory 
process upon high-dose microbial exposure. It may well be supposed that persistent signalling 
through the same pathway results in a sustained tolerogenic state characterised by non- or hypo-
responsiveness to different immunogenic environmental stimuli377. Maintenance of any such state may 
be ensured by regulatory mechanisms at multiple levels, including effective control of proximal 
signalling as well as downstream NF-kB dependent pathways377,378. TNFAIP3 is known to attenuate 
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TLR4-induced NF-kB activation by inhibiting the activation and functional activity of TRAF6, and 
possibly other signalling intermediates upstream of IKK. Recent findings from a murine model of 
allergic asthma have attributed a key role to TNFAIP3 in mediating the protective effect of in vivo LPS 
and farm dust exposure, and have allocated the effect particularly to the structural cells of the airway 
epithelium261. The current study was the first to replicate these findings in primary human cells in vitro. 
Analyses revealed significant upregulation of TNFAIP3 mRNA and protein levels in asthmatic 
children’s PBMCs in response to LPS and farm dust stimulation, providing evidence for its 
relevant functional role in microbial-induced immunoregulation in humans as well. Given the fact 
that it was possible to detect these effects in peripheral immune cells, a ubiquitously relevant rather 
than cell-type specific molecular mechanism may be proposed as determining the protective effect of 
the diverse microbial environment. In fact, findings from animal models have also suggested a similar 
role of TNFAIP3 in intestinal epithelial cells379. This is particularly intriguing as it may provide an 
explanatory molecular approach to the extensively studied protective effect of farm milk consumption, 
which may hardly involve the airway epithelium but may certainly implicate immunological processes 
at the mucosal surface of the intestine.  
Notably, the expression of both positive and negative regulators of TNFAIP3 was virtually 
unaffected, suggesting the existence of alternative molecular mechanisms to regulate TNFAIP3 
activity upon farm dust exposure. 
Upregulation of TNFAIP3 may reflect a crucial regulatory mechanism through which farm dust 
exposure can suppress TLR4-mediated NF-kB induced inflammatory responses. The significant 
decrease in IL-18 levels in the presence of farm dust and LPS clearly supports this assumption, as it 
suggests that the NF-kB dependent induction of other pro-inflammatory target genes may be reduced 
as well. However, more functional readouts are certainly needed to assess further downstream effects 
associated with the inhibition of NF-kB activation. 
 
Besides barrier epithelial cells in the lung, gut and skin, antigen-presenting DCs are decisive sensors 
and transducers of TLR-mediated microbial-derived signals encountered in the farming environment33. 
A large body of evidence from animal and human studies points to their crucial involvement in the 
asthma-protective effect of farming exposures142,178,206-208,332. In fact, the above-discussed findings have 
been consistently replicated in DCs isolated from PBMCs from a small subsample of the present cohort 
(see publication321). Farm dust and LPS exposure may modulate immune responses by substantially 
influencing the phenotype and activation state of DCs, as indicated by the striking changes in 
expression of the co-regulatory molecules CD80, CD86 and CD274. Strong upregulation of CD80, 
accompanied by significant downregulation of CD86, was observed in response to LPS and G, Fi, and 
Am farm dust treatment. This also became evident in a significant decrease of CD86/CD80 ratio. Such 
opposing dynamics of the two co-stimulatory molecules may well be considered as an intriguing 
finding, since a comparable dichotomy in CD80/CD86 surface expression has not been reported in 
similar studies before. In view of the above-mentioned assumption of the differential roles of CD80 
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vs. CD86 in modulating T cell development, however, elevated CD80 together with reduced CD86 
levels may point to a DC-induced Th1/Treg polarising programme, which may inhibit pathogenic Th2 
cell development in asthmatic subjects. In support of this, additional measurements in the same study 
population revealed significant farm dust induced upregulation of CTLA-4, the inhibitory receptor for 
CD80 and CD86, while expression of the stimulatory receptor CD28 was reduced321. In line with these 
findings, Schuijs et al. recently demonstrated in their landmark study that chronic low-dose LPS or 
farm dust treatment significantly decreased the allergen-induced production of GM-CSF261, a cytokine 
which was shown to programme maturing DCs for the induction of Th2 cells380 and to reduce the 
threshold for allergen responsiveness381. Likewise, two independent studies conducted in human DCs 
have shown that incubation with different bacterial species isolated from cowshed dust modulated the 
immune response by inducing DC-dependent Th1 polarisation142,332.  
 
The net co-regulatory signal delivered by DCs of healthy and asthmatic children is further represented 
by the relation of co-inhibitory CD274 to co-stimulatory CD86 molecule expression. The remarkable 
increase observed for CD274 expression and concomitant CD274/CD86 ratio following LPS and farm 
dust stimulation supported the hypothesis of a farm dust induced ‘inhibitory’ phenotype of DCs. The 
vital role of CD274 (PD-L1) in mediating regulatory T (Treg) cell induction has been characterised 
previously369. A high CD274/CD86 ratio on plasmacytoid DCs (pDCs) in particular has been 
associated with elevated numbers of Treg cells382. The ability of pulmonary pDCs to suppress features 
of allergic asthma and inhibit the generation of effector T cells201 has been linked to their increased 
expression of CD274202. Therefore, it seems likely that microbial exposure delivered by LPS or farm 
dust stimulation may induce the development of Treg cells through a CD274-dependent mechanism, 
and there is recent evidence from animal models supporting this notion. Gollwitzer et al. have 
demonstrated that distinct changes in airway microbiota colonisation during the neonatal period 
sustainably prevented allergic airway inflammation by promoting the CD274-dependent induction of 
functional Treg cell subsets383.  
Taken together, the remarkable increase of the CD274/CD86 ratio accompanied by a 
significantly reduced CD86/CD80 ratio upon LPS and farm dust (G, Fi, Am) treatment may 
illustrate a switch in co-regulatory molecule expression on DCs promoting the development of 
Treg cells suppressing Th17- and/or Th2-mediated immune responses. 
 
Regardless of potential limitations in methodology and experimental setup as discussed in section 4.2, 
in vitro stimulation experiments yielded interesting results. The present data demonstrate strong anti-
inflammatory effects and potential asthma-protective properties of LPS and farm dust treatment in 
allergic asthmatic children. They point to a multicomponent mode of action, most likely involving the 
NF-kB inhibitor TNFAIP3 as a major determinant through which farm dust develops its beneficial 
potential. It may well be proposed that farming exposure leads to reduced proximal innate 
receptor signalling and, by activating TNFAIP3 and altering maturation processes and 
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functional activities of DCs, may dampen the TLR4-driven NF-kB dependent innate and 
subsequent adaptive immune response to environmental allergens. 
 
The anti-inflammatory effects of G, Fi and Am farm dust and LPS treatment were consistently 
observed in both healthy and asthmatic children, indicating that beneficial effects of farming 
exposure may be relevant regardless of the clinical phenotype. Yet, allergic asthmatic patients 
downregulated pro-inflammatory TLR4, MyD88 and TRAF6 as well as CD86 to a significantly greater 
extent. Likewise, upregulation of TNFAIP3 protein was stronger in asthmatic compared to healthy 
children when stimulated with the German, Finnish and Amish farm dust extracts. In this way, 
stimulation was able to restore gene expression features of a healthy immunophenotype in asthmatic 
children, and in particular raised their comparatively low basal expression of NF-kB inhibitor 
TNFAIP3 to ‘healthy levels’. This is a remarkable finding, as it strongly suggests that farming exposure 
may counterbalance, or rather overcome the manifest inflammatory immune phenotype of allergic 
asthmatic children at the early stage of symptomatic disease and may even be able to suppress an 
underlying predisposition in some children. Thus, the current data point to a significant potential for a 
farm dust derived treatment approach in asthmatic children. 
The question of clinical applicability, however, implies the need of defining a distinct composition of 
farm-derived microbial agents and products which provides the ‘most protective’ effects. The current 
study demonstrated very consistent anti-inflammatory effects for 24-hour stimulation with a 
0.1µg/ml LPS dose and with the German, Finnish and Amish farm dust extracts, whereas greatly 
divergent effects were observed upon stimulation with the dust samples from Chinese rural 
Conghua. These differences seemed to be largely due to the differential LPS content of the 
environmental dust extracts, which was by far the lowest in the Chinese samples. This is in line with 
previous epidemiological and immunological findings demonstrating a dose-dependent effect of 
endotoxin (LPS), with particularly high levels conferring asthma-protection118,135,333. In fact, the 
Chinese dust samples used in this work’s experiments may not reflect the protective in vivo exposure 
that the other dust samples do, since they had been collected in the family’s living rooms in China, 
where the amount of dust was rather low. Supporting this assumption, follow-up experiments of the 
study group using Chinese dust samples from hens’ stables with higher LPS content again revealed 
comparable anti-inflammatory effects as observed for the German, Finnish and Amish samples 
(personal communication). 
Remarkably, stimulation with 0.1µg/ml LPS yielded effects very similar to stimulation with the 
German, Finnish and Amish dust samples, suggesting no clear benefit of farm dust treatment in the 
present experimental approach. This was in line with findings from an animal model, which also 
showed comparable asthma-protective effects for LPS and farm dust261. However, since the different 
LPS concentrations between the farm dust extracts and LPS were not adjusted to a defined common 
stimulation dose, direct comparison of LPS and farm dust induced effects is not valid. The present data 
therefore cannot answer the widely discussed issue of defining a safe and ‘protective’ LPS dose, nor 
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do they help reveal potential ‘add-on’ signals in farm dust extracts, which might further contribute to 
the beneficial effects of in vivo farming exposure. In particular, it was not possible to identify 
distinctively protective microbial species, since unfractionated dust samples were used in the current 
model. Although high concentrations of environmental endotoxin may clearly represent the relative 
abundance of gram-negative bacteria, they cannot sufficiently reflect the diversity of microbial sources 
encountered in asthma-protective farming environments143,384. Indeed, 16S rRNA sequencing analyses 
performed in the German and Finnish dust samples also revealed a certain percentage of gram-positive 
non-LPS containing bacteria from the Firmicutes and Actinobacter phyla. According to the current 
state of knowledge, it remains unclear whether the relative contribution of these and other microbes 
found in farm-derived dust samples, including gram-positive bacterial species141,144, parasites and 
fungi385, or even plant-derived products179, plays a role in mediating the protective effects. Most recent 
studies, however, have provided substantial evidence for a specific composition of bacterial 
communities rather than individual species being the key determinant for asthma-protection386,146, and 
thereby support the present model-based approach.  
4.3.4 Immune profile of farm children at ages 4.5, 6 and 10 years 
The current in vitro model suggested profound effects of farming exposures on major signalling 
pathways within innate immunity. In order to investigate how sustained microbial stimulation in vivo 
might affect these regulatory innate immune genes, gene expression analyses were performed in 
immune cells of farm children at three different time points (4.5 years, 6 years, 10 years of age). Indeed, 
continuous farm exposure was reflected in the innate immune signature of farm children’s peripheral 
blood cells when compared to non-farm children. Analyses revealed a distinct pattern of consistently 
decreased pro- and anti-inflammatory genes particularly in the 4.5- and 6-year-old farm 
children. 
 
It is reasonable to assume that the immune homoeostasis of farm children, who face repeated 
stimulation by a wide range of microbial antigens and environmental allergens, depends largely on 
developing and maintaining a state of non-responsiveness to these stimuli. From a molecular 
perspective, this is considered to be the result of a multi-levelled counter-regulatory process, similar to 
the phenomenon described for chronic low-dose LPS (endotoxin) exposure, termed ‘endotoxin 
tolerance’ (ET)387,388. Since LPS is known as a major component within the microbial cocktail of the 
farming environment, a comparable mechanism may well be proposed for chronic farm exposure. 
Induced by repeated and prolonged (LPS) stimulation, TLRs, the first site to sense antigens, change 
into a refractory, tolerogenic state, and they become hypo-responsive or even insensitive to ligand re-
stimulation378. During ET, profound gene reprogramming processes lead to transient silencing of pro-
inflammatory genes such as TLRs, while genes encoding anti-inflammatory cytokines or regulatory 
effector molecules were shown to be over-expressed upon LPS re-exposure389. Molecular mechanisms 
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underlying the regulation of ET-associated genes are considered to involve TLR4-induced epigenetic 
changes such as chromatin remodelling389.  
The farming environment may serve as an in vivo model to put some of these in vitro findings into a 
practical context. Gene expression in farm children is likely to be governed by epigenetic 
modifications390 as well as genetic variants, which may therefore also contribute to defining the 
individual ‘protected’ immune phenotype. Such genetic alterations have been observed for both the 
TLR4235,391,392 and the TNFAIP3261 gene in response to environmental microbial exposures and may 
also explain the partial discrepancy of the current data compared to previous findings from farming 
cohorts. Analyses in the present PASTURE/EFRAIM study subsample did not reveal significant 
differences in TLR4 gene expression between farm and non-farm children at any age. In contrast, 
elevated levels of TLR4 and several other innate immune receptor genes and related signalling cascade 
molecules were found in immune cells of children with early life or prenatal farm exposure in the 
ALEX241, PARSIFAL240,122,188 and also the PASTURE393 study. 
Consistent with the ET hypothesis, TNFAIP3 along with other negative regulators of TLR-induced 
signalling was shown to be induced in LPS tolerised macrophages378. Experimental studies in mice 
have further demonstrated that TNFAIP3 is critically involved in maintaining immune homoeostasis 
in the gut by regulating constitutive TLR stimulation derived from commensal microbiota394. Based on 
these findings, increased levels of TNFAIP3, which were found in children from the U.S. Amish 
farming population118, indicate a molecular mechanism to control constant TLR4-dependent signalling 
induced by the variety of microbial cues in the farming environment. However, the phenotype of farm 
children’s immune cells in the present PASTURE study cohort did not fully reflect the ET model and 
did not confirm the findings from the Amish farming cohort in particular. Data from this work showing 
significantly decreased tolerogenic markers TNFAIP3 and CD274 in the farm children compared to 
non-farm children at the age of 4.5 and 6 are somehow surprising. The findings were replicated at a 
highly significant level in the TRILATERAL cohort comprising 112 7-year-old children from rural 
Conghua and urban Hong Kong321, which suggests a stable and true finding. 
It is the current conception that the farming environment exerts most effective protective effects when 
exposure happens in the very early period of life and already prenatally395. Although it is known that 
major maturation processes and long-term antigen memory are also established during that phase, our 
common understanding of the exact kinetics and the speed of the principal immunological changes that 
occur postnatally and during infancy is still limited115. An experimental animal model of asthma has 
shown that the CD274-dependent development of Treg cells suppressing the development of aberrant 
inflammatory processes is induced by microbial stimulation immediately after birth383. Similarly, 
analyses in cord blood samples of infants with maternal farm exposure already exhibited increased 
numbers of Treg cells186, and a higher percentage of Tregs was still found in farm-exposed children of 
the PASTURE cohort at the age of 4.5 years187. However, members of our research group have found 
a significant decrease in Treg cells between the age of 4.5 and 6 years in the same population308, and 
likewise, school-aged Amish farm children did not show differential Treg numbers when compared to 
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the Hutterite children118. These findings suggest that distinct timeframes in which regulatory immune 
processes develop may exist, and that effects of long-term microbial exposure may manifest in a certain 
immune phenotype at different stages. On the basis of that notion, the present data may not reflect the 
immediate changes during the early establishment of immune homoeostasis in farm children. 
Decreased expression of both regulatory and inflammatory innate immune genes in farm 
children at school age may therefore either be causally linked to their protection from allergic 
disease, or may be due to a secondary effect of downregulation, reflecting a suppressed steady 
state, a ‘tolerant’ immune phenotype maintained after a period of continuous in vivo microbial 
exposure. Data from U.S. and European farming studies reinforce this conception, showing generally 
decreased levels of Th2- and Th17-, but also Th1- and Treg cell-associated cytokines in LPS-stimulated 
peripheral blood leucocytes of farm children at school age118,135. A recently published study by 
Kirjavainen et al. could demonstrate similar effects of suppressed cytokine responses to LPS even in 
PASTURE/LUKAS 6-year-old non-farm children when they were exposed to an indoor microbiota 
composition similar to farm homes146. 
 
Given the understanding that the generation of tolerance is a dynamic process, it is reasonable to 
suggest that key regulatory molecules such as TNFAIP3, CD274 and CD80 are upregulated in farm 
children’s immune cells during the crucial phase of immune maturation in infancy, while 
downregulation may occur once immune homoeostasis is established in the healthy child. Such an 
educated, or ‘tolerised’ immune system of farm children may not be set at a defined state of constitutive 
unresponsiveness, but rather allow dynamic responses to different environmental cues. This was shown 
upon stimulation with LPS and the different farm dust extracts in the present farming cohort. Similar 
to their non-farming or urban peers respectively, all 4.5-, 6- and 10-year-old farm children consistently 
demonstrated a significant decrease in expression of TLR4, while increasing TNFAIP3, CD274 and 
CD80 in response to LPS and farm dust stimulation. This indicates that the capacity to downregulate 
inflammatory molecules and to induce regulatory anti-inflammatory processes is preserved in 
farm children.  
Interestingly, the 10-year-old German farm children exhibited significantly altered immune responses 
upon stimulation with the German farm dust sample compared to those observed when treated with 
LPS or the Amish or Finnish dust samples, respectively. This is a striking finding, as it strongly argues 
that the immune response is specific to the environmental exposure that the system had been 
conditioned for. Although these preliminary findings definitely need confirmation on a larger scale, 
they point to a mechanism of long-term immunological tolerance in farm children, with 
sustainably altered immune responses to a distinctive ‘cocktail’ of microbial stimuli ‘known’ 
from continuous early life in vivo exposure.  
 
Despite the protective effect of such environmental exposure, a small number of farm children still 
develop asthma, which illustrates clearly the contribution of non-environmental factors when 
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determining the manifestation of the disease. Indeed, the current data supported this notion in some 
part. When stratified by phenotype in the 6-year-old German farming group, peripheral blood samples 
of asthmatic farm children exhibited significantly decreased TNFAIP3 expression when compared to 
their healthy farming peers. This finding provides further evidence for a key role of TNFAIP3 at the 
interface between disease-determining and disease-protecting factors and further reinforces the notion 
that - apart from environmental determinants - inherited factors may also play a decisive role in 
defining the allergic asthmatic phenotype in children396. While strong genetic factors may primarily 
determine the development of asthma in farm children, non-inheritable environmental exposures 
may be more relevant for disease manifestation in non-farm children. Thus, protective 
environmental conditions may not be strong enough to overcome a certain genetic risk profile. 
This further implies that the individual’s effective protection from asthma and allergic disease also 
requires a genotype which is accessible to the protective environmental stimuli. These considerations, 
however, remain speculative at this point, since the genetic background of the investigated study cohort 
will still be unknown when this work is completed. However, genome-wide analysis data from the 
whole PASTURE study population are to be expected in the near future and may provide a clearer 
view on the heritability component of allergic asthma, particularly in the farming population. 
Notwithstanding this, previous large-scale GWAS studies in asthma397,398 have already taught us that 
complementary explanations besides single heritable factors must exist to determine the phenotype of 
allergic asthma in children399. It is becoming clear that the impact of non-heritable environmental 
factors on the human immune system cannot be underestimated400, and that this particularly applies to 
exposures in farming environments and the associated changes in innate immunity functions and 
asthma risk118.  
 
Overall, the current results indicate that sustained early life in vivo farming exposure modulates the 
expression of genes encoding innate immune signalling molecules, although the immunological 
mechanisms underlying the observed effects remain undefined. Future large-scale studies may be able 
to particularly elucidate the role of TNFAIP3 and related innate immune pathways in the context of 
environmentally mediated childhood asthma protection.  
4.4 Concluding remarks and outlook 
In conclusion, the immunological studies conducted on children’s peripheral blood immune cells 
within the scope of this work demonstrated a straightforward approach providing robust and consistent 
findings on the role of TNFAIP3 and related innate immune signalling pathways in the development 
of childhood allergic asthma and its environmentally mediated protection. The findings presented 
provide further insight into the potential mechanisms underlying the epidemiological ‘farm-effect’ on 
asthma by revealing significant immunomodulatory properties of in vitro and in vivo farming exposure. 
Corroborated by earlier studies in both mice and humans, the present data suggest that strong 
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immunostimulatory signals encountered in the farming environment may decrease asthma risk by 
activating regulatory TNFAIP3-dependent processes and sustainably altering innate immune 
pathways. Even if definite practical implications cannot yet be deduced, the results of this study point 
to a significant potential of a microbial-based treatment approach for the prevention of allergic asthma 
in children.  
 
Considerable support for this concept comes from the emerging field of microbiome research, which 
continues to reinforce the major impact of the human microbial ecosystem on the development of 
immune-mediated disorders401. Growing evidence suggests that reduced exposure to a biodiverse 
microbial environment early in life may cause major disruptions in endogenous commensal microbiota 
composition, which in turn results in dysregulated, i.e. non-tolerant immune function promoting 
allergic inflammation145,402,403. The notion that ‘appropriate’ intestinal colonisation early in life may 
prevent allergic disease has fuelled the development of bacterial probiotics404,405, but clinical effects of 
interventions have so far been disappointing406. From the clinical perspective, however, adjusting 
microbiota imbalances through targeted modification of the external microbial exposures and/or the 
internal lung and gut microenvironment remains a promising concept for future asthma treatment. 
Coupling findings from the farming studies with the novel possibilities in microbiome profiling and 
profound immunological research might help to overcome the challenges of designing such a novel 
interventional approach405. Based on most recent findings, it may now be possible to select specific 
compositions of beneficial farm-related microbes, to use them in well-structured interventional 
studies146 and evaluate the immunological changes and related clinical outcomes they may provoke. 
Modifying the indoor microbial environment may thereby constitute a feasible, non-invasive approach, 
implying the natural routes of exposure via inhalation, oral intake, or skin contact.  
 
Considering the vast number of children with severely uncontrolled or residual disease under current 
standard treatment, the key to reducing the global burden of asthma will essentially rely on establishing 
novel effective strategies for both disease prevention and therapy. Many years have passed since the 
‘hygiene hypothesis’ was posed, and its theories have inspired researchers around the globe. Today, 
human research is on the verge of ultimately deciphering a causal relationship between early life 
microbial exposures and childhood asthma protection. Taking advantage of the valuable knowledge 
provided by epidemiological and immunological research over the last few decades may now allow for 
the development of translational interdisciplinary clinical trials and thus eventually transfer 
immunological findings from ‘bench to bedside’.  




Asthma has become one of the most common chronic diseases among children in developed Western 
countries, with its prevalence still rising in other parts of the world. Distinct microbial exposures 
encountered in traditional farming environments early in life have been associated with robust 
protection from developing the disease. The practical relevance of this protective ‘farm-effect’, 
however, remains limited as long as the causal mediators and molecular mechanisms have not been 
fully identified. In this context, recent findings in mouse models of asthma have suggested a key role 
for the enzyme TNFAIP3, which attenuates NF-kB dependent inflammation, but equivalent 
immunological studies in humans are missing. 
 
The objective of the present study was therefore to unravel the role of the anti-inflammatory regulator 
TNFAIP3 and related innate immune signalling pathways in the development of allergic asthma and 
its environmentally mediated protection in children. The study aimed to investigate target gene and 
protein expression in peripheral blood mononuclear cells (PBMCs) of allergic asthmatic children 
during disease manifestation. It further aimed to examine the effect of in vitro stimulation with farm 
dust extracts and bacterial lipopolysaccharide (LPS) on the expression of these target molecules. 
Moreover, the study aimed to assess whether children with continuous early life in vivo farm exposure 
showed modified TNFAIP3 pathway gene expression in immune cells at the age of 4.5, 6 and 10 years.  
 
Therefore, peripheral blood samples of asthmatic and healthy children from urban and farm 
environments from two distinct study population cohorts were analysed. As part of the cross-sectional 
CLARA/CLAUS study, a representative nested study sample comprising allergic asthmatic (AA) and 
healthy control (HC) school-age children (n = 48) was recruited. PBMCs were isolated from whole 
blood samples and stimulated in vitro with four different farm-derived dust extracts (from Germany, 
Finland, China and from the Amish farming environment) as well as LPS for 24 hours. Furthermore, 
from the prospective birth cohort study PASTURE/EFRAIM, a nested sample of farm (F) and non-
farm (NF) children (n = 100) was selected. Unstimulated and LPS-stimulated whole blood samples 
were analysed at the children’s age of 4.5, 6 and 10 years. For both cohorts, gene expression and protein 
levels of TNFAIP3 and NF-kB signalling-associated candidate molecules (TLR4, MyD88, TRAF6, 
TNIP2, TAX1BP1, MALT1, CD80, CD86, CD274, PDCD1) were assessed by qPCR and Western 
Blot analysis respectively. 
 
The following results were achieved and are presented in this thesis: 
(i) Analyses in unstimulated PBMC samples revealed significantly reduced expression of the anti-
inflammatory TNFAIP3 gene and protein in allergic asthmatic children compared to healthy 
controls, while expression of the pro-inflammatory pathway genes TLR4 and MyD88 was 
increased in allergic asthmatic subjects.  
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(ii) In vitro stimulation with LPS and all four farm dust extracts except the Chinese sample restored 
TNFAIP3 expression of asthmatic patients to healthy levels and significantly reduced the 
expression of the pro-inflammatory TLR4-pathway-related target genes (TLR4, MyD88, TRAF6). 
The observed anti-inflammatory effects were accompanied by significant downregulation of 
dendritic cell associated co-stimulatory molecule CD86 and upregulation of the co-inhibitory 
molecule CD274 upon stimulation.  
(iii) Unstimulated whole blood samples of farm children at ages 4.5, 6 and 10 years exhibited 
decreased expression of both pro- and anti-inflammatory genes compared to their non-farming 
peers. However, the capacity to induce anti-inflammatory TNFAIP3 and CD274 expression and 
to downregulate pro-inflammatory TLR4 levels upon LPS and farm dust stimulation was 
preserved at all ages. 
 
The results of this study in children’s peripheral immune cells indicate that farming exposures in vitro 
and in vivo may inhibit critical inflammatory processes in human asthma development by activating 
regulatory TNFAIP3-dependent processes and shaping innate immune pathways. These findings 
increase the potential for novel farm-derived microbe-based treatment and prevention strategies, and 
thus may ultimately pave the way for improving asthma management on a global scale.




Asthma bronchiale zählt in den westlichen Industrienationen mittlerweile zu einer der häufigsten 
chronischen Erkrankungen im Kindesalter, wobei in anderen Teilen der Welt weiterhin ein Anstieg der 
Prävalenz verzeichnet wird. Es hat sich gezeigt, dass insbesondere der frühe Kontakt zu bestimmten 
mikrobiellen Bestandteilen in der Bauernhof-Umgebung einen wirksamen Schutz vor der Erkrankung 
vermittelt. Dieser sogenannte "Bauernhof-Effekt" ist jedoch von geringer praktischer Relevanz, 
solange die ursächlichen Mediatoren und zugrundeliegenden molekularen Mechanismen nicht 
vollständig entschlüsselt sind. In diesem Zusammenhang weisen nun jüngste Forschungsergebnisse an 
Asthma-Mausmodellen auf eine Schlüsselrolle des Enzyms TNFAIP3 hin, welches NF-kB-vermittelte 
Entzündungsprozesse hemmt. Dabei fehlen aktuell entsprechende immunologische Untersuchungen 
am Menschen. 
 
Ziel der vorliegenden Studie war es daher, die Rolle des entzündungshemmenden Regulators TNFAIP3 
und zugehöriger Signalwege der angeborenen Immunität bei der Entstehung von allergischem Asthma 
bronchiale im Kindesalter und seinem umweltvermittelten Schutz zu entschlüsseln. Vor diesem 
Hintergrund sollten Gen- und Proteinexpression von TNFAIP3 und entsprechenden Zielmolekülen in 
peripheren mononukleären Blutzellen (PBMCs) von Kindern mit allergischem Asthma bei 
Krankheitsmanifestation untersucht und anschließend die Auswirkung von in-vitro-Stimulation mit 
Bauernhofstaubextrakten und bakteriellem Lipopolysaccharid (LPS) auf die Expression dieser 
Zielmoleküle betrachtet werden. Darüber hinaus sollte untersucht werden, ob Immunzellen von 
Bauernhofkindern nach anhaltender in-vivo-Bauernhofexposition im Alter von 4,5, 6 und 10 Jahren 
veränderte Expressionsmuster ausgewählter Zielgene innerhalb des TNFAIP3-Signalweges aufweisen. 
 
Mithilfe von zwei verschiedenen Studienkohorten wurden hierfür Blutproben von Kindern mit Asthma 
bronchiale und von gesunden Kindern aus städtischen sowie ländlichen Gebieten analysiert. Im 
Rahmen der CLARA/CLAUS-Querschnittsstudie wurde eine repräsentative Kohorte von Schulkindern 
mit allergischem Asthma (AA) sowie gesunden Kontrollen (HC) (n = 48) rekrutiert. Aus 
Vollblutproben wurden PBMCs isoliert und in vitro mit vier verschiedenen Bauernhofstaubextrakten 
(aus Deutschland, Finnland, China und von den Amischen aus Amerika) sowie mit LPS für 24 Stunden 
stimuliert. Des Weiteren wurde aus der prospektiven Geburtskohorte PASTURE/EFRAIM eine 
Stichprobe von Kindern ausgewählt, die am Bauernhof aufgewachsen sind (F) und solchen, die nicht 
am Bauernhof aufgewachsen sind (NF) (n = 100). Deren unstimulierte und LPS-stimulierte Blutproben 
wurden im Alter von 4,5, 6 und 10 Jahren untersucht. In beiden Studienpopulationen erfolgte die 
Auswertung der Gen- und Proteinexpression von TNFAIP3 und Zielmolekülen des NF-kB Signalwegs 
(TLR4, MyD88, TRAF6, TNIP2, TAX1BP1, MALT1, CD80, CD86, CD274, PDCD1) mittels qPCR 
und Western-Blot. 
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Folgende Ergebnisse wurden erzielt und sind in der vorliegenden Arbeit dargestellt: 
(i) In unstimulierten PBMCs zeigte sich bei Kindern mit allergischem Asthma im Vergleich zu 
gesunden Kontrollen eine signifikant reduzierte Expression des entzündungshemmenden 
Regulators TNFAIP3 auf Gen- und Proteinebene bei zugleich erhöhter Expression der 
entzündungsfördernden Moleküle des Signalwegs (TLR4, MyD88).  
(ii)  In-vitro-Stimulation mit LPS und allen vier Bauernhofextrakten mit Ausnahme der chinesischen 
Staubprobe konnte die verminderte Expression von TNFAIP3 bei Asthmatikern auf das Niveau 
gesunder Kinder anheben und zugleich die Expression der entzündungsfördernden Zielgene des 
TLR4-Signalwegs (TLR4, MyD88, TRAF6) signifikant reduzieren. Der beobachtete 
entzündungshemmende Effekt der Stimulation zeigte sich außerdem in einer deutlichen 
Expressionsreduktion des mit dendritischen Zellen assoziierten kostimulatorischen Moleküls 
CD86 bei gleichzeitiger Expressionserhöhung des koinhibitorischen Moleküls CD274. 
(iii) Unstimulierte Vollblutproben von Bauernhofkindern im Alter von 4,5, 6 und 10 Jahren wiesen 
im Vergleich zu Proben von nicht-Bauernhofkindern eine verminderte Expression sowohl 
entzündungsfördernder als auch -hemmender Gene auf. Die Fähigkeit zur Expressionserhöhung 
der entzündungshemmenden Regulatoren TNFAIP3 sowie CD274 sowie Reduktion des 
entzündungsfördernden Gens TLR4 bei LPS- und Bauernhofstaubstimulation blieb jedoch in 
jedem Alter erhalten. 
 
Die Daten der vorliegenden Studie an peripheren Immunzellen von Kindern deuten darauf hin, dass 
Bauernhof-Expositionen in vitro und in vivo maßgebliche Entzündungsprozesse bei der Entstehung 
von Asthma bronchiale hemmen, indem möglicherweise regulatorische TNFAIP3-vermittelte Prozesse 
aktiviert und Signalwege der angeborenen Immunität modifiziert werden. Diese Ergebnisse eröffnen 
neue Möglichkeiten für die Entwicklung mikrobiell-basierter Präventions- und Therapiestrategien und 
können somit letztlich zu einem optimierten und umfassenderen Konzept zur Entstehung und 
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10.1 Supplementary tables and figures 
Table E1 provides an overview of the number of samples that had been excluded from further 
statistical analysis. These samples did not meet the criteria of quality control (i.e. technical replicates 
with a difference of Ct values > 0.4, as well as melting curve abnormalities), as they are described in 





Stimulating conditions were lipopolysaccharide (LPS) and dust extracts from German (G), Finnish (Fi), and 
Chinese (Ch) farming environments, and from farms of the Amish population (Am). n, number of excluded 




























TLR4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
MyD88 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
TRAF6 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
TNFAIP3 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
TNIP2 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
TAX1BP1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
MALT1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
CD80 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
CD86 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
CD274 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
PDCD1 2 (5.4) 2 (5.4) 3 (8.1) 4 (10.8) 2 (5.4) 3 (8.1) 
























































Figure E1. TNFAIP3 protein levels at different molecular weight. 
TNFAIP3 protein levels, as assessed by Western Blot analysis in unstimulated PBMCs of HC (n=11) and AA 
(n=14). (A) TNFAIP3 protein, predicted 82kDa size. (B) ‘total TNFAIP3’ (~100 kDa + 82kDa). Results from 
densitometric analysis of protein bands. Normalized protein expression, relative to b-Actin. Lines at mean value. 
A.U., arbitrary units. (C) representative immunoblot membrane-cut-out. Molecular weight in kDa. b-Actin was 
used as loading-control. P values reflect Welch’s t test. *p < 0.05. 







































































































Figure E2. Fold change of TNFAIP3 regulatory gene expression upon LPS and farm dust stimulation. 
(A) TNIP2, (B) TAX1BP1 and (C) MALT1 gene expression fold change, compared to unstimulated conditions 
(2-DDCt, log2 scale), as assessed by qPCR in PBMCs of HC (n=22) and AA (n=16) after 24 hrs stimulation with 
LPS or farm dust extracts (G, Fi, Ch, Am). Scatter dot plots represent single sample values with means and 95% 
CI. P values reflect Welch’s t test for fold change comparison between HC and AA. *p < 0.05; ns, not significant.  
































































































































4.5 years 6 years
A
B
Figure E3. TNFAIP3 and TLR4 mRNA expression in NF and F children without asthma. 
Baseline gene expression levels of TNFAIP3 (A) and TLR4 (B), as measured by qPCR in unstimulated whole 
blood samples of healthy farm (F) and non-farm (NF) children, assessed at ages 4.5 years (n=25, 13 F/ 12 NF) 
and 6 years (n=43, 23 F/20 NF). Expression relative to 18S, displayed as 2-DCt mean values with 95% CI. P values 
reflect Welch’s t test for DCt comparison between NF and F. *p < 0.05; ns, not significant. 
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CD274
4.5 years 6 years
Figure E4. CD80 and CD274 mRNA expression in NF and F children without asthma. 
Baseline gene expression levels of dendritic cell markers CD80 (A) and CD274 (B), as measured by qPCR in 
unstimulated whole blood samples of healthy farm (F) and non-farm (NF) children, assessed at ages 4.5 years 
(n=25, 13 F/ 12 NF) and 6 years (n=43, 23 F/20 NF). Expression relative to 18S, displayed as 2-DCt mean values 
with 95% CI. P values reflect Welch’s t test for DCt comparison between NF and F. *p < 0.05; ns, not significant. 
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10.2 CLARA/CLAUS questionnaire 
 
 










Fragebogen für die Eltern 
 
Wir freuen uns, dass Sie an unserer Asthmastudie teilnehmen. Bitte kreuzen Sie die 
folgenden Fragen an. Ihre Antworten werden vertraulich behandelt. Wenn Sie eine Frage 
nicht beantworten möchten, lassen Sie sie bitte aus. 
Wir danken Ihnen herzlich für Ihre Mitarbeit! 
 
Bei Studieneinschluss erhobene Daten: 
Körpergröße (in cm) 
 
 
Gewicht (in kg) 
 
 
Wir beginnen mit Fragen zu pfeifenden und keuchenden Atemgeräuschen. Mit 
pfeifenden Atemgeräuschen meinen wir ein pfeifendes Geräusch, das aus dem 
Brustkorb kommt, aber nicht geräuschvolles Atmen durch die Nase. 
1.  Hat Ihr Kind jemals pfeifende bzw. keuchende Atemgeräusche gehabt? 
Ja ..................................................... ̈  
                Falls Ja,  
                wann sind diese zum ersten Mal aufgetreten:_____________ 
Nein ................................................. ̈  Þ weiter mit Frage 12  
2.  Hatte Ihr Kind in den letzten 12 Monaten pfeifende bzw. keuchende 
Atemgeräusche? 
Ja ........................................................ ¨ 
Nein .................................................  ¨ Þ weiter mit Frage 12  
3.  Wie oft hatte Ihr Kind in den letzten 12 Monaten pfeifende bzw. keuchende 
Atemgeräusche? 
Gar nicht ............................................ ¨ 
1-3 mal .............................................. ¨ 
4-12mal .............................................. ¨ 
Mehr als 12 mal .................................. ¨ 
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4.  Hatte Ihr Kind in den letzten 12 Monaten jemals Atemnot, als die pfeifenden/ 
keuchenden Atemgeräusche auftraten? 
Ja  .................. ¨ 
                  Nein                                   .................. ¨ 
5.  Wie häufig ist Ihr Kind in den letzten 12 Monaten nachts wegen pfeifender 
oder keuchender Atemgeräusche aufgewacht?  
                    Seltener als einmal pro Monat ............            ¨ 
Einmal pro Monat ...............................            ¨ 
                    Mindestens zweimal pro Monat ...........            ¨ 
6.  Wodurch wurden bei Ihrem Kind die pfeifenden / keuchenden Atemgeräusche 
ausgelöst? 
     Ja      Nein 
Anstrengung ................................ ̈  .......... ̈  
Erkältung .................................... ̈  .......... ̈  
Kontakt mit Tieren ...................... ̈  .......... ̈  
Kontakt mit Hausstaub ................. ̈  .......... ̈  
Kontakt mit Gras ......................... ̈  .......... ̈  
Sonstiges ..................................... ̈  .......... ̈  
______________________________________ 
7.  Wie häufig hatte Ihr Kind in den letzten 12 Monaten pfeifende oder 
keuchende Atemgeräusche, ohne dass es erkältet war? 
Nie .................................................... ¨ 
Seltener als einmal pro Monat ............. ¨ 
Einmal pro Monat ............................... ¨ 
Mindestens zweimal pro Monat .......... ¨ 
8.  Ist das Kind zwischen diesen Episoden völlig beschwerdefrei? 
Ja ..................................................... .... ¨Þ weiter mit Frage 12  
                 Nein ..................................................... ¨ 
9.  Hat Ihr Kind zwischen diesen Episoden folgende Beschwerden 
bei Anstrengung? 
    Ja      Nein 
Husten ........................................ ̈  .......... ̈  
Pfeifende Atemgeräusche ............. ̈  .......... ̈  
Atemnot ...................................... ̈  .......... ̈  
Sonstiges:________________________________ 




    Ja      Nein 
Husten ........................................ ̈  .......... ̈  
Pfeifende Atemgeräusche ............. ̈  .......... ̈  
Atemnot ...................................... ̈  .......... ̈  
                    Sonstiges:________________________________ 
 
Nachts? 
    Ja      Nein 
Husten ........................................ ̈  .......... ̈  
Pfeifende Atemgeräusche ............. ̈  .......... ̈  
Atemnot ...................................... ̈  .......... ̈  





10.  Hat Ihr Kind jemals in den letzten 12 Monaten von einem Arzt 
Medikamente gegen pfeifende oder keuchende Atemgeräusche, oder 
Giemen oder Atemnot verschrieben bekommen?  
(Gemeint sind damit nicht nur Medikamente zum Schlucken, sondern auch 
Inhalationen oder Sprays) 
Ja  .................. ¨ 
Nein  .................. ¨  Þ weiter mit Frage 12  
 
11.  Welche Medikamente waren dies?  
Bitte geben Sie den Markennamen möglichst genau an! Und sofern Sie es 













12.  Hat Ihr Kind jemals in den letzten 12 Monaten von einem Arzt 
Medikamente aus einem anderen Grund verschrieben bekommen? 
(Gemeint sind damit nicht nur Medikamente zum Schlucken, sondern auch 
Inhalationen oder Sprays) 
Ja  .................. ¨ 
Nein  .................. ¨  Þ weiter mit Frage 14  
 
13.  Welche Medikamente waren dies?  
Bitte geben Sie den Markennamen möglichst genau an! Und sofern sie es 





                    3.  ________________________________________ 
Es folgen Fragen zu Beschwerden der Nase und der Augen 
 
14.  Hat Ihr Kind jemals Niesanfälle oder eine laufende, verstopfte oder juckende 
Nase, obwohl es nicht erkältet war? 
Ja ...................................................... ̈  
Falls Ja, wann ist dies zum ersten Mal aufgetreten: 
 
Nein .................................................. ̈  Þ weiter mit Frage 18  
 
15.  Hatte Ihr Kind in den letzten 12 Monaten Niesanfälle oder eine laufende, 
verstopfte oder juckende Nase, obwohl es nicht erkältet war? 
Ja ...................................................... ̈  
                     Nein ................................................. ̈  Þ weiter mit Frage 18  
16.  Hatte Ihr Kind in den letzen 12 Monaten gleichzeitig mit diesen 
Nasenbeschwerden juckende oder tränende Augen? 
Ja ...................................................... ̈  
                     Nein ................................................. ̈  






17.  Wann in den letzen 12 Monaten traten diese Nasen-Beschwerden auf?  
Mehrere Antworten sind möglich. 
 
Januar           ¨            Mai         ¨............. September ¨ 
Februar         ¨            Juni         ¨............  Oktober  ¨ 
März             ¨............Juli ......   ¨............ November ¨ 
April             ¨............August ..  ¨.............Dezember ¨ 
 
18.  Ist von einem Arzt bei Ihrem Kind schon einmal Heuschnupfen oder eine 
allergische Rhinitis bzw. Rhinokonjunktivitis festgestellt worden? 
Ja ...................................................... ̈  
                     Nein ................................................. ̈  
Es folgen Fragen zu Hauterkrankungen 
19.  Hatte Ihr Kind jemals eine Neurodermitis/atopische Dermatitis/ atopisches 
Ekzem  
Ja  .................. ¨ 
Falls Ja, wann ist diese zum ersten Mal aufgetreten:  
Nein  .................. ¨  Þ weiter mit Frage 29  
20.  Wurde bei Ihrem Kind die Diagnose einer Neurodermitis/atopischen 
Dermatitis/ atopisches Ekzem von einem Arzt gestellt? 
Ja  .................. ¨ 
                    Nein .................................................. ¨   
21.  Hatte Ihr Kind in den letzten 12 Monaten eine Neurodermitis/atopische 
Dermatitis/ atopisches Ekzem  
Ja  .................. ¨ 
Nein  .................. ¨   
22.  War der Hautausschlag je an einer der folgenden Stellen? 
    Ja      Nein 
Gesicht ....................................... ̈  .......... ̈  
Hals ............................................ ̈  .......... ̈  
Ellenbeugen / Kniekehlen ............ ̈  .......... ̈  
Hand- / Fußgelenke ..................... ̈  .......... ̈  
Brust/Rücken .............................. ̈  .......... ̈  
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23.  Hat sich die Lokalisation des Ausschlages im Laufe der Zeit geändert? 
 
Ja  .................. ¨ 
Falls Ja, wo war er zu Beginn? Wo befindet er sich heute? 
 
Zu Beginn:  
    Ja      Nein 
Gesicht ....................................... ̈  .......... ̈  
Hals ............................................ ̈  .......... ̈  
Ellenbeugen / Kniekehlen ............ ̈  .......... ̈  
Hand- / Fußgelenke ..................... ̈  .......... ̈  
Brust/Rücken .............................. ̈  .......... ̈  
 
Heute:  
    Ja      Nein 
Gesicht ....................................... ̈  .......... ̈  
Hals ............................................ ̈  .......... ̈  
Ellenbeugen / Kniekehlen ............ ̈  .......... ̈  
Hand- / Fußgelenke ..................... ̈  .......... ̈  
Brust/Rücken .............................. ̈  .......... ̈  
 
                    Nein      ¨   
 
24.  Wenn Sie die Zeiten, in denen Ihr Kind diesen Hautausschlag hatte, 
zusammenzählen: Wie lange haben Sie diesen Hautausschlag insgesamt 
beobachtet? 
Für insgesamt weniger als 3 Monate ....  ¨ 
Für insgesamt 3-6 Monate ...................  ¨ 
Für insgesamt 6-12 Monate .................  ¨ 
Für länger als 12 Monate  ...................  ¨ 
 
25.  Ist der Hautausschlag wieder völlig verschwunden, oder „kommt und geht“ 
der Hautausschlag? 
Der Hautausschlag ist vollständig  
Verschwunden ....................................  ¨ 
Der Hautausschlag „kommt und geht“ .  ¨ 
Der Hautausschlag ist noch da ............  ¨ 







26.  Wie alt war Ihr Kind, als der Hautausschlag vollständig verschwunden ist?  
 ______ Monate 
27.  Wie häufig ist Ihr Kind nachts wegen Juckreiz aufgewacht? 
Seltener als einmal pro Monat oder nie ........ ̈  
Einmal pro Monat ....................................... ̈  
Mindestens zweimal pro Monat ................... ̈  
 
28.  Haben Sie die Haut Ihres Kindes in den letzten 12 Monaten mit einer 
cortisonhaltigen Creme / Salbe oder einer Tacrolimus- bzw. Pimecrolimus-
haltigen Salbe (Protopic, Elidel) behandelt? 
Ja ................ ¨ 
Nein ............ ¨ 
Es folgen Fragen zu Nahrungsunverträglichkeiten oder –allergien 
 
29.  Hat Ihr Kind eine Nahrungsmittelallergie? 
                                     Ja ...................................... ̈  
                                     Nein .................................. ̈   Þ weiter mit Frage 32  
 
30.  Wie äußert sich diese Nahrungsmittelallergie? 
Ausschlag/rote Flecken um den Mund herum............¨ 
Ausschlag/rote Flecken an anderen Körperstellen......¨ 
Schwellung der Lippen   .......................................... ̈  
Juckreiz   ................................................................ ̈  
Durchfall  ............................................................... ̈  
Erbrechen ............................................................... ̈  
Verschlechterung der Neurodermitis ........................ ̈  
Pfeifende Atemgeräusche  ....................................... ̈  
Atemnot  ................................................................. ̈  
Kreislaufreaktion/Blutdruckabfall ............................ ̈  













31.  Auf welche Nahrungsmittel reagiert Ihr Kind? 
 Ja Nein 
Milch und Milchprodukte ........................................ ̈  ¨ 
Hühnereier .............................................................. ̈  ¨ 
Fisch ...................................................................... ̈  ¨ 
Weizenmehl oder andere Getreideprodukte ............... ̈  ¨ 
Nüsse ..................................................................... ̈  ¨ 
Soja ........................................................................ ̈  ¨ 
Zitrusfrüchte ........................................................... ̈  ¨ 
Anderes Obst oder Gemüse ...................................... ̈  ¨ 
Andere Nahrungsmittel ............................................ ̈  ¨ 
Welche? ____________________________ 
 
32.  A) Haben Sie Ihr Kind gestillt? 
Ja                 ¨    Wie lange haben Sie Ihr Kind gestillt?............................. 
Nein             ¨ ......................................................  
 
33.  Hat Ihr Kind jemals Hypoallergene Nahrung bekommen? 





                                     Ja .....................................  ¨ 
Falls Ja, 
Zur Vorbeugung einer Nahrungsmittelallergie .........  ¨ 
Aufgrund einer manifesten Nahrungsmittelallergie ..  ¨ 
Welches Hypoallergne Nahrung haben sie verwendet: 
(Bitte geben Sie den Namen möglichst genau an) 
 
                                     Nein                                  ¨ 
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Es folgen Fragen zu anderen Erkrankungen 
34.  Wurde bei Ihrem Kind jemals von einem Arzt/einer Ärztin eine spastische 
Bronchitis, obstruktive Bronchitis oder asthmatische Bronchitis 
diagnostiziert? 
Nein, nie ............................................ ¨ 
Ja, einmal .......................................... ¨ 
Ja, mehrmals ...................................... ¨ 
 
35.  Wurde bei Ihrem Kind in den letzten 12 Monaten von einem Arzt/einer 
Ärztin eine der folgenden Diagnosen gestellt? 
 Ja Nein 
Asthma .......................................  ............. ̈   ¨ 
Neurodermitis, atopische Dermatitis 
oder endogenes Ekzem ................  ............. ̈   ¨ 
Allergische Rhinitis/Heuschnupfen  ........... ̈   ¨ 
 
36.  Hatte Ihr Kind bisher eine der folgenden Erkrankungen im ersten 
Lebensjahr? 
 Ja Nein 
Mittelohrentzündung ............................................... ̈  ¨ 
Pseudokrupp  .......................................................... ̈  ¨ 
Lungenentzündung .................................................. ̈  ¨ 
Bronchitis ............................................................... ̈  ¨ 
Bronchiolitis ........................................................... ̈  ¨ 
Keuchhusten ........................................................... ̈  ¨ 
Andere Infektionen ................................................. ̈  ¨ 
Welche? __________________________________________  
Waren stationäre Aufenthalte im Krankenhaus notwendig .... ̈  ..... ̈  
Warum? __________________________________________ 
 







37.  Hatte Ihr Kind bisher eine der folgenden Erkrankungen nach dem ersten 
Lebensjahr? 
 Ja Nein 
Mittelohrentzündung ............................................... ̈  ¨ 
Pseudokrupp  .......................................................... ̈  ¨ 
Lungenentzündung .................................................. ̈  ¨ 
Bronchitis ............................................................... ̈  ¨ 
Bronchiolitis ........................................................... ̈  ¨ 
Keuchhusten ........................................................... ̈  ¨ 
Andere Infektionen ................................................. ̈  ¨ 
Welche? __________________________________________  
Waren stationäre Aufenthalte im Krankenhaus notwendig .... ̈  ..... ̈  
Warum? __________________________________________ 
__________________________________________________ 
38.  Hatten Sie den Eindruck, dass Ihr Kind im Säuglings- oder Kleinkindalter 
vermehrt geschwitzt hat? 
                                     Ja .................................................  ¨ 
                                     Nein                                 ¨   
Fragen zu Verhalten und Erkrankungen der Mutter in der Schwangerschaft 
39.  Hatten Sie in der Schwangerschaft eine Infektion, die die Einnahme eines 
Antibiotikums erfordert hat? 
Ja .................................................................. ̈  
Nein .............................................................. ̈    
Falls Ja, 
Welche Art der Infektion: 
Welches Antibiotikum haben Sie eingenommen: 
 
40.  Waren stationäre Aufenthalte im Krankenhaus, außer für die Geburt 
notwendig? 
Ja .................................................................. ̈  
Nein .............................................................. ̈    
Falls Ja, 
Warum: 






41.  Haben Sie in der Schwangerschaft Medikamente eingenommen? 
 Ja Nein 
Paracetamol ................................................... ̈  ¨ 
Andere Medikamente:   
 
Angaben zur Wohnungs- und Lebenssituation 
42.  A) Wie viele jüngere Geschwister hat Ihr Kind? 
 
Bitte auch Stiefgeschwister mitzählen, die in Ihrer Familie leben! 
 
Schwestern....................... Brüder...............................  
 
B) Wie viele ältere Geschwister hat Ihr Kind? 




43.  Wird oder wurde Ihr Kind regelmäßig zusammen mit anderen Kindern 
durch eine Tagesmutter oder bei den Großeltern betreut? Die eigenen 
Geschwister sind dabei nicht gemeint. 
Ja, ...................................................... ¨ 
 
Im 3. bis 6. Lebensjahr       Im 1. oder 2. Lebensjahr  Bei Geburt 
          ¨                 ¨                                   ¨ 
 
Mit wie vielen anderen Kindern: _____ 
Nein ................................................... ¨ 
44.  Wird oder wurde Ihr Kind regelmäßig zusammen mit anderen Kindern in 
einer Kinderkrippe oder im Kindergarten betreut? Die eigenen Geschwister 
sind dabei nicht gemeint. 
Ja, ...................................................... ¨ 
 
Im 3. bis 6. Lebensjahr       Im 1. oder 2. Lebensjahr  Bei Geburt 
            ¨                        ¨                                   ¨ 
 
Mit wie vielen anderen Kindern? _____ 
                    Nein                                                   ¨ 
         
 
158 
45.  Welche der folgenden Haustiere haben/hatten Sie innerhalb der Wohnung? 
Mehrere Antworten sind möglich. 
 
 
 Zur Zeit       Im 1. oder 2. Lebensjahr  Bei Geburt 
Keine  ¨                          ¨                                   ¨ 
Hund ¨                ¨                                   ¨ 
Katze  ¨                          ¨                                   ¨ 
 
 


















46.  Hat/hatte Ihr Kind sonst regelmäßig (ca. 1x/Woche) Kontakt zu folgenden 
Tieren (z.B. in der Wohnung von Freunden/ Verwandten)? Mehrere 
Antworten sind möglich. 
 
Zur Zeit      1. oder 2. Lebensjahr      Bei Geburt Nein 
Hund ¨ ¨                             ¨                            ¨ 
Katze  ¨ ¨                             ¨                            ¨ 






47.  Gab es in Ihrer Wohnung jemals Feuchtigkeitsflecken bzw. Schimmelbefall 
an Wänden oder Decken? 
Feuchtigkeitsflecken in Bad oder Küche sind dabei nicht gemeint, sondern nur in 
Räumen wie Wohnzimmer, Schlafzimmer oder Kinderzimmer. 
 Ja Nein 
Feuchtigkeitsflecken, aber ohne Schimmelbefall ......................... ¨ ...... ̈  
 Zur Zeit       Im 1. oder 2. Lebensjahr  Bei Geburt 
                                 ¨                          ¨                             ¨ 
 
Ja Nein 
Feuchtigkeitsflecken mit Schimmelbefall ................................... ¨ ...... ̈  
 Zur Zeit       Im 1. oder 2. Lebensjahr  Bei Geburt 
                                         ¨                              ¨                            ¨ 
 
Es folgen Fragen zu Ihrer Familie  









¨  Autoimmunerkrankung, wie z.B. Diabetes, rheumatoide Arthritis. 
 
¨ Schilddrüsenerkrankung, bitte angeben welche    
 
¨ Darmerkrankung (M. Crohn, ulzerative Kolitis) 
 
¨   Weitere:       
 
¨ Nein 
49.  Falls die Mutter an einer allergischen Erkrankung  (Heuschnupfen, allergisches 
Asthma bronchiale, Neurodermitis/atopische Dermatitis/endogenes Ekzem) leidet, 
war diese aktiv während der Schwangerschaft? 
                      Ja    ¨ 
                      Nein    ¨   
 
















¨  Autoimmunerkrankung, wie z.B. Diabetes, rheumatoide Arthritis. 
 
¨ Schilddrüsenerkrankung, bitte angeben welche    
 
¨ Darmerkrankung (M. Crohn, ulzerative Kolitis) 
 
¨ Weitere:       
¨ Nein  
 




Ja  ....................................... ̈  
Nein  ....................................... ̈   
Falls Ja, bei wem: 
 
Heuschnupfen? 
Ja  ....................................... ̈  
Nein  ....................................... ̈   
Falls Ja, bei wem: 
 
Neurodermitis/atopische Dermatitis/endogenes Ekzem? 
Ja  ....................................... ̈  
Nein  ....................................... ̈   
Falls Ja, bei wem: 
 
Es folgen Fragen zum Rauchverhalten 
52.  Rauchen Sie oder Ihre Familie in Ihrer Wohnung/Haus? 
Ja .................................... ̈  
Nein ................................ ̈    
 






53.  Haben sie in der Schwangerschaft geraucht? 
                                     Ja ...................................... ̈  
Falls ja, wie viele Zigaretten am Tag (durchschnittlich): 
                                     Nein                               ¨   
 
54.  Haben Sie und Ihre Familie in den letzten 12 Monaten mit dem Rauchen in 
der Wohnung aufgehört bzw. das Rauchen innerhalb der Wohnräume 
eingeschränkt?  
Ja .................................... ̈  
Nein ................................ ̈    
Es wurde nie geraucht ...... ̈   Þ weiter mit Frage 56  
55.  Wie viele Zigaretten werden durchschnittlich am Tag in Ihrer Wohnung 
(damit meinen wir auch die Küche) geraucht? Zigaretten, die auf dem 
Balkon oder der Terrasse geraucht werden, brauchen nicht mitgezählt zu 
werden. Wie viele davon von...  (keine=0) 
  
Mutter _____ pro Tag 
Partner _____ pro Tag 
Andere Personen _____ pro Tag 
Insgesamt _____ pro Tag 
Es folgen noch allgemeine Fragen 
56.   
Wurde Ihr Kind in Deutschland geboren? 
 
¨ Ja  
¨ Nein Es wurde in ......................geboren. 
 Es kam mit .......................Jahren nach Deutschland? 
 
57.  Welche Staatsangehörigkeit hat Ihr Kind?  
¨ Deutsch 
¨ Andere à Welche? ______________ 
 
58.  In welchem Land wurde die (leibliche) Mutter des Kindes geboren? 
¨ Deutschland 
¨ Türkei 
 ¨ Andere à Welche? ______________ 
 
59.  In welchem Land wurde der (leibliche) Vater des Kindes geboren? 
¨ Deutschland 
¨ Türkei 
 ¨ Andere à Welche? ______________ 
 










Wir danken Ihnen herzlich für das Ausfüllen des Fragebogens! 
 
Bei Fragen können Sie sich jederzeit gerne an uns wenden.  
Studienleitung:        
PD Dr. med. Bianca Schaub 
Studienärztin Elisabeth Klucker, Tel: 089/ 44005-7878 
 
 
60.   Welches ist der höchste Schulabschluss der Mutter bzw. des Vaters des 
Kindes? 
                                                                             Mutter      Vater 
 
Keine abgeschlossen Schulausbildung                      ¨                ¨ 
 
Hauptschule, Volksschule                                        ¨                ¨ 
 
Realschule, Mittlere Reife                                        ¨                ¨ 
 
Gymnasium, Abitur, Fachabitur                               ¨                ¨ 
 
Hochschule, Fachhochschule, Universität                 ¨                ¨ 
 
Andere Ausbildung                                                  ¨                ¨ 
 
Welche                                              . 
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